
# Financial performance



# Deputy Secretary, Financial and Corporate Services and Chief Financial Officer's report

### **Expenses**

NSW Health is a provider of patient-centred healthcare services. Approximately \$21.2 billion (65 per cent) of costs incurred during 2024-25 were labour related, including the costs of employee salaries and contracted visiting medical officers. Other operating and financing costs include approximately \$2.2 billion in pharmaceutical, medical, and surgical supplies; and \$770 million in maintenance related expenses.

Grants and subsidies to third parties for the provision of public health related services totalled approximately \$1.9 billion in 2024-25, including payments of \$912 million in operating grants being paid to affiliated health organisations.

### Revenue

Key revenue items include a range of fees for medical services rendered, consisting of the Department of Veterans' Affairs, private health funds for privately insured patients, workers compensation and non-patient fees (\$1.4 billion); the sales and recoveries of pharmaceutical supplies, mainly the recoup of costs from the Commonwealth through Medicare for highly specialist drugs (\$389 million); and compensable payments received from motor vehicle insurers for the costs of people hospitalised or receiving treatment as a result of a motor vehicle accident (\$223 million).

Commonwealth Payments as part of the National Health Reform Agreement are receipted under grants and contributions (\$8.9 billion).

NSW Health's full year capital expenditure for 2024-25 (excluding capital expensing) was \$2.6 billion for works in progress and completed works. The total spent on capital in 2024-25 represents 7.7 per cent of the total Property, Plant, Equipment and Intangibles asset base.

### Net assets

NSW Health's net assets at 30 June 2025 are \$31.2 billion. This is made up of total assets of \$39.5 billion, netted off by total liabilities of \$8.3 billion. The net assets are represented by accumulated funds of \$17.7 billion and an asset revaluation reserve of \$13.4 billion.

The audited financial statements for the NSW Ministry of Health are provided in the report. Audited financial statements have also been prepared in respect of each of the reporting entities controlled by the NSW Ministry of Health. These statements have been included in a separate volume of the NSW Health 2024-25 Annual Report. The NSW Ministry of Health and all its controlled entities received an unqualified audit opinion.

## Adjunct Professor Alfa D'Amato

Deputy Secretary, Financial and Corporate Services and Chief Financial Officer NSW Health

# Financial management

### Asset management

As from 1 July 2024, NSW Health has been supporting the development of asset management capability and capacity by providing funding directly to local health districts and specialty health networks for resources to promote uplift in asset management maturity.

NSW Health implemented the Asset Management Capability Funding Program which is designed to strengthen planning and delivery of services, through funded asset management-specific resources. These resources will minimise gaps in asset management related expertise and capacity, and is based on local needs, identified through the annual asset management maturity assessment process. This Program is aligned to NSW Health's strategic asset management priorities to enable better health outcomes for patients and the community.

### Non-government funding

Each year, NSW Health allocates funding to non-government organisations (NGOs) to deliver community-based services supporting health and wellbeing, particularly for vulnerable or hard-to-reach populations.

Aboriginal health; aged care; children; youth and families; chronic care and disability; community transport; drug and alcohol; mental health; palliative care; population health; and women's health are among the services for which NSW Health provides funding.

# **Aboriginal Health**

Grant recipient	Amount (\$)	Description
Aboriginal Health and Medical Research Council NSW (AH&MRC)  Aboriginal Medical Service	2,957,400 799,000	Supports the peak body for Aboriginal Community Controlled Health Services in NSW and its core activities including building the capacity of member services in priority areas such as governance, financial managemen and business processes, and workforce development. Funding supports the AH&MRC to contribute to NSW Health policy and program development processes aimed at improving the health outcomes of Aboriginal people across NSW, and to be a formal partner with NSV Health on Aboriginal health issues  Provision of population health and chronic care primary
Co-Operative Ltd  Albury Wodonga Aboriginal Health	262,300	health services; provision of drug and alcohol services for the Aboriginal community in the Sydney region Provision of population health and chronic care primary
Service	·	health services to the Aboriginal community in the Albury Wodonga area
Armajun Health Service Aboriginal Corporation	348,500	Provision of population health and chronic care services to the Aboriginal community in the Armidale, Glen Innes, Inverell, Tenterfield, and Tingha regions
Awabakal Ltd	900,100	Provision of population health, chronic care, and drug and alcohol primary care services; provision of ear health and family health services for the Aboriginal community in the Newcastle region
Biripi Aboriginal Corporation Medical Centre	510,000	Provision of population health, chronic care and drug and alcohol primary health services, and provision of family health services for the Aboriginal community in the Tare area
Bourke Aboriginal Corporation Health Service	442,700	Provision of population health, chronic care, and drug and alcohol primary health services, and provision of family health services for the Aboriginal community in Bourke and surrounding areas
Bulgarr Ngaru Medical Aboriginal Corporation	741,900	Provision of population health and chronic care primary health services, and provision of family health services in the Richmond and Clarence valley regions
Bullinah Aboriginal Health Service Ltd	280,400	Provision of population health and chronic care primary health services to the Aboriginal community in the Ballina region
CatholicCare Wilcannia-Forbes Ltd	232,400	Provision of family health services in Narromine and Bourke
Condobolin Aboriginal Health Service Inc	452,400	Provision of population health and chronic care primary health services to the Aboriginal community in the Condobolin area
Coomealla Health Aboriginal Corporation	220,900	Provision of population health and chronic care primary health services to the Aboriginal community in the Dareton and Wentworth area
Coonamble Aboriginal Health Service	754,600	Provision of population health and chronic care primary health services, and provision of family health services in the Coonamble, Dubbo, and Gilgandra regions
Cummeragunja Health and Development Aboriginal Corporation	223,500	Provision of population health and chronic care primary health services for Aboriginal community in the Cummeragunja, Moama, and surrounding areas
Dubbo Neighbourhood Centre Inc	120,500	Provision of family health services for communities in the Dubbo area
Durri Aboriginal Corporation Medical Service	738,100	Provision of population health, chronic care, and drug and alcohol primary health services for the Aboriginal communities in the Kempsey, Nambucca Valley area

Grant recipient	Amount (\$)	Description
Eleanor Duncan Aboriginal Services Ltd	506,900	Provision of population health, chronic care and ear health primary health services and provision of family health services for the Aboriginal communities in the Central Coast area
Galambila Aboriginal Health Service Inc	386,700	Provision of population and chronic care primary health services for Aboriginal communities in the Coffs Harbour area
Griffith Aboriginal Medical Service Inc	280,400	Provision of population health and chronic care primary health services to the Aboriginal community in the Griffith and Hay region
Illaroo Co-operative Aboriginal Corporation	77,900	Personal care worker for the Rose Mumbler Retirement Village
Illawarra Aboriginal Medical Service	424,800	Provision of population health, chronic care, and drug and alcohol primary health services for the Aboriginal community in the Illawarra area
Intereach Ltd	141,300	Provision of family health services in the Deniliquin area
Katungul Aboriginal Corporation Community and Medical Services	412,400	Provision of population health, chronic care and ear health primary health services for Aboriginal communities of the Far South Coast region and Bega
Maari Ma Health Aboriginal Corporation	487,300	Provision of population health and chronic care primary health services and family health services in Broken Hill and across Far West NSW
Ngaimpe Aboriginal Corporation	257,800	Residential drug and alcohol treatment and referral program providing statewide services, located in the Central Coast area
Orana Haven Aboriginal Corporation	214,000	Residential drug and alcohol treatment and referral program providing statewide services located near Brewarrina
Orange Aboriginal Medical Service	348,500	Provision of population health and chronic care primary health services for Aboriginal communities in the Orange area
Pius X Aboriginal Corporation	223,100	Provision of population health and chronic care primary health services to the Aboriginal community in the Moree area
Riverina Medical and Dental Aboriginal Corporation	649,800	Provision of population health, chronic care, drug and alcohol and ear health primary health services and provision of family health services for the Aboriginal community in the Riverina region
South Coast Medical Service Aboriginal Corporation	325,500	Provision of population health, chronic care and drug and alcohol primary health services for the Aboriginal community in the Nowra area
South Coast Women's Health and Welfare Aboriginal Corporation	616,000	Provision of population health and chronic care primary health services and provision of family health services to Aboriginal women and their families in the South Coast region
Tamworth Aboriginal Medical Service Inc	317,900	Provision of population health and chronic care primary health services to the Aboriginal community in the Tamworth area
Tharawal Aboriginal Corporation	445,700	Provision of population health, chronic care and drug and alcohol primary health services for the Aboriginal community in the Campbelltown area
The Oolong Aboriginal Corporation	288,200	Residential drug and alcohol treatment and referral program providing statewide services located in the Nowra area
Tobwabba Aboriginal Medical Service	325,600	Provision of population health and chronic care primary health services and provision of family health services for the Aboriginal community in Forster and surrounding areas

Grant recipient	Amount (\$)	Description
Ungooroo Aboriginal Corporation	280,400	Provision of population health and chronic care primary health services to the Aboriginal community in the Singleton and Muswellbrook areas
Walgett Aboriginal Medical Service	543,600	Provision of population health, chronic care, and drug and alcohol primary health services and provision of family health services for the Aboriginal community in the Walgett, Brewarrina and surrounding areas
Weigelli Centre Aboriginal Corporation	107,600	Residential drug and alcohol treatment and referral program providing statewide services located in the Cowra area
Wellington Aboriginal Corporation Health Service	1,498,900	Provision of population health, chronic care and drug and alcohol primary health services and provision of family health services for the Aboriginal communities around Wellington and Greater Western Sydney
Werin Aboriginal Corporation	280,400	Provision of population health and chronic care primary health services to the Aboriginal community in the Port Macquarie area
Yoorana Gunya Family Healing Centre Aboriginal Corporation	520,700	Provision of population health and chronic care primary health services and provision of family health services for the Aboriginal community in Forbes and surrounding areas
Total	19,946,100	

# Drug and alcohol

Grant recipient	Amount (\$)	Description
Aboriginal Health and Medical Research Council NSW	218,900	Develop capacity of NSW Aboriginal Community Controlled Health Organisations to identify and respond to alcohol and other drug related harm
Aboriginal Medical Service Co-Operative Ltd	379,100	Delivery of alcohol and other drug treatment and support services for Aboriginal people in Redfern
Odyssey House NSW	933,800	Delivery of alcohol and other drug prevention, community development, treatment and research services for people and communities with cultural and linguistic diversity, primarily in Western and South Western Sydney
Network of Alcohol and other Drugs Agencies Inc	1,905,800	Represent and develop capacity of NSW non-government organisations delivering alcohol and other drug prevention, harm minimisation, and treatment services
The Oolong Aboriginal Corporation	417,700	Alcohol and other drug residential rehabilitation in Nowra primarily for Aboriginal men, with priority access for Magistrates Early Referral into Treatment program participants
Uniting NSW.ACT	5,033,100	Medically supervised injecting-centre
Total	8,888,400	

# Health promotion

Grant recipient	Amount (\$)	Description
Family Drug Support	450,600	Provides a 24-hour 7 days telephone service, information, support and referral to families affected by alcohol and other drug issues
Life Education NSW Ltd	2,631,500	Delivers alcohol and other drugs and healthy lifestyle related education to primary school children in NSW
Asthma Australia Ltd	631,700	Asthma Australia aims to build the capacity of the health workforce to provide evidence-based care to people with asthma, develop and implement programs and services that support people with asthma to proactively self manage their disease and help develop policies and systems to create safer environments for people with asthma
Kidsafe NSW Inc	305,900	Kidsafe NSW undertakes public awareness campaigns and provides information, training and advice on child injury prevention to key stakeholders and the community
Total	4,019,700	

# Oral health

Grant recipient	Amount (\$)	Description
Aboriginal Medical Service Co-Operative Ltd	460,900	Aboriginal Oral Health Services
Albury Wodonga Aboriginal Health Service	656,400	Aboriginal Oral Health Services
Armajun Health Service Aboriginal Corporation	625,800	Aboriginal Oral Health Services
Awabakal Ltd	414,400	Aboriginal Oral Health Services
Biripi Aboriginal Corporation Medical Centre	234,600	Aboriginal Oral Health Services
Bourke Aboriginal Corporation Health Service	451,800	Aboriginal Oral Health Services
Condobolin Aboriginal Health Service	272,000	Aboriginal Oral Health Services
Coonamble Aboriginal Health Service	172,000	Aboriginal Oral Health Services
Durri Aboriginal Corporation Medical Service	568,200	Aboriginal Oral Health Services
Eleanor Duncan Aboriginal Services Ltd	449,100	Aboriginal Oral Health Services
Griffith Aboriginal Medical Service Inc	172,000	Aboriginal Oral Health Services
Illawarra Aboriginal Medical Service	529,700	Aboriginal Oral Health Services

Grant recipient	Amount (\$)	Description
Katungul Aboriginal Corporation Community and Medical Services	427,200	Aboriginal Oral Health Services
Maari Ma Health Aboriginal Corporation	465,000	Aboriginal Oral Health Services
Orange Aboriginal Medical Service	569,000	Aboriginal Oral Health Services
Pius X Aboriginal Corporation	234,000	Aboriginal Oral Health Services
Riverina Medical and Dental Aboriginal Corporation	618,600	Aboriginal Oral Health Services
South Coast Medical Service Aboriginal Corporation	355,600	Aboriginal Oral Health Services
Tamworth Aboriginal Medical Service Inc	164,500	Aboriginal Oral Health Services
Tharawal Aboriginal Corporation	469,800	Aboriginal Oral Health Services
Tobwabba Aboriginal Medical Service	451,800	Aboriginal Oral Health Services
University of Sydney	315,100	Aboriginal Oral Health Services
Walgett Aboriginal Medical Service	232,100	Aboriginal Oral Health Services
Total	9,309,600	

# HIV, blood-borne viruses and sexually transmitted infections (STI)

Grant recipient	Amount (\$)	Description
Aboriginal Health and Medical Research Council NSW	151,300	Delivery of education and training in Primary Health Care (Sexual Health) and specialised short courses and skill set training covering HIV, hepatitis C and B, and STIs to support Aboriginal health workers in Aboriginal Community Controlled Health Services and local health districts to implement the NSW HIV, STI, hepatitis C and hepatitis B strategies
ACON Health Ltd	13,905,000	A statewide community-based organisation providing HIV and STI prevention, education, and support services to gay and other men who have sex with men. Services and programs include: HIV and STI prevention, health promotion, education and community engagement programs for gay and other men who have sex with men to increase access to HIV and STI testing, treatment and prevention

Australasian Society For HIV, Viral Hepatitis and Sexual Health Medicine	726,300	Provides general practitioner (GP) engagement and delivery of training for authorisation as required for prescribing of drugs used in the treatment of HIV and hepatitis B; training that supports GPs involved with patients who have HIV and STI; sexual health and viral hepatitis training for nurses; HIV, STI and viral hepatitis training content and materials for GPs and other health care providers
Bobby Goldsmith Foundation	2,209,400	Provision of client-centred services across NSW for HIV positive people with complex care needs to support client stability, and address barriers to retention in care and target service gaps in partnership with specialist HIV community services
Diabetes NSW	3,111,000	Provision of syringes and pen needles at no cost to NSW registrants of the National Diabetic Services Scheme
Hepatitis NSW Inc	2,395,600	A statewide community-based organisation that provides information, support, referral, testing, education and advocacy services for people in NSW affected by hepatitis C and hepatitis B
NSW Users and AIDS Association Inc	1,858,200	Statewide community-based organisation that provides HIV and hepatitis C prevention education, harm reduction, access to testing, advocacy, resources, referral and support services for people who inject drugs
Positive Life NSW Inc	1,194,800	Statewide community-based health promotion and education, advocacy, and implementation of policy and programs for people living with HIV
Sex Workers Outreach Project Inc	1,647,500	Statewide peer-based health education and outreach services to sex industry workers to prevent the transmission of HIV, viral hepatitis and STI
Total	27,199,100	

# **External Health Services**

Grant recipient	Amount (\$)	Description
Royal Flying Doctor Service Of Australia (South Eastern Section)	2,530,810	Provision of Rural Aerial Health Service
Total	2,530,810	

# **Rural Doctors Services**

Grant recipient	Amount (\$)	Description
NSW Rural Doctors Network	1,993,100	Core funding supports a range of programs aimed at ensuring sufficient numbers of suitably trained and experienced medical practitioners are available to meet the healthcare needs of rural NSW communities. Funding is also provided for the NSW Rural Medical Undergraduates Initiatives Program, which provides financial assistance to medical students undertaking rural NSW placements; and the NSW Rural Resident Medical Officer Cadetship Program, which supports selected medical students in their final two years of study who commit to completing two of their first three postgraduate years in a NSW regional hospital
Total	1,993,100	

# Mental Health

Grant recipient	Amount (\$)	Description
Aboriginal Health and Medical Research Council NSW	233,500	Mental Health statewide coordination to support and develop the capacity of Aboriginal Community Controlled Health Organisation to deliver mental health and wellbeing services and provide strategic advice to NSW Health on key issues affecting mental health and wellbeing service delivery in the Aboriginal Community Controlled sector
Aboriginal Medical Service Co- operative Limited	386,600	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Albury Wodonga Aboriginal Health Service incorporated	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Awabakal Ltd	132,400	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
BEING - Mental Health Consumers Incorporated	76,500	The peak body for mental health consumers in NSW, BEING represent the interest of mental health consumers in NSW and advocate on behalf of consumers for changes in policy, legislation and service provision. BEING also deliver projects that support the expansion and growth of the lived experience workforce
Black Dog Institute	1,896,200	Education and training programs for health professionals, schools and school communities. The Black Dog Institute Clinic is a psychiatric assessment clinic receiving referrals from GPs and Psychiatrists who are seeking diagnosis and treatment planning for patients who have already unsuccessfully undertaken pharmacological and psychological interventions for their mood disorder

Grant recipient	Amount (\$)	Description
Bulgarr Ngaru Medical Aboriginal Corporation	135,400	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
CatholicCare Wilcannia-Forbes Limited	1,021,300	NSW Family and Carer Mental Health Program - supports families and carers of people with a mental illness through individual support, support groups, advocacy and training and education
Coomealla Health Aboriginal Corporation	132,400	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community.
Cummeragunja Housing and Development Aboriginal Corporation	132,400	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Galambila Aboriginal Corporation	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Katungul Aboriginal Corporation Regional Health and Community Services	124,700	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Lifeline Australia	4,003,300	Support for Lifeline Centres in NSW to provide the Lifeline crisis support telephone service
Mental Health Association NSW Ltd	122,900	Wayahead is the peak body for mental health promotion in NSW. Wayahead promotes mental health and wellbeing, supports the people of NSW to access mental health services and delivers mental health projects across NSW
Mental Health Carers Arafmi NSW Inc	43,900	Mental Health Carers NSW (MHCN) is the peak body for mental health carers in NSW. MHCN represent the interest of mental health carers in NSW and information they gather from carers is used to advocate for changes in policy, legislation and service provision to better recognise and support carers
Mental Health Co-ordinating Council Limited	746,000	NSW mental health peak organisation funded to support the mental health community managed organisation sector to provide quality services
Mission Australia	1,012,100	NSW Family and Carer Mental Health Program - supports families and carers of people with a mental illness through individual support, support groups, advocacy and training and education
Riverina Medical and Dental Aboriginal Corporation	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Schizophrenia Fellowship Of New South Wales Ltd	3,176,400	NSW Family and Carer Mental Health Program - supports families and carers of people with a mental illness through individual support, support groups, advocacy and training and education
Schizophrenia Fellowship Of New South Wales Ltd	571,800	One Door Mental Health Core Grant to provide support, referral, advocacy and information to people experiencing mental health issues

Grant recipient	Amount (\$)	Description
South Coast Medical Service Aboriginal Corporation	254,000	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
South Coast Women's Health and Welfare Aboriginal Corporation	128,200	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Stride Mental Health Limited	999,500	NSW Family and Carer Mental Health Program - supports families and carers of people with a mental illness through individual support, support groups, advocacy and training and education
Tharawal Aboriginal Corporation	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Peer Support Australia	172,550	School based, peer-led mentoring program supporting the mental, social and emotional wellbeing of children and young people
The Peer Support Foundation Ltd	86,275	School based, peer-led mentoring program supporting the mental, social and emotional wellbeing of children and young people
Life Education NSW Limited	86,275	School based, peer-led mentoring program supporting the mental, social and emotional wellbeing of children and young people
The Trustees Of The Society Of St Vincent De Paul (NSW)	264,900	Frederic House is a residential aged care facility that targets older men with mental health and/or substance use issues. This top up funding supports the facility and services provided, particularly the provision of specialist mental health staffing
Uniting NSW.ACT	2,028,500	NSW Family and Carer Mental Health Program - supports families and carers of people with a mental illness through individual support, support groups, advocacy and training and education
Walgett Aboriginal Medical Service Ltd	235,300	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Weigelli Centre Aboriginal Corporation inc	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Wellington Aboriginal Corporation Health Service	247,100	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Yerin Aboriginal Health Services Limited	117,900	Increased access to culturally safe, holistic and flexible mental health and wellbeing services led by Aboriginal Community Controlled Health Organisations that are responsive to the needs to the local community
Total	19,157,800	

# Community services - NSW children, youth and families

Grant recipient	Amount (\$)	Description
Australian Breastfeeding Association (NSW Branch)	197,900	The Australian Breastfeeding Association (ABA) promotes, protects and supports breastfeeding by advocating for the importance of human milk. The ABA provides peer support to women and families and supports health professionals with resources, workshops and seminars
Australian Red Cross Society	428,900	Residential program that builds the capacity of young pregnant women, over 20 weeks gestation, with complex needs, and newly parenting young men and women aged 12 to 25 to live and parent independently and respond appropriately to the needs of their children
CatholicCare Sydney Trust	109,900	This organisation promotes natural family planning within the community and providing community-based information sessions for individuals and families about natural fertility methods
Red Nose Saving Little Lives	217,100	Red Nose provides bereavement support to NSW families who experience the death of their baby or child during pregnancy, birth and infancy, including miscarriage, ectopic pregnancy, termination of pregnancy, stillbirth, neonatal and infant death and sudden death of a child
Royal Far West Children's Health Scheme	4,788,200	The Paediatric Developmental Program at Royal Far West provides specialist comprehensive multidisciplinary assessment, diagnosis, planning, review and treatment for rural and remote children up to age 12 with complex developmental and behavioural issues. The Program includes support for parents and carers. The service targets the needs of families residing north of Taree, west of Lithgow and south of Nowra, who cannot access the services they need locally
Youth Action	158,000	Youth Action is the peak body for young people and youth services in NSW. Youth Action has received funding to develop and implement the NSW Youth Health Literacy Project. This aims to improve the health outcomes of young people aged 12 to 24 years old through promoting their health literacy and access to healthcare
Youthsafe	235,900	Youthsafe partners with key stakeholders to prevent unintentional injury of young people aged 12 to 26 years. The focus is on injuries from use of roads, participation in workplaces and sport, and socialising with friends
Total	6,135,900	

# Aged Care, disability and community care

Grant recipient	Amount (\$)	Description
CF Together	352,700	CF Together, previously known as Cystic Fibrosis Community Care, provides counselling, support and assistance to people with Cystic Fibrosis and their families. It also delivers community outreach and works to improve equitable delivery of services and multidisciplinary engagement
Palliative Care NSW Inc	116,900	Palliative Care NSW provides information and education to healthcare professionals and the general public to raise awareness and enable informed choices about quality palliative and end of life care. The organisation designs and delivers strategies and policies to support the growth and uptake of palliative care in NSW, and assists primary and specialist health professionals who provide palliative care in the community

Grant recipient	Amount (\$)	Description
Parkinsons NSW	34,200	Parkinson's NSW supports people living with Parkinson's Disease, their families and carers. It provides essential services through the Parkinson's NSW Infoline, counselling services, network of Support groups, Parkinson's Nurse specialists in regional NSW, and education and information programs
Total	503,800	

# **Community Services**

Grant recipient	Amount (\$)	Description
Albury Wodonga Aboriginal Health Service	304,200	This organisation provides child and family health services including the provision of child health and development checks
Association for the Wellbeing of Children in Healthcare	249,100	AWCH co-ordinates and supports the AWCH Ward Grandparent Program in NSW public hospitals and advocates for the needs of children and young people through, education, policy development, awareness raising and partnerships
Centre for Disability Studies Ltd	264,800	CDS provides a Complex Care Service for adults with intellectual disability and complex health needs, working with the person's General Practitioner to ensure high quality health care. CDS provides comprehensive multidisciplinary health assessments, health care plans, advice and referrals
NSW Council of Social Service	338,600	NCOSS provides capacity building activities that increase sustainability in health-related activities that promote the development of health policies, strategies, service design and delivery to better address the health needs of disadvantaged people
Health Consumers NSW	498,800	HCNSW provides a voice for patients, their family members and carers, patient leaders and health consumer representatives in NSW, as well as health consumer organisations representing specific disease and population groups. Key activities include support for consumer representative networks, and training and education for consumers and NSW Health staff
The United Hospital Auxiliaries of NSW Inc	256,300	Funding supports delivery of head-office administrative and communications support to the affiliated hospital auxiliaries and UHA Volunteers located in public hospitals, multipurpose services, community health centres, day care services and other public health facilities across NSW
Women's Health NSW	288,200	Women's Health NSW is the peak body for non-government, community-based, women's health centres in NSW. It is responsible for promoting a coordinated approach to policy and planning, service delivery, staff development, training, education and consultation between members, NSW Health and other government and non-government agencies
Total	2,200,000	

# Community Services - Transport

Grant recipient	Amount (\$)	Description
Access Sydney Comm Transport	53,100	Community transport services
Active Care Network	214,200	Community transport services
Activus Transport	28,900	Community transport services
Bankstown Canterbury Community Transport	27,300	Community transport services
Cabonne Shire Council	21,800	Community transport services
Community Transport Central Coast Ltd	57,200	Community transport services
Connect You Too Ltd	88,800	Community transport services
Hart Services	53,400	Community transport services
Holdsworth Community Ltd	34,800	Community transport services
Hornsby Ku-Ring-Gai Community Aged/Disabled Transport Service	24,700	Community transport services
Inverell Hacc Services Inc	22,500	Community transport services
Linked Community Services	34,800	Community transport services
Linked Community Services (Care 'N' Go)	34,600	Community transport services
Live Better Services	55,300	Community transport services
Mid Western Regional Council	33,200	Community transport services
Neighbourhood Central	48,800	Community transport services
Ourcare Services	26,500	Community transport services
Stryder	49,300	Community transport services
The Community Transport Company Ltd	48,600	Community transport services
Transcare Hunter	11,200	Community transport services
Warrumbungle Shire Council	11,100	Community transport services
Wee Waa and District Hacc Assoc Inc	39,300	Community transport services
Total	1,019,400	

# Aboriginal Maternal and Infant Health

Grant recipient	Amount (\$)	Description
Durri Aboriginal Corp Medical Service	268,400	Employment of a community midwife and Aboriginal Health Workers to provide Aboriginal Maternal and Infant Health Service to improve the health outcomes of Aboriginal mothers, and mothers with Aboriginal partners, and their babies
Maari Ma Health Aboriginal Corporation	402,100	Employment of a community midwife and Aboriginal Health Workers to provide Aboriginal Maternal and Infant Health Service (AMIHS) to improve the health outcomes of Aboriginal mothers, and mothers with Aboriginal partners, and their babies
Walgett Aboriginal Medical Service	268,400	Employment of a community midwife and Aboriginal Health Workers to provide Aboriginal Maternal and Infant Health Service to improve the health outcomes of Aboriginal mothers, and mothers with Aboriginal partners, and their babies

Total 938,900

# Other funding grants in 2024-25

Grant recipient	Amount (\$)	Description
2Connect Youth & Community Inc	148,964	Alcohol and other drugs youth treatment services
Aboriginal Community Housing Ltd	155,625	Alcohol and Other Drug Hub Grant funding
Aboriginal Corporation for Drug and Alcohol Network NSW	170,000	To support Aboriginal engagement in the ICE response
Aboriginal Drug and Alcohol Residential Rehabilitation Network Ltd	182,064	Aboriginal Drug and Alcohol Residential Rehabilitation Organisation and Service Development
Aboriginal Health and Medical Research Council NSW	257,832	Suicide Prevention Project Officer
Aboriginal Medical Service Co-Operative Ltd	200,000	Awarding of Aboriginal Model of Care Program grants
Aboriginal Medical Service Co-Operative Ltd	40,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
ACON Health Ltd	29,000	Drug and Alcohol Harm Reduction Campaign
ACON Health Ltd	200,000	End of Life and Palliative Care Grants Program.
ACON Health Ltd	105,000	Establishment of ACON – Kaleido Health Service Grant
ACON Health Ltd	1,812,614	Suicide prevention services for People of Diverse Sexualities and Genders
Anglican Community Services	1,187,652	Mental Health Community Living Supports for Refugees
Aria Research Pty Ltd	670,000	Medical Devices Fund
Armajun Health Service Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Armajun Health Service Aboriginal Corporation	60,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
Armidale Centacare New England North West Ltd	319,727	Alcohol and Other Drugs Youth Treatment Services
Association of Children's Welfare Agencies Inc	18,300	Centre for Community Welfare Training – Workforce Development Training grant
Association of Drug Referral Centres Ltd	220,148	Alcohol and Other Drugs Youth Treatment Services.
Australian Professional Association for Trans Health (AusPATH)	25,000	One-off contribution to support AusPATH's development of a new information platform in support of trans and gender diverse health
Australian Commission on Safety and Quality in Health Care	2,979,813	Contribution for Australian Commission on Safety And Quality In Health Care
Australian Community Support Organisation Ltd	666,500	Alcohol and Other Drugs funding
Australian Crime Commission	50,000	Enhance wastewater monitoring in regional NSW
Australian Digital Health Agency	10,132,950	NSW contribution to Australian Digital Health Agency
Australian Health Practitioner Regulation Agency	420,000	Registration pathway for specialist international medical graduates under the National Registration and Accreditation

Grant recipient	Amount (\$)	Description
Australian Medical Council	1,717,161	Australian Medical Council National ePortfolio
Australian Mens Shed Association	47,500	Men's Mental health and Suicide Prevention Program
Australian Pain Management Association Ltd	100,000	Contribution to support services for individuals living with chronic pain in NSW
Australian Red Cross Society	659,807	Mental Health Community Living Supports for refugees
Australian Theatre for Young People	75,000	Mental Health Arts and Cultural Funding Program as part of the 2025 Sydney Festival
Awards Australia Pty Ltd	15,000	Contribution towards Health Award
Babana Aboriginal Men's Group Inc	50,000	Men's Mental health and Suicide Prevention Program
BEING- Mental Health Consumers Inc	878,207	BEING core funding grant
BEING- Mental Health Consumers Inc	150,000	Funding for Research into Consumer Engagement Grant
Bellambi Neighbourhood Centre Inc	85,000	Contribution to Bellambi Neighbourhood Centre Inc
Beyond Blue Ltd	1,386,614	Beyond Blue Core Funding
Black Dog Institute	310,000	Workforce Capacity and Recovery
Bobby Goldsmith Foundation	1,000	Contribution to Bobby Goldsmith for expansion of support in Western Sydney additional Case Worker
Bourke Aboriginal Corporation Health Service	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Bubble Enterprises Ltd	100,000	Contribution to Love Your Sister's fundraising activities to support cancer research in NSW
Bulgarr Ngaru Medical Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Bullinah Aboriginal Health Service Ltd	151,472	Building on Aboriginal Communities' Resilience initiative
Bullinah Aboriginal Health Service Ltd	40,000	Contribution to Bullinah Aboriginal Health Service Disaster Resilience Project initiative
Bullinah Aboriginal Health Service Ltd	200,000	End of Life and Palliative Care Grants Program
Bullinah Aboriginal Health Service Ltd	138,661	Building on Aboriginal Communities' Resilience initiative
Butterfly Foundation	100,000	Mental Health Funding for In-School-Based Eating Disorder Prevention: BodyKind Initiative in NSW
Cancer Council NSW	89,000	Grant for expansion of Generation Vape Research project
Cancer Council NSW	19,051	Tobacco In Australia Funding
Careflight Ltd	3,600,000	To operate CareFlight Rapid Response Helicopter
CatholicCare Sydney Trust	11,750	Men's Mental health and Suicide Prevention Program
CatholicCare Wilcannia-Forbes Ltd	50,000	Men's Mental health and Suicide Prevention Program
Children of the Bomaderry Aboriginal Childrens Home Inc	100,000	Funding Enhancement for Stolen Generation Survivors Health Support
Children of the Bomaderry Aboriginal Children's Home Inc	195,000	Health Care Coordinator positions for Stolen Generations Organisations
Community Broadcasting Association of Australia Ltd	99,320	End of Life and Palliative Care Grants Program
Community Restorative Centre	549,875	Alcohol and Other Drugs Treatment Access Expansion Grants

Grant recipient	Amount (\$)	Description
Community Restorative Centre	149,398	Drug and Alcohol Treatment Services Grant
Community Restorative Centre	13,500	Men's Mental health and Suicide Prevention Program
Community Restorative Centre	2,500	Post-custodial support skills development program
Condobolin Aboriginal Health Service Inc	200,000	Aboriginal Central West Mental Health and Wellbeing program
Condobolin Aboriginal Health Service Inc	277,323	Building on Aboriginal Communities' Resilience initiative
Coomealla Health Aboriginal Corporation	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Coomealla Health Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Coonamble Aboriginal Health Service	554,645	Building on Aboriginal Communities' Resilience initiative
Coordinare Ltd	1,877,594	Funding to South East NSW Primary Health Network to support joint development phase of Collaborative Commissioning
Coordinare Ltd	1,038,750	Goulburn Urgent Care Service Grant
Coordinare Ltd	220,460	NSW universal aftercare service funding - South Eastern NSW
Coota Girls Aboriginal Corporation	100,000	Funding Enhancement to improve Stolen Generation Survivors health and wellbeing
Coota Girls Aboriginal Corporation	195,000	Health Care Coordinator positions for Stolen Generations Organisations
Cummeragunja Health and Development Aboriginal Corporation	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Deadly Runners Pty Ltd	200,000	Funding to support Aboriginal health and wellbeing
Department Of Communities And Justice	30,609	National Coronial Information System Contribution
Department of Health and Aged Care	1,528,583	NSW contribution to Haemopoietic progenitor cell sector
Department of Health and Aged Care	213,591	NSW contribution to the Health Star Rating Scheme
Department of Health and Aged Care	4,558,056	Postvention support services for people in NSW impacted by suicide
Department of Health and Aged Care	1,954,904	NSW contribution for Health Chief Executive Forum Cost- Shared Budget
Directions Health Services	925,922	Alcohol and Other Drug Hub Grant funding
Directions Health Services	825,830	Alcohol and Other Drugs psychosocial counselling and support for people using Methamphetamine
Directions Health Services	2,137,250	Alcohol and Other Drugs Treatment Access Expansion Grants
Directions Health Services	28,800	Men's Mental health and Suicide Prevention Program
Directions Health Services	632,663	Post Custodial Support Grant
Dubbo Neighbourhood Centre Inc	268,515	Grant to Dubbo Neighbourhood Centre for Women's Safety Coordinator
Durri Aboriginal Corp Medical Service	200,000	Alcohol and Other Drugs "ICE Inquiry" prevention programs for Aboriginal young people and their families
Durri Aboriginal Corp Medical Service	277,323	Building on Aboriginal Communities' Resilience initiative
E Moore Family Trust	100,000	Health and exercise programs to support the mobility, independence and wellbeing of older adults
EIS Health Ltd	20,000	Contribution to support pilot testing of Sexual Health Continuing Professional Activity Guides in General Practice

Grant recipient	Amount (\$)	Description
EIS Health Ltd	409,318	NSW universal aftercare service funding - Central and Eastern Sydney
EIS Health Ltd	1,687,500	Urgent Care Service Grant - Belmore
EIS Health Ltd	1,657,500	Urgent Care Service Grant - Caringbah
EIS Health Ltd	1,687,500	Urgent Care Service Grant - Green Square
Eleanor Duncan Aboriginal Services Ltd	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Eleanor Duncan Aboriginal Services Ltd	200,000	Alcohol and Other Drugs "ICE Inquiry" prevention programs for Aboriginal young people and their families
Eleanor Duncan Aboriginal Services Ltd	317,500	Alcohol and Other Drugs Treatment Access Expansion Grants
Eleanor Duncan Aboriginal Services Ltd	277,323	Building on Aboriginal Communities' Resilience initiative
Eleanor Duncan Aboriginal Services Ltd	45,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
Eleanor Duncan Aboriginal Services Ltd	500,000	Funding for Head to Health Kids Hubs for Aboriginal Community Controlled Health Organisation in NSW
Eleanor Duncan Aboriginal Services Ltd	341,313	Alcohol and Other Drugs Treatment Access Expansion Grants
Family Planning NSW	400,000	Equitable Access to Reproductive Health Services in Regional NSW
Family Planning NSW	70,288	NSW Pregnancy Choices Helpline
Feel The Magic Ltd	150,000	Postvention support for children, young people, and families bereaved by suicide
Fight Against Cancer - Macarthur Incorporated	50,000	Funding to support Campbelltown Hospital and Camden Hospitals to assist in the care and comfort of children and adults diagnosed with cancer
Filling The Gap Ltd	150,000	Funding for National Dental Foundation Program.
Galambila Aboriginal Health Service Inc	277,323	Building on Aboriginal Communities' Resilience initiative
Gallipoli Turkish Cultural Foundation Ltd	37,573	Men's Mental health and Suicide Prevention Program
Gandangara Health Services Ltd	311,250	Alcohol and Other Drugs Funding: Ice Response
Gayaa Dhuwi (Proud Spirit) Australia Ltd	100,000	The Proud Futures 2025 Conference and the Aboriginal Remote Community-Led Social and Emotional Wellbeing Project
Gidget Foundation Australia	1,867,500	Mental Health Recovery Funding
Ginhar Indigenous Corporation	49,400	Men's Mental health and Suicide Prevention Program
Goanna Foundation Ltd	50,000	Men's Mental health and Suicide Prevention Program
Gotcha 4 Life Foundation Ltd	120,000	Mentally Fit Primary School Programs in NSW
Grand Pacific Health Ltd	622,500	Alcohol and Other Drug Hub Grant funding
Grand Pacific Health Ltd	1,985,911	Housing and Accommodation Support Initiative
Grand Pacific Health Ltd	758,777	Mental Health Community Living Supports for refugees
Grand Pacific Health Ltd	1,237,044	Rural Adversity Mental Health Program Coordination and Management
Griefline	125,000	Griefline funding
Griffith Aboriginal Medical Service Inc	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Griffith Aboriginal Medical Service Inc	277,323	Building on Aboriginal Communities' Resilience initiative
Griffith Aboriginal Medical Service Inc	20,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations

Grant recipient	Amount (\$)	Description
Health Professional Councils Authority	40,000	Financial support for administration of the Aboriginal and Torres Strait Islander Health Practice Council
Health Professional Councils Authority	311,002	Treasury Managed Fund contribution for workers compensation, motor vehicles, and property
Healthy North Coast Ltd	109,318	NSW universal aftercare service funding - Healthy North Coast
HNECC Ltd	1,609,318	NSW universal aftercare service funding - Hunter New England and Central Coast
Human Nature Adventure Therapy Ltd	49,945	Men's Mental health and Suicide Prevention Program
Humpty Dumpty Foundation Ltd	250,000	Support the NSW public hospitals, including Michelle Beets Awards and medical equipment
Hunter Primary Care Ltd	99,563	Alcohol and Other Drugs Youth Treatment Services
Huntington's Australia Ltd	112,986	Funding to support the Foundation's objectives, including the Michelle Beets Award
Illawarra Aboriginal Medical Service	60,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
Illawarra Aboriginal Medical Service	500,000	Funding for Head to Health Kids Hubs for Aboriginal Community Controlled Health Organisation in NSW
Illawarra International Womens Day Inc	12,000	Funding to support community health, wellbeing and equality initiatives
Ingham Institute For Applied Medical Research	93,717	Initial Assessment and Referral Decision Support Tool Child and Adolescent Mental Health Mapping Project
Intersex Human Rights Australia Ltd	80,000	Contribution to Intersex Human Rights Australia
Inventia Life Science Pty Ltd	3,469,000	Medical Devices Fund
Iris Foundation Australia Ltd	50,000	Funding to support women's health and wellbeing
Jirrawich	15,000	Funding towards Indigenous Rugby League Event for Suicide Prevention
Juvenile Arthritis Foundation Australia Ltd	25,000	Contribution towards the provision of the Australian Juvenile Arthritis Registry
Karitane	5,000,000	Capital Works contribution to the Karitane Fairfield Integrated Child and Family Hub
Karitane	1,357,000	Funding for Virtual Residential Parenting Service
Karitane	1,500,000	Planning for the Carramar/Fairfield Child and Family Health Hub
Karitane	43,000	Funding for Virtual Residential Parenting Service
Karralika Programs Inc	1,777,238	Alcohol and Other Drugs Treatment Access Expansion Grants
Karralika Programs Inc	601,055	Alcohol and Other Drugs Youth Treatment Services
Katoomba Neighbourhood Centre Ltd	50,000	Men's Mental health and Suicide Prevention Program
Katungul Aboriginal Corporation Community and Medical Services	277,323	Building on Aboriginal Communities' Resilience initiative
Katungul Aboriginal Corporation Community and Medical Services	75,000	Contribution to support family, carers, and friends of people using alcohol or other drugs
Kedesh Rehabilitation Services Ltd	206,279	Drug and Alcohol Treatment Services Grant
Kids of Macarthur Health Foundation Trust	50,000	Funding to support the purchase of paediatric medical equipment for NSW Public Hospitals
Kinchela Boys Home Aboriginal Corporation	195,000	Coordinator position funding

Grant recipient	Amount (\$)	Description
Kinchela Boys Home Aboriginal Corporation	100,000	Funding Enhancement to improve Stolen Generation Survivors health and wellbeing
Kiray Putjung Aboriginal Corporation	49,920	Men's Mental health and Suicide Prevention Program
LevTech Lifesciences Pty Ltd	2,077,961	Medical Devices Fund
Lifeline Australia	8,228,672	Lifeline Australia additional funding for phone and text crisis support service
Lifeline Australia	1,685,938	Lifeline Text crisis support service
Lifeline Central West Inc	20,000	Contribution to help deliver post-traumatic stress disorder support for people living in NSW's central west
Little Wings Ltd	600,000	Funding to support organisation's objectives
Lives Lived Well Ltd	454,035	Alcohol and Other Drugs psychosocial counselling and support for people using Methamphetamine
Lives Lived Well Ltd	1,099,750	Alcohol and Other Drugs Treatment Access Expansion Grants
Lives Lived Well Ltd	2,121,243	Drug and Alcohol Package Women and Children Residential Rehabilitation
Lives Lived Well Ltd	217,492	Drug and Alcohol Treatment Services Grant
Maari Ma Health Aboriginal Corporation	200,000	Alcohol and Other Drugs "ICE Inquiry" prevention programs for Aboriginal young people and their families
Maari Ma Health Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Maari Ma Health Aboriginal Corporation	5,000	Contribution to support family, carer and friends of people using alcohol or other drugs
Maari Ma Health Aboriginal Corporation	365,450	Drug and Alcohol Treatment Services Grant
Maaruma-Li Aboriginal Corporation Aboriginal Medical Service	20,000	Maaruma-Li Aboriginal Medical Service establishment grant
Macular Disease Foundation Australia	180,000	Funding to support the provision of support services for individuals living with macular disease
Marathon Health Ltd	47,724	Men's Mental health & Suicide Prevention Program
McGrath Foundation Ltd	5,079,000	McGrath Foundation Breast Care Nurses enhancement funding
Mental Health Assoc NSW Inc	1,717,032	WayAhead Core Funding
Mental Health Carers ARAFMI NSW Inc	25,000	Funding to develop a statewide community of practice for the Family and Carer Peer Workforce
Mental Health Carers ARAFMI NSW Inc	593,949	Mental Health Carers NSW Core Funding
Mental Health Carers ARAFMI NSW Inc	150,000	Research grant to improve engagement with carers from diverse backgrounds across NSW
Mental Health Coordinating Council Inc	425,524	Learning and Development Unit
Mental Health Coordinating Council Inc	237,500	Mental Health Coordinating Council (MHCC) NSW Peer Workforce Training Program
Mental Health Coordinating Council Inc	94,270	Professional development training for the Alcohol and Other Drug and Mental Health Workforce
Mentoring Men Ltd	50,000	Men's Mental health and Suicide Prevention Program
Merana Aboriginal Community Association for the Hawkesbury	50,000	Men's Mental health and Suicide Prevention Program
Metro North Hospital and Health Service	9,051	Support payment for NSW Aboriginal Palliative Care Health Workers to attend the Walawaani Conference in Brisbane

Grant recipient	Amount (\$)	Description
Mindgardens Neuroscience Network Ltd	150,000	Mindgardens Functional Neurological Disorders Clinic Extension Grant
Mindgardens Neuroscience Network Ltd	1,487,511	Tertiary Referral Service for Psychosis
Miracle Babies Foundation Ltd	65,000	Funding to support Foundation's initatives
Mission Australia	622,500	Alcohol and Other Drug Hub Grant funding
Mission Australia	859,530	Alcohol and Other Drugs Continuing Care Sector Development
Mission Australia	549,875	Alcohol and Other Drugs Treatment Access Expansion Grants
Mission Australia	877,089	Alcohol and Other Drugs Youth Treatment Services
Mission Australia	57,226	Benjamin Short Grove Specialist Residential Aged Care Facility
Mission Australia	2,425,415	Community Living Support Services
Mission Australia	6,114,191	Housing and Accommodation Support Initiative
Medical Research Commercialisation Fund Pty Ltd	475,000	Medical Research Commercialisation fund
Murrumbidgee Primary Health Network	409,318	NSW universal aftercare service funding - Murrumbidgee
Murrumbidgee Primary Health Network	438,625	Urgent Care Service grant
Muslim Community Radio	33,300	Men's Mental health and Suicide Prevention Program
National Blood Authority	10,727,211	National Blood Authority Operational costs
National Indigenous Australians Agency	81,500	The National Indigenous Australians Agency's engagement of the Oolong Grant Administrator
National Stroke Foundation	180,000	Funding to support the organisation's stroke education initiatives
Neami Ltd	4,282,094	Community Living Support Services
Neami Ltd	10,102,602	Housing and Accommodation Support Initiative
Nelune Foundation	100,000	Contribution to the Foundation's initiatives supporting cancer care services in NSW public hospitals
The Network of Alcohol and other Drugs Agencies Inc	164,738	Alcohol and Other Drugs Continuing Care Sector Development
The Network of Alcohol and other Drugs Agencies Inc	5,000	Analysis of First Nations data in NADAbase
The Network of Alcohol and other Drugs Agencies Inc	25,000	Capacity building grant program in research, evaluation, and monitoring
New Horizons Enterprises Ltd	7,664,399	Community Living Support Services
New Horizons Enterprises Ltd	3,949,018	Housing and Accommodation Support Initiative Plus
New Horizons Enterprises Ltd	9,100,847	Housing and Accommodation Support Initiative
New Horizons Enterprises Ltd	3,167,071	Mental Health Community Living Supports for refugees
New Horizons Enterprises Ltd	3,074,608	Youth Aftercare Pilot
Newcastle University Rugby Union Club	10,800	Men's Mental health and Suicide Prevention Program
Northern Illawarra community Connections Inc	50,000	Support for Bulli Community Free Food Pantry Initiative
NSW Council For Intellectual Disability	98,640	End of Life and Palliative Care Grants Program
NSW Rural Doctors Network	710,800	Collaborative Care Funding
<u></u>	· <u>·</u>	

Grant recipient	Amount (\$)	Description
NSW Rural Doctors Network	215,520	National Rural Generalist Pathways Program
NSW Rural Doctors Network	200,000	Regional Psychiatry Services to support Central West NSW Mental Health and Wellbeing Program
NSW Rural Doctors Network	1,829,000	The expansion of the Rural Resident Medical Officer Cadetship program
NSW Users and Aids Association Inc	529,000	Core Alcohol and Other Drugs funding
NSW Users and Aids Association Inc	6,000	Development of the Alcohol and Other Drugs Care Charter Implementation Guide
NSW Users and Aids Association Inc	175,320	Hepatitis C activities
NSW Users and Aids Association Inc	250,000	Lived and Living Experience Grant Funding
NSW Users and Aids Association Inc	122,000	Overdose Prevention Grant Funding
NSW Users and Aids Association Inc	66,991	Peer Based Harm Reduction Services for NSW drug checking trial
NSW Users and AIDS Association Inc	487,625	Peer Based Harm Reduction Services for NSW Music Festivals Grant
Obesity Australia Pty Ltd	85,000	Contribution to the work of obesity collective in improving engagement and address weight stigma
Odyssey House NSW	158,250	Alcohol and other drug residential rehabilitation for people with children, regardless of gender
Odyssey House NSW	1,981,624	Community Drug Action Program in NSW
Odyssey House NSW	371,671	Drug and Alcohol Treatment Services Grant
Odyssey House NSW	463,000	Family Recovery Centre Grant
Odyssey House NSW	518,750	Post Custodial Support Grant
Open Minds Australia Ltd	2,022,906	Community Living Support Services
Open Minds Australia Ltd	1,452,963	Housing and Accommodation Support Initiative
Orana Haven	277,323	Building on Aboriginal Communities' Resilience initiative
Orange Aboriginal Medical Service	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Orange Aboriginal Medical Service	1,037,087	Alcohol and Other Drugs funding
Orange Aboriginal Medical Service	277,323	Building on Aboriginal Communities' Resilience initiative
Orange Aboriginal Medical Service	200,000	Central West Mental Health Wellbeing program
Orange Aboriginal Medical Service	20,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
Orange Aboriginal Medical Service	500,000	Funding for Head to Health Kids Hubs for Aboriginal Community Controlled Health Organisation in NSW
Orange Push for Palliative Inc	26,927	Contribution to support palliative care patients and their families
Orygen Research Centre	400,000	Pilot Program for Moderated Online Social Therapy
Palliative Care NSW Inc	200,000	End of Life and Palliative Care Grants Program
Palliative Care NSW Inc	220,000	Enhanced service level to support palliative care consumers and system in NSW
Palliative Care NSW Inc	300,000	Palliative Care Volunteer Services Support Program
Path 2 Change Ltd	100,000	Mental Health contribution to Pathway Wheels Program
Pharmaceutical Society of Australia Ltd	141,601	Opioid Treatment Program: Community Pharmacy Professional Support Package
Pius X Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative

Grant recipient	Amount (\$)	Description
Port Macquarie Neighbourhood Centre Inc	50,000	Men's Mental health and Suicide Prevention Program
Ray Kelly Fitness Pty Ltd	85,000	Contribution to support the leadership in Diabetes Care Training program
Red Frogs Australia	5,000	Peer Based Harm Reduction Services at Music Festivals
Resolve SBB Trust	1,758,957	Social Benefit Bond
Respite Care for QBN Inc	25,000	Support people suffering from chronic illness
RichmondPRA Limited	2,895,063	Community Living Support Services
RichmondPRA Limited	3,791,670	Housing and Accommodation Support Initiative Plus
RichmondPRA Limited	12,186,788	Housing and Accommodation Support Initiative
RichmondPRA Limited	3,100,000	National Disability Insurance Scheme mental health officers' program
Riverina Medical and Dental Aboriginal Corporation	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Riverina Medical and Dental Aboriginal Corporation	75,000	Contribution to support family, carer and friends of people using alcohol or other drugs
Riverina Medical and Dental Aboriginal Corporation	311,250	Post Custodial Support Grant
Rotary Club of Dubbo Macquarie Inc	10,665	Men's Mental health and Suicide Prevention Program
Rotary Club Of Warners Bay Inc	50,000	Contribution to support Men's Health Education Rural Van
Royal Aust College Of General Practitioners	152,019	General Practice Education and Training package and provide GP representation
Royal Far West	570,000	Contribution to support the Paediatric Development Program
Royal Hospital For Women Foundation	50,000	Financial assistance to support the Foundation's fundraising activities
Royal Society for the Welfare of Mothers and Babies	2,574,285	Tresillian Funding for five regional family care centres
Royal Society for the Welfare of Mothers and Babies	5,891,430	Tresillian Funding for seven family care centres, four residential beds Macksville and five Tresillian2U vans
Royal Society for the Welfare of Mothers and Babies	1,317,981	Tresillian Virtual Residential Parenting Service
Samaritans Foundation Diocese of Newcastle	400,563	Drug and Alcohol Treatment Services Grant
Samaritans Foundation Diocese of Newcastle	5,508	Men's Mental health and Suicide Prevention Program
Sane Australia	50,000	Men's Mental health and Suicide Prevention Program
Schizophrenia Fellowship of NSW Ltd	207,110	One Door Forensic Reintegration Program
Service NSW	12,861,386	Pre IVF Testing Rebate
Shared Reading NSW Inc	40,800	Men's Mental health and Suicide Prevention Program
Shedway Ltd	50,000	Men's Mental health and Suicide Prevention Program
Shoalhaven Suicide Prevention and Awareness Network Inc	20,000	Men's Mental health and Suicide Prevention Program
Sydney North Health Network Ltd	409,318	NSW universal aftercare service funding - Sydney North

Grant recipient	Amount (\$)	Description
Social Futures Ltd	1,037,500	Alcohol and Other Drug Hub Grant funding
Sonder Youth Ltd	25,000	One off contribution to expand the 2025 Changemakers Camp program across regional NSW
South Coast Medical Service Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
South Coast Medical Service Aboriginal Corporation	70,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
South Western Sydney Primary Health Network Ltd	1,467,000	Campbelltown Medicare Urgent Care Service
South Western Sydney Primary Health Network Ltd	1,341,125	Gregory Hills Urgent Care Service
South Western Sydney Primary Health Network Ltd	909,318	NSW universal aftercare service funding - South Western Sydney
South Western Sydney Primary Health Network Ltd	10,000	Pilot testing Sexual Health Continuing Professional Guides in General Practice
Souths Cares Pbi Ltd	49,050	Men's Mental health and Suicide Prevention Program
Spinal Cord Injuries Australia	27,120	Men's Mental health and Suicide Prevention Program
Sporting Chance Cancer Foundation Fund	100,000	Funding to support children cancer outreach program
St Vincent de Paul Society NSW	1,023,748	Alcohol and Other Drug Hub Grant funding
St Vincent de Paul Society NSW	4,137,435	Alcohol and Other Drugs Continuing Care Sector Development
St Vincent de Paul Society NSW	93,259	Drug and Alcohol Treatment Services Grant
State Library of New South Wales	182,760	Drug Info at Your Library grant
Stolen Generations Council (NSW-ACT) Inc	100,000	Funding Enhancement to improve Stolen Generation Survivors' health and wellbeing
Stolen Generations Council (NSW-ACT) Inc	195,000	Stolen Generations Council funding for coordinator position
Street Side Medics Limited	200,000	Funding to support the organisation's objectives
Stride Mental Health Ltd	2,024,253	LikeMind funding to provide integrated care and support in community
Suicide Prevention Australia Ltd	45,161	Targeted activities for NSW Suicide Prevention Legislation
Survivors and Mates Support Network Limited	1,095,000	To deliver the Healing and Recovery for Survivors and Supporters project
Survivor's R Us Inc	98,000	Equipment and fit out enhancements to support the organisation delivery of mental health initiatives
Sydney Childrens Hospitals Foundation Ltd	75,000	Funding to support the Sydney Children's Hospital Network
Talk2meBro Inc	250,000	Funding to support the organisation's provision of mental health programs to the community
Talk2meBro Inc	50,000	Men's Mental health and Suicide Prevention Program
Tamworth Aboriginal Medical Service - Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Tamworth Aboriginal Medical Service - Aboriginal Corporation	75,000	Contribution to support family, carer and friends of people using alcohol or other drugs

Grant recipient	Amount (\$)	Description
Technical and Further Education Commission	428,400	Alcohol and Other Drugs Skillset Training Grant
Temora Business Enterprise Group	50,000	Men's Mental health and Suicide Prevention Program
Tharawal Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Tharawal Aboriginal Corporation	40,000	Funding for Dental Services and Equipment Upgrades in Aboriginal Community Controlled Health Organisations
The Association of Independent Schools of NSW Ltd	26,460	Support The Optimisation Of Live Life Well In Schools
The Bill Crews Charitable Trust	722,500	Alcohol and other drugs funding: ICE Response
The Bill Crews Charitable Trust	250,000	The provision of primary healthcare for homeless and vulnerable community members in Sydney
The Buttery Ltd	487,625	Alcohol and Other Drug Hub Grant funding
The Buttery Ltd	1,746,113	Alcohol and Other Drugs Treatment Access Expansion Grants
The Buttery Ltd	58,115	Alcohol and Other Drugs Youth Treatment Services
The Buttery Ltd	498,467	Continuing Care Sector Development
The Buttery Ltd	407,657	Drug and Alcohol Treatment Services Grant
The Buttery Ltd	1,475,074	Housing and Accommodation Support Initiative Plus
The Buttery Ltd	581,000	Post Custodial Support Grant
The Gender Centre Inc	500,000	The Gender Centre funding
The Lebanese Moslem Association	150,000	Contribution to support the provision of preventative health and wellbeing initiatives
The Link Foundation AOD Ltd	250,000	Contribution to the provision of counselling and support services for families and individuals impacted by substance misuse
The Man Walk Australia Inc	100,000	Funding to support men's mental health and wellbeing
The Man Walk Australia Inc	45,500	Men's Mental health and Suicide Prevention Program
The Men's Table Ltd	50,000	Men's Mental health and Suicide Prevention Program
The Peregrine Centre Pty Ltd	1,124,586	Rural Mental Health Research Partnership Grant
The Salvation Army (NSW) Property Trust	1,037,500	Alcohol and Other Drug Hub Grant funding
The Salvation Army (NSW) Property Trust	250,058	Drug and Alcohol Treatment Services Grant
The Ted Noffs Foundation	2,640,438	Alcohol and Other Drugs Treatment Access Expansion Grants
The Ted Noffs Foundation	202,556	Alcohol and Other Drugs Youth Treatment Services
The Twenty Ten Association Inc	200,000	Safe and Supported project, a project to support the mental health of young LGBTIQA+ people in NSW
Tobwabba Aboriginal Medical Service	70,000	Contribution to support family, carer and friends of people using alcohol or other drugs
Top Blokes Foundation	50,000	Men's Mental health and Suicide Prevention Program
Ungooroo Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative
Uniting (NSW ACT)	2,902,943	Community Living Support Services
Uniting (NSW ACT)	4,057,642	Housing and Accommodation Support Initiative Plus
Uniting (NSW ACT)	3,852,796	Housing and Accommodation Support Initiative
Uniting (NSW ACT)	2,024,253	LikeMind funding to provide integrated care and support in community
University of Newcastle	20,000	End of Life and Palliative care Research Grant program

Grant recipient	Amount (\$)	Description
University of Newcastle	5,075	Support The Optimisation Of Live Life Well In Schools
University of Newcastle	200,000	The Australian Research Council Linkage Project on the Financial Sustainability of the Healthcare System in Australia
University of NSW	191,000	End of Life and Palliative Care Grants Program
University of NSW	85,077	Enhancing Behavioural Surveillance to Address Gap and Disparities in Australia's HIV Response.
University of NSW	25,000	Follow up study on HIV and STI screening practices
University of NSW	199,680	Implementation research to guide elimination of HIV transmission in NSW
University of NSW	562,849	Intellectual Disability Mental Health Chair
University of NSW	25,000	Funding to support the organisation's research into pancreatic cancer
University of NSW	268,029	Support evaluation of Collaborative Commissioning
University of Sydney	350,000	Brain Injury Psychiatry Program
University of Sydney	70,640	Building the mental health capacity of alcohol and other drug workers – The Matilda Centre
University of Sydney	40,000	Centre for Population Health - Youth Sector Training Needs grant
University of Sydney	102,377	Chair Medical Physics variation
University of Sydney	100,000	Evaluation of the Central West NSW Mental Health and Welling Program
University of Sydney	352,649	Funding for Chair of Population Oral Health
University of Sydney	15,000	Midwives and Obstetricians Helping Mothers to Quit
University of Sydney	25,638	Sexuality and sexual health education pre-service teacher mapping
University of Sydney	196,160	Supervisor support program for Dentistry student placements in the Far West Local health district
University of Sydney	50,000	The impacts of e-micromobility on physical activity
University of Sydney	140,000	Understanding The Sexual Health Needs of "Pacific Australian Labour Mobility" Scheme Workers and Providers in NSW
University of Sydney	100,000	Workforce wellbeing and utilisation of digital Social and Emotional Wellbeing tools
University of Technology Sydney	296,000	End of Life and Palliative Care Grants Program
University of Technology Sydney	21,000	Scholarship for University of Technology Sydney Graduate Program Fees
University Of Wollongong	2,140,062	Funding for Project Air
University of Wollongong	116,000	End of Life and Palliative Care Grants Program
Walgett Aboriginal Medical Service	277,323	Building on Aboriginal Communities' Resilience initiative
Walk It Off Australia Inc	47,500	Men's Mental health and Suicide Prevention Program
Waminda South Coast Women's Health and Wellbeing Aboriginal Corporation	200,000	Aboriginal Mental Health and Wellbeing Model of Care Program
Waminda South Coast Women's Health and Wellbeing Aboriginal Corporation	2,913,860	Alcohol and Other Drugs Treatment Access Expansion Grants
Waminda South Coast Women's Health and Wellbeing Aboriginal Corporation	277,323	Building on Aboriginal Communities' Resilience initiative

Grant recipient	Amount (\$)	Description
Waminda South Coast Women's Health and Wellbeing Aboriginal Corporation	200,000	End of Life and Palliative Care Grants Program
Warrawong Residents Forum Inc	30,000	Contribution to Warrawong Resident Forum to provide food services for the community
Waves of Wellness Foundation Ltd	49,000	Men's Mental health & Suicide Prevention Program
We Help Ourselves	856,827	Drug and Alcohol Treatment Services Grant
Wee Waa Local Aboriginal Land Council	50,000	Contribution to support the organisation's business study for an Aboriginal Medical Centre in the Wee Waa township
Weigelli Centre Aboriginal Corp	150,000	Central West Mental Health Wellbeing program
Wellington Aboriginal Corporation Health Service	200,000	Alcohol and Other Drugs "ICE Inquiry" prevention programs for Aboriginal young people and their families
Wellington Aboriginal Corporation Health Service	554,645	Building on Aboriginal Communities' Resilience initiative
Wellington Aboriginal Corporation Health Service	400,000	Funding for Head to Health Kids Hubs for Aboriginal Community Controlled Health Organisation in NSW
Wellington Aboriginal Corporation Health Service	285,598	Post Custodial Support Grant
Wellways Australia Ltd	3,540,869	Community Living Support Services
Wellways Australia Ltd	13,091,618	Housing and Accommodation Support Initiative
Wellways Australia Ltd	2,610,878	Youth Community Living Support Services
Wentwest Ltd	109,318	NSW universal aftercare service funding - Western Sydney
Wentwest Ltd	1,657,500	Urgent Care Service Grant - Auburn
Wentwest Ltd	768,750	Urgent Care Service Grant - Castle Hill
Wentwest Ltd	478,125	Urgent Care Service Grant – Quakers Hill
Wentworth Healthcare Limited	109,318	NSW universal aftercare service funding - Nepean Blue Mountains
Wentworth Healthcare Limited	1,020,000	Urgent Care Service Grant - North Richmond
Western Health Alliance Ltd	520,460	NSW universal aftercare service funding - Western NSW
Western Health Alliance Ltd	1,273,124	Urgent Care Service Grant - Orange
Western Sydney University	30,000	Co-design and co-evaluation of an Alcohol and Other Drug Education Program
Womens Alcohol And Drug Advisory Centre Inc	230,390	Drug and Alcohol Treatment Services Grant
Womens Health NSW Inc	100,000	Assisting Access to Abortion Care and Long acting reversible contraception
Womens Health NSW Inc	91,000	Women's Health Centre election commitment funding enhancement
Yellow Dove Australia Ltd	49,850	Men's Mental health and Suicide Prevention Program
Yoorana Gunya Family Healing Centre Aboriginal Corp	277,323	Building on Aboriginal Communities' Resilience initiative
Yoorana Gunya Family Healing Centre Aboriginal Corp	150,000	Central West Mental Health Wellbeing program
Yoorana Gunya Family Healing Centre Aboriginal Corp	500,000	Funding for Head to Health Kids Hubs for Aboriginal Community Controlled Health Organisation in NSW

Grant recipient	Amount (\$)	Description
Yoorana Gunya Family Healing Centre Aboriginal Corp	200,000	Mental Health and Wellbeing program.
Yourtown	4,223,000	Kids helpline service.
Total	328,924,646	

# Research grants in 2024-25

Grant recipient	Amount (\$)	Description
The Sax Institute	1,800,000	Sax Institute Core Funding.
University of Newcastle	406,250	NSW Prevention Research Support Program – Priority Research Centre for Health Behaviour
University of NSW	412,500	NSW Prevention Research Support Program – National Drug and Alcohol Research Centre
University of NSW	333,750	NSW Prevention Research Support Program – Kirby Institute
University of NSW	300,000	NSW Prevention Research Support Program – Centre for Primary Health Care and Equity
University of Sydney	93,750	NSW Prevention Research Support Program – Women and Babies Research
University of Sydney	406,250	NSW Prevention Research Support Program – Prevention Research Collaboration
University of Sydney	125,000	NSW Prevention Research Support Program – Edith Collins Centre
University of Wollongong	303,750	NSW Prevention Research Support Program – Early Start
University of NSW	150,000	Alcohol and Other Drugs Linked Analyses Grant
University of Sydney	100,000	Clinical Audit of Public Antenatal Medical Records Grant
University of NSW	130,816	BUBs Quit study
University of Newcastle	1,679,685	Community pharmacy trial - participation support
University of Newcastle	570,000	Clinical trial – pharmacist management of urinary tract infections
University of NSW	80,000	Integrating mathematical modelling and public health surveillance – partner contribution
University of Melbourne	60,000	Grant to explore further development of the Safe & TogetherTM Model to provide culturally safe responses to addressing family violence in Aboriginal communities
The Australian and New Zealand Intensive Care Society	431,501	Bi-national intensive care databases
Australian Cardiovascular Alliance Ltd	165,000	Cardiovascular and stroke research investments on health outcomes
Association of Australian Medical Research Institutes Ltd	2,000,000	Collaborative research infrastructure enablement pilot grant
Black Dog Institute	835,432	Medical Research Support Program
Centenary Institute of Cancer Medicine & Cell Biology	1,235,813	Medical Research Support Program
Children's Cancer Institute	982,478	Medical Research Support Program
Children's Medical Research Institute	1,143,196	Medical Research Support Program
Garvan Institute of Medical Research	11,099,234	Medical Research Support Program
Hunter Medical Research Institute	7,846,311	Medical Research Support Program
Ingham Institute for Applied Medical Research	3,459,907	Medical Research Support Program
Neuroscience Research Australia The George Institute for Global	2,803,580 6,158,908	Medical Research Support Program  Medical Research Support Program
Health The Heart Research Institute Ltd		
The Westmead Institute Ltd	851,810	Medical Research Support Program
Medical Research Victor Chang Cardiac Research	3,063,152	Medical Research Support Program  Medical Research Support Program
Institute Ltd		

Grant recipient	Amount (\$)	Description
Woolcock Institute of Medical Research Ltd	1,531,438	Medical Research Support Program
Biotalk Pty Ltd	240,625	Sustainable operating model for the special enterprise Franklin Women
University of Newcastle	498,928	Schizophrenia Research Grants Program
University of NSW	746,872	Schizophrenia Research Grants Program
Ingham Institute for Applied Medical Research	499,940	NSW Translational Research Grants Scheme
University of Newcastle	461,682	NSW Translational Research Grants Scheme
Western Sydney University	499,619	NSW Translational Research Grants Scheme
Garvan Institute of Medical Research	500,000	Early Mid-Career Grants funding
Lifehouse Australia Trust	499,979	Early Mid-Career Grants funding
Macquarie University	500,000	Early Mid-Career Grants funding
Melanoma Institute Australia	495,392	Early Mid-Career Grants funding
University of Sydney	497,000	Early Mid-Career Grants funding
University of Sydney	498,335	Early Mid-Career Grants funding
Canberra Health Services	695,017	Rural, Regional and Remote Clinical trial support units
National Heart Foundation of Australia	250,000	NSW Cardiovascular Research Network
University of Newcastle	450,000	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of Newcastle	449,000	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of NSW	2,539,106	Cardiovascular Disease Senior and Early Mid-Career Grant Funding
University of NSW	444,828	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of Sydney	3,137,028	Cardiovascular Disease Senior and Early Mid-Career Grant Funding
University of Sydney	449,623	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of Sydney	498,800	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of Technology Sydney	750,000	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
University of Technology Sydney	449,417	NSW Cardiovascular Research Capacity Program – Senior and Early Mid-career Research Grant
Victor Chang Cardiac Research Institute Ltd	1,400,000	Cardiovascular Disease Precision Medicine for Public Health
Total	69,675,811	

# Financial statements

This section of the report presents the Auditor's report and financial statements of the NSW Ministry of Health.

The financial statements for all NSW Health entities can be found in volumes two and three of the NSW Health 2024-25 Annual Report on the NSW Health Website at health.nsw.gov.au/AnnualReport.



### INDEPENDENT AUDITOR'S REPORT

### Ministry of Health

To Members of the New South Wales Parliament

### **Opinion**

I have audited the accompanying financial statements of the Ministry of Health and the consolidated entity (Ministry of Health) which comprise the Statement by the Accountable Authority, the Statement of Comprehensive Income for the year ended 30 June 2025, the Statement of Financial Position as at 30 June 2025, the Statement of Cash Flows for the year then ended, andnotes to the financial statements, including a Statement of Material Accounting Policies and other explanatory information of the Ministry of Health. The consolidated entity comprises the Ministry of Health and the entities it controlled at the year's end or from time to time during the financial year.

In my opinion, the financial statements:

- have been prepared in accordance with Australian Accounting Standards and the applicable financial reporting requirements of the *Government Sector Finance Act 2018* (GSF Act), the Government Sector Finance Regulation 2024 (GSF Regulation) and the Treasurer's Directions
- presents fairly the financial position, financial performance and cash flows of the Ministry of Health.

My opinion should be read in conjunction with the rest of this report.

### **Basis for Opinion**

I conducted my audit in accordance with Australian Auditing Standards. My responsibilities under the standards are described in the 'Auditor's Responsibilities for the Audit of the Financial Statements' section of my report.

I am independent of the Ministry of Health in accordance with the requirements of the:

- Australian Auditing Standards
- Accounting Professional and Ethical Standards Board's APES 110 'Code of Ethics for Professional Accountants (including Independence Standards)' (APES 110).

Parliament promotes independence by ensuring the Auditor-General and the Audit Office of New South Wales are not compromised in their roles by:

- providing that only Parliament, and not the executive government, can remove an Auditor-General
- mandating the Auditor-General as auditor of public sector agencies
- precluding the Auditor-General from providing non-audit services.

I have fulfilled my other ethical responsibilities in accordance with APES 110.

I believe the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

### **Key Audit Matters**

Australian Auditing Standard ASA 701 'Communicating Key Audit Matters in the Independent Auditor's Report' applies to the audit of the general purpose financial statements of listed entities or when an auditor is required by legislation to communicate key audit matters in the auditor's report. There is no legislative requirement to communicate key audit matters in my independent audit report on the Ministry of Health. I have voluntarily included a narrative on Key Audit Matters to enhance the readability of my audit opinion.

Key audit matters are those matters that, in my professional judgement, were of most significance in my audit of the financial statements of the Ministry of Health for the year ended 30 June 2025. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon. I do not provide a separate opinion on these matters.

### **Key Audit Matter**

### How my audit addressed the matter

### Valuation of property, plant and equipment

Refer to Note 23 Property, plant and equipment
At 30 June 2025, the Ministry of Health reported
\$32.6 billion in infrastructure, property, plant and
equipment measured at fair value and comprised
of:

- \$30 billion land and buildings
- \$1.7 billion plant and equipment
- \$0.9 billion infrastructure.

I considered this area a key audit matter due to the:

- financial significance, geographical distribution and specialised or unique nature of health assets;
- high degree of management judgement required in respect of classifying project costs as capital or expense; and
- complexities associated with the application of AASB 13 Fair Value Measurement being dependent on assumptions that require significant judgement in areas such as:
  - identifying components of buildings and determining their current replacement cost
  - forecasting remaining useful lives
  - assessing the conditions of the assets
  - assessing the financial impact of indicators of impairment.
- 2024–25 amendments to AASB 13 for NFP public sector entities (AASB 2022-10), which required a management impact assessment on valuation assumptions, increasing audit focus
- the scale and risk profile of Capital Work in Progress (WIP), including ageing and cancelled projects, readiness for capitalisation and cut-off, and the basis for allocating overheads to projects.

To address the key audit matter, we:

- assessed the adequacy of management's review of the valuation process;
- assessed the competence, capabilities and objectivity of management's valuers;
- reviewed the scope and instructions provided to the valuers and obtained an understanding of the methodology used and its appropriateness with reference to relevant Australian Accounting Standards and Treasurer's Directions;
- assessed the appropriateness of the components of buildings used for measuring gross replacement cost with reference to common industry practice;
- performed targeted procedures for WIP, including:
  - sample testing of invoices and approvals, and ensured appropriate capitalisation of costs;
  - reviewed reasonability of overhead allocations capitalised:
  - performed WIP ageing analytics to identify outliers (delays, impairment indicators, cancellations);
- evaluated whether the useful lives applied to the various asset classes were consistent with management's planned usage of those assets;
- assessed assumptions used by the valuer to determine the asset values;
- assessed the reasonableness and appropriateness of judgement used by management to assess non-financial assets for impairment. This included the process employed to monitor impairment indicators;
- evaluated management's implementation of the amendments to AASB 13 (AASB 2022-10) by reviewing the impact assessment and supporting position papers, assessing key valuation judgements for compliance with AASB 13;
- assessed the adequacy of the financial statement disclosures against the requirements of applicable Australian Accounting Standards and Treasurer's Directions.

### Recognition and measurement of Commonwealth grants and contributions revenue

Refer to Note 10 Grants and other contributions

Of the \$9.9 billion recognised as grants and other contributions revenue during the year, over \$8.9 billion related to the funding arrangements through the National Health Reform Agreement (NHRA) in 2024–25.

I considered this area a key audit matter due to the:

- significance of the balance relative to the Ministry of Health's Statement of Comprehensive Income;
- different types of performance obligations attached to each revenue stream;
- Ministry of Health's complex IT system (EDWARD) for capturing various activities occurred at all NSW Health entities for activity-based funding (ABF) streams.

To address the key audit matter, we:

- documented and understood the nature of the key revenue streams relating to the NHRA and other grants;
- reviewed the terms and conditions contained within the key funding agreements entered with the grantors;
- assessed the IT general controls of the new EDWARD system and the accounting treatments applied to each type of grant funding stream;
- understood and assessed the implications resulting from expiration of any agreement; and
- reviewed a sample of transactions to ensure the appropriate accounting treatment had been applied.

### Other Information

The Ministry of Health's annual report for the year ended 30 June 2025 includes other information in addition to the financial statements and my Independent Auditor's Report thereon. The Secretary of the Ministry of Health is responsible for the other information. At the date of this Independent Auditor's Report, the other information I have received comprise the climate-related financial disclosures included in the Sustainability Chapter of Ministry of Health's annual report.

My opinion on the financial statements does not cover the other information. Accordingly, I do not express any form of assurance conclusion on the other information.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work I have performed, I conclude there is a material misstatement of the other information, I must report that fact.

I have nothing to report in this regard.

### Secretary's Responsibilities for the Financial Statements

The Secretary is responsible for the preparation and fair presentation of the financial statements in accordance with Australian Accounting Standards and the GSF Act, GSF Regulation and Treasurer's Directions. The Secretary's responsibility also includes such internal control as the Secretary determines is necessary to enable the preparation and fair presentation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Secretary is responsible for assessing the ability of the Ministry of Health and the consolidated entity to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting.

### Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to:

- obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error
- issue an Independent Auditor's Report including my opinion.

Reasonable assurance is a high level of assurance but does not guarantee an audit conducted in accordance with Australian Auditing Standards will always detect material misstatements. Misstatements can arise from fraud or error. Misstatements are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions users take based on the financial statements.

A description of my responsibilities for the audit of the financial statements is located at the Auditing and Assurance Standards Board website at: <a href="https://www.auasb.gov.au/media/5fkcysek/ar5-2024.pdf">www.auasb.gov.au/media/5fkcysek/ar5-2024.pdf</a>. The description forms part of my auditor's report.

The scope of my audit does not include, nor provide assurance:

- that the Ministry of Health carried out its activities effectively, efficiently and economically
- about the assumptions used in formulating the budget figures disclosed in the financial statements
- about the security and controls over the electronic publication of the audited financial statements on any website where they may be presented
- about any other information which may have been hyperlinked to/from the financial statements.

Bola Oyetunji

Auditor-General for New South Wales

29 September 2025 SYDNEY

# **Statement by the Accountable Authority**





We state, pursuant to section 7.6(4) of the Government Sector Finance Act 2018 ('GSF Act'):

- 1. The financial statements of the Ministry of Health for the year ended 30 June 2025 have been prepared in accordance with:
  - a. Australian Accounting Standards (AAS) (which include Australian Accounting Interpretations);
  - b. applicable requirements of the GSF Act, the Government Sector Finance Regulation 2024; and
  - c. Treasurer's Directions issued under the GSF Act.
- 2. The financial statements present fairly the Ministry of Health's financial position as at 30 June 2025 and the financial performance and cash flows for the year then ended.

Susan Pearce AM

Secretary, NSW Health

26 September 2025

Adjunct Professor Alfa D'Amato

Deputy Secretary, Financial and Corporate Services and Chief Financial Officer, NSW Health

26 September 2025

# Statement of Comprehensive Income for the year ended 30 June 2025

	Consolidated Actual 2025	Consolidated Budget 2025	Consolidated Actual 2024	Parent Actual 2025	Parent Actual 2024
Notes		\$000	\$000	\$000	\$000
Continuin a constitue					
Continuing operations  Expenses excluding losses					
Employee related expenses 2	19,851,794	19,485,465	18,901,233	340,898	282,330
Operating expenses 3	9,047,365	8,795,240	8,858,313	1,423,176	1,490,349
Depreciation and amortisation 4	1,577,540	1,547,631	1,477,854	11,706	11,420
Grants and subsidies 5	1,879,123	1,923,916	1,842,193	27,284,986	25,981,175
Finance costs 6	136,714	120,837	126,514	7	17
Total expenses excluding losses	32,492,536	31,873,089	31,206,107	29,060,773	27,765,291
5	, , , , , , , , , , , , , , , , , , , ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, , , , ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, , .
Revenue					
Appropriations 7	19,859,008	20,367,312	19,138,955	19,859,008	19,138,955
Acceptance by the Crown <sup>1</sup> of					
employee benefits and other					
liabilities 11	513,641	516,469	589,971	10,141	10,681
Sale of goods and services from					
contracts with customers 8	3,316,451	3,093,350	2,999,160	199,407	143,559
Investment revenue 9	115,374	92,579	113,634	20,858	18,606
Grants and other contributions 10	9,879,351	9,732,896	9,342,292	9,405,345	8,717,139
Other income 12	97,747	65,614	100,861	20,393	19,918
Total revenue	33,781,572	33,868,220	32,284,873	29,515,152	28,048,858
Operating result	1,289,036	1,995,131	1,078,766	454,379	283,567
Gains / (losses) on disposal 13	(17,611)	-	(11,747)	(17)	(5)
Impairment losses on financial assets 18	(111,613)	-	(84,680)	(1,420)	120
Other gains / (losses) 14	(25,816)	(35,740)	(92,122)	(6,246)	(47)
Net result from continuing operations	1,133,996	1,959,391	890,217	446,696	283,635
Net result from discontinued operations	-	-		-	-
Net result	1,133,996	1,959,391	890,217	446,696	283,635
Other comprehensive income					
Items that will not be reclassified to					
net result in subsequent periods					
Changes in revaluation surplus of	4 404 070		1 100 101	40.000	F 070
property, plant and equipment 23	1,181,078	-	1,190,421	43,690	5,673
Total other comprehensive income	1,181,078	1 050 001	1,190,421	43,690	5,673
TOTAL COMPREHENSIVE INCOME	2,315,074	1,959,391	2,080,638	490,386	289,308

 $<sup>^{1}\</sup>mbox{Crown}$  represents 'The Crown in right of the State of New South Wales'.

The accompanying notes form part of these financial statements.

# Statement of Financial Position as at 30 June 2025

		Consolidated Actual	Consolidated Budget	Consolidated Actual	Parent Actual	Parent Actual
		2025	2025	2024	2025	2024
100570	Notes	\$000	\$000	\$000	\$000	\$000
ASSETS						
Current assets	17	0.100.750	2.415.002	0.701.000	1.070.000	C00 FC1
Cash and cash equivalents	17	3,139,759	2,415,063	2,781,203	1,070,802	683,561
Receivables	18	1,419,461	1,179,151	1,267,496	283,292	318,899
Contract assets	19	7,843	2,260	2,677	6,301	636
Inventories	20	291,594	326,923	325,036	97,144	38,808
Financial assets at fair value	21	74,601	73,909	68,521	-	-
Other financial assets	22	389	-	<del>-</del>	184,620	281,133
		4,933,647	3,997,306	4,444,933	1,642,159	1,323,037
Non-current assets held for sale		-	304	304	-	<u>-</u>
Total current assets		4,933,647	3,997,610	4,445,237	1,642,159	1,323,037
Non-current assets						
Receivables	18	137,635	23,959	120,924	6,700	5,903
Financial assets at fair value	21	5,686	11,505	6,351	-	-
Other financial assets	22	97,252	93,056	90,771	-	-
Property, plant and equipment						
- Land and buildings	23	29,958,255	30,220,869	27,945,803	199,838	165,945
- Plant and equipment	23	1,679,207	1,793,626	1,620,131	15,919	17,155
- Infrastructure systems	23	912,348	862,752	851,435	1,104	853
Total property, plant and equipment		32,549,810	32,877,247	30,417,369	216,861	183,953
Right-of-use assets	24	707,473	669,387	738,947	120	639
Intangible assets	25	1,074,587	1,201,222	985,749	15,180	9,749
Total non-current assets		34,572,443	34,876,376	32,360,111	238,861	200,244
Total assets		39,506,090	38,873,986	36,805,348	1,881,020	1,523,281
LIABILITIES						
Current liabilities						
Payables	28	2,473,167	2,017,187	2,084,717	549,146	685,275
Contract liabilities	29	39,311	57,031	36,785	33	647
Borrowings	30	197,320	199,873	186,875	70	171
Provisions	31	3,632,133	3,232,583	3,469,465	77,346	102,774
Other current liabilities	32	50,584	111,893	102,755	25,276	187
Total current liabilities		6,392,515	5,618,567	5,880,597	651,871	789,054
Non-current liabilities						
Payables	28	72,185	74,801	106,396	-	-
Contract liabilities	29	83	556	198	-	-
Borrowings	30	1,497,733	1,443,579	1,560,822	50	485
Provisions	31	79,021	55,959	77,776	7,742	6,836
Other non-current liabilities	32	300,693	290,215	310,512	2,814	2,766
Total non-current liabilities		1,949,715	1,865,110	2,055,704	10,606	10,087
Total liabilities		8,342,230	7,483,677	7,936,301	662,477	799,141
Net assets		31,163,860	31,390,309	28,869,047	1,218,543	724,140

# Statement of Financial Position as at 30 June 2025 (continued)

	Consolidated	Consolidated	Consolidated	Parent	Parent
	Actual	Budget	Actual	Actual	Actual
	2025	2025	2024	2025	2024
Notes	\$000	\$000	\$000	\$000	\$000
EQUITY					
Reserves	13,439,633	12,818,902	12,256,774	205,159	161,469
Accumulated funds	17,724,227	18,571,407	16,612,273	1,013,384	562,671
Total equity	31,163,860	31,390,309	28,869,047	1,218,543	724,140

The accompanying notes form part of these financial statements.

# Statement of Changes in Equity for the year ended 30 June 2025

		Accumulated	Asset Revaluation	
CONSOLIDATED	Notes	Funds \$000	Surplus \$000	Total \$000
Balance at 1 July 2024	140163	16,612,273	12,256,774	28,869,047
Net result for the year	_	1,133,996	-	1,133,996
Other comprehensive income:	-	1,100,000		1,100,000
Net changes in revaluation surplus of property, plant and				
equipment	23	_	1,181,078	1,181,078
Total comprehensive income for the year	_	1,133,996	1,181,078	2,315,074
Transfer of asset revaluation surplus to accumulated funds on	-	1,100,000	1,101,070	2,010,071
disposal of assets		(1,781)	1,781	_
Transactions with owners in their capacity as owners		(1,701)	1,701	
Increase / (decrease) in net assets from equity transfers	33	(20,261)	_	(20,261)
Balance at 30 June 2025	-	17,724,227	13,439,633	31,163,860
	-	15,704,871	11,083,538	26,788,409
Balance at 1 July 2023  Net result for the year	_	890,217	11,003,336	890,217
-	_	030,217		090,217
Other comprehensive income:				
Net changes in revaluation surplus of property, plant and	23		1,190,421	1,190,421
equipment		890,217	1,190,421	2,080,638
Total comprehensive income for the year	_	690,217	1,190,421	2,060,036
Transfer of asset revaluation surplus to accumulated funds on		17 10 5	(17.105)	
disposal of assets	_	17,185 <b>16,612,273</b>	(17,185) <b>12,256,774</b>	28,869,047
Balance at 30 June 2024	_	10,012,273	12,256,774	28,869,047
			Asset	
		Accumulated	Revaluation	
		Funds	Surplus	Total
PARENT	Notes	\$000	\$000	\$000
Balance at 1 July 2024	_	562,671	161,469	724,140
Net result for the year	_	446,696	-	446,696
Other comprehensive Income				
Net changes in revaluation surplus of property, plant and				
equipment	23	-	43,690	43,690
Total other comprehensive income	_	-	43,690	43,690
Total comprehensive income for the year	_	446,696	43,690	490,386
Transactions with owners in their capacity as owners				
Increase / (decrease) in net assets from equity transfers	33	4,017	-	4,017
Balance at 30 June 2025	_	1,013,384	205,159	1,218,543
Balance at 1 July 2023	_	279,036	155,796	434,832
Net result for the year		283,635	-	283,635
Other comprehensive income	_			
Net changes in revaluation surplus of property, plant and				
equipment	23	<u>-</u>	5,673	5,673
Total comprehensive income for the year	_	283,635	5,673	289,308
Balance at 30 June 2024	_	562,671	161,469	724,140

The accompanying notes form part of these financial statements.

# Statement of Cash Flows for the year ended 30 June 2025

Notes	Actual 2025	Consolidated Budget 2025	Actual 2024	Parent Actual 2025	Parent Actual 2024
CASH FLOWS FROM OPERATING	\$000	\$000	\$000	\$000	\$000
ACTIVITIES					
Payments					
Employee related	(19,389,063)	(18,981,069)	(18,377,656)	(345,861)	(277,899)
Suppliers for goods and services	(9,580,670)	(10,279,593)	(9,625,010)	(1,510,787)	(1,659,334)
Grants and subsidies	(2,076,404)	(1,923,916)	(1,970,728)	(27,275,724)	(25,854,643)
Finance costs	(136,713)	(120,837)	(126,514)	(7)	(17)
Total payments	(31,182,850)	(31,305,415)	(30,099,908)	(29,132,379)	(27,791,893)
Receipts					
Appropriations	19,859,008	20,367,312	19,138,955	19,859,008	19,138,955
Reimbursements from the Crown <sup>1</sup>	320,115	-	288,001	8,333	7,241
Sale of goods and services	3,188,389	3,068,662	2,869,576	62,469	103,037
Interest received	106,008	86,064	102,322	20,867	18,490
Grants and other contributions	9,672,598	9,732,896	9,201,205	9,190,905	8,583,824
Other	1,165,602	1,565,674	1,203,285	284,575	275,898
Total receipts	34,311,720	34,820,608	32,803,344	29,426,157	28,127,445
NET CASH FLOWS FROM			_		_
OPERATING ACTIVITIES 39	3,128,870	3,515,193	2,703,436	293,778	335,552
CASH FLOWS FROM INVESTING ACTIVITIES					
Proceeds from sale of property, plant					
and equipment and intangibles	6,507	15,000	5,333	4,017	_
Proceeds from sale of financial assets	-	-	36,581	-	-
Purchases of property, plant and			·		
equipment and intangibles	(2,583,950)	(2,862,896)	(2,247,417)	(7,026)	(3,727)
Other	49	(282,212)	47	96,513	(74,580)
NET CASH FLOWS FROM					
INVESTING ACTIVITIES	(2,577,394)	(3,130,108)	(2,205,456)	93,504	(78,307)

Statement of Cash Flows for the year ended 30 June 2025 (continued)

	Consolidated	Consolidated	Consolidated	Parent	Parent
	Actual	Budget	Actual	Actual	Actual
	2025	2025	2024	2025	2024
Notes	\$000	\$000	\$000	\$000	\$000
CASH FLOWS FROM FINANCING					
ACTIVITIES					
Repayment of borrowings and advances	(36,042)	(205,621)	(30,307)	-	-
Payment of principal portion of					
service concession financial liability	(1,655)	-	(1,557)	-	-
Payment of principal portion of lease					
liabilities	(160,400)	-	(163,440)	(41)	(170)
Proceeds / (payment) of derivatives	4,729	-	3,041	-	-
NET CASH FLOWS FROM					
FINANCING ACTIVITIES	(193,368)	(205,621)	(192,263)	(41)	(170)
NET INCREASE //DECREASE) IN					
NET INCREASE / (DECREASE) IN	250 100	170 464	205 717	207 241	257.075
CASH AND CASH EQUIVALENTS	358,108	179,464	305,717	387,241	257,075
Opening cash and cash equivalents	2,781,203	2,235,599	2,475,288	683,561	426,486
Effects of exchange rate changes on					
cash and cash equivalents	448	-	198	-	-
CLOSING CASH AND CASH					
EQUIVALENTS 17	3,139,759	2,415,063	2,781,203	1,070,802	683,561

<sup>&</sup>lt;sup>1</sup>Crown represents 'The Crown in right of the State of New South Wales'.

The accompanying notes form part of these financial statements.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 1. Statement of material accounting policy information

## (a) Reporting entity

The Ministry of Health (the Ministry or Parent) is a NSW government entity and is controlled by the State of New South Wales, which is the immediate and ultimate parent. The Ministry is a not-for-profit entity (as profit is not its principal objective) and it has no cash generating units. The Ministry and its controlled entities are consolidated as part of the NSW Total State Sector Accounts.

The Ministry and its controlled entities are collectively referred to as the consolidated entity.

The Ministry controls the Local Health Districts established from 1 January 2011, as well as other controlled entities constituted under the *Health Services Act 1997* which include:

- Agency for Clinical Innovation
- Albury Base Hospital
- Albury Wodonga Health Employment Division
- Bureau of Health Information
- Cancer Institute NSW
- Central Coast Local Health District
- Clinical Excellence Commission
- Far West Local Health District
- Graythwaite Charitable Trust (per Supreme Court order)
- Health Administration Corporation
- Health Education and Training Institute
- Hunter New England Local Health District
- Illawarra Shoalhaven Local Health District

- Justice Health and Forensic Mental Health Network
- Mid North Coast Local Health District
- Murrumbidgee Local Health District
- Nepean Blue Mountains Local Health District
- Northern NSW Local Health District
- Northern Sydney Local Health District
- South Eastern Sydney Local Health District
- South Western Sydney Local Health District
- Southern NSW Local Health District
- Sydney Local Health District
- The Sydney Children's Hospitals Network
- Western NSW Local Health District
- Western Sydney Local Health District

The Health Administration Corporation includes the operations of:

- Ambulance Service of NSW
- eHealth NSW
- Health Infrastructure
- Single Digital Patient Record Implementation Authority
- Health System Support Group
- HealthShare NSW
- NSW Health Pathology

The consolidated financial statements also include results for the parent entity thereby capturing the central administrative function of the Ministry.

These consolidated financial statements for the year ended 30 June 2025 have been authorised for issue by the Secretary, NSW Health on the date the accompanying statement was signed.

#### (b) Principles of consolidation

The consolidated financial statements comprise the financial statements of the parent entity and its controlled entities, after elimination of all inter-entity transactions and balances. The controlled entities are consolidated from the date the parent entity obtained control and until such time as control passes.

The financial statements of the controlled entities are prepared for the same reporting period as the parent entity using uniform accounting policies for like transactions and other events in similar circumstances. As a result, no adjustments were required for any dissimilar accounting policies.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 1. Statement of material accounting policy information (continued)

#### (c) Basis of preparation

The consolidated financial statements are general purpose financial statements which have been prepared on an accruals basis and in accordance with:

- applicable Australian Accounting Standards (AAS) (which include Australian Accounting Interpretations);
- the requirements of the Government Sector Finance Act 2018 ('GSF Act'), the Government Sector Finance Regulation 2024; and
- Treasurer's Directions issued under the GSF Act.

Property, plant and equipment, assets held for sale and certain financial assets and liabilities are measured using the fair value basis. Other financial statement items are prepared in accordance with the historical cost convention except where specified otherwise.

Judgements, key assumptions, and estimations management has made are disclosed in the relevant notes to the consolidated financial statements.

The consolidated financial statements have been prepared on a going concern basis, which assumes the consolidated entity will be able to meet its obligations as and when they fall due.

All amounts are rounded to the nearest one thousand dollars (unless otherwise stated) and are expressed in Australian currency, which is the consolidated and the parent entity's presentation and functional currency.

#### (d) Statement of Compliance

The consolidated financial statements and notes comply with Australian Accounting Standards which include Australian Accounting Interpretations.

## (e) Comparative information

Except when an Australian Accounting Standard permits or requires otherwise, comparative information is presented in respect of the previous period for all amounts reported in the financial statements.

Certain comparative information has been reclassified and/or restated to ensure consistency with current year presentation and classification. These include:

- Note 26 Fair value measurement of non-financial assets: The fair value hierarchy disclosure has been updated in the
  current year to include leasehold improvements, work in progress and newly completed assets which are carried at
  cost, for better alignment with property, plant and equipment note. Prior year comparatives have accordingly been
  updated.
- Note 27 Restricted assets: The restricted asset balances, which previously reported the opening and closing equity balances, have now been revised to present the opening and closing balances of restricted cash and cash equivalents, along with restricted TCorpIM fund investments, for each category of restricted financial assets.
- Note 35 Trust funds: The trust fund balances, which previously reported the opening and closing equity balances, have now been revised to present the opening and closing balances of trust fund cash and cash equivalents for each category of trust funds.
- Note 41 Financial instruments: The market risk sensitivity analysis, which demonstrates the sensitivity to a reasonably
  possible change in interest rates, has been revised to exclude assets and liabilities not exposed to interest rate risks.
   Prior year comparatives have accordingly been updated.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 1. Statement of material accounting policy information (continued)

## (f) Changes in accounting policy, including new or revised Australian Accounting Standards

#### (i) Effective for the first time in FY2024-25

The following new Australian Accounting Standard has been applied for the first time in 2024-25:

 AASB 2022-10 Amendments to Australian Accounting Standards - Fair Value Measurements of Non-Financial Assets of Not-for-Profit Public Sector Entities (AASB 2022-10)

The nature and effect of the changes as a result of adoption of this amendment is described below.

AASB 2022-10 amends AASB 13 Fair Value Measurement to add authoritative implementation guidance and related illustrative examples for fair value measurement of non-financial assets of not-for-profit public sector entities not held primarily for their ability to generate net cash inflows. The guidance specifies that the entity is required to consider whether the asset's highest and best use differs from its current use, clarifies the 'financial feasible' criteria, specifies that an entity uses its own assumptions as a starting point for unobservable inputs and provides guidance on how the cost approach is to be applied to measure the assets fair value.

The consolidated entity has reviewed its accounting policies with reference to the guidance and concluded that the impact of applying this amendment did not materially affect the financial statements.

Several other amendments and interpretations apply for the first time in 2024-25, the impact of which is not material to the consolidated financial statements.

As a result, the accounting policies applied in 2024-25 are consistent with those of the previous financial year.

## (ii) Issued but not yet effective

NSW public sector entities are not permitted to early adopt new Australian Accounting Standards, unless NSW Treasury determines otherwise.

The following new AAS has not been applied and is not yet effective:

• AASB 18 Presentation and Disclosure in Financial Statements (AASB 18)

AASB 18 aims to improve how entities communicate in their financial statements, with a particular focus on information about financial performance in the statement of profit or loss. AASB 18 will replace AASB 101 Presentation of Financial Statements.

The key presentation and disclosure requirements established by AASB 18 are:

- the presentation of newly defined subtotals in the statement of profit or loss;
- the disclosure of management-defined performance measures; and
- enhanced requirements for grouping information (i.e. aggregation and disaggregation).

For not-for-profit public sector entities, AASB 18 applies to annual reporting periods beginning on or after 1 January 2028.

The impact of AASB 18 is yet to be determined by the consolidated entity.

There are other standards and amendments issued but not yet effective, the impacts of which are not anticipated to be material.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 2. Employee related expenses

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Salaries and wages*	16,993,122	16,201,303	237,904	220,797
Superannuation - defined benefit plan	40,968	40,405	406	514
Superannuation - defined contribution plan	1,861,167	1,678,773	21,629	18,160
Long service leave	459,598	608,930	10,803	11,458
Redundancies	21,575	9,936	644	850
Workers' compensation insurance	457,540	344,882	53,232	14,783
Payroll tax and fringe benefits tax	17,824	17,004	16,280	15,768
	19,851,794	18,901,233	340,898	282,330

<sup>\*</sup> Salaries and wages includes annual leave, accrued days off (ADO) and parental leave.

Refer to Note 31 for further details on recognition and measurement of employee related expenses.

Employee related costs of \$116.57 million (2024: \$49.99 million) (parent entity: \$4.58 million (2024: \$Nil)) have been capitalised in property, plant and equipment and intangible assets and are excluded from the above amounts.

In 2024, junior medical officers (JMO) litigation was settled for \$229.80 million, of which \$190.89 million was recognised under employee related expense (Note 2) and \$38.91 million recognised under general expenses (Note 3) in the consolidated entity.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 3. Operating expenses

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Agency expenses	87,320	142,661	210	564
Aircraft expenses	152,018	144,924	-	-
Auditor's remuneration	5,975	5,739	1,269	1,099
Blood and blood products	203,257	219,780	50,285	53,401
Capital project expense	27,001	71,311	5,356	-
Consultants	3,347	5,204	1,352	1,648
Contractors	110,054	184,999	6,897	9,194
Cost of sales	7,854	2,414	-	-
Disability equipment support services	14,635	9,543	-	-
Domestic supplies and services	197,534	188,414	1,347	795
Electricity, gas and water	240,819	220,192	1,211	936
Expenses relating to short-term leases	51,984	47,719	16	13
Expenses relating to leases of low-value assets	21,309	21,152	874	924
Food supplies	139,680	140,728	-	-
Information management expenses	527,172	477,336	37,470	42,572
Insurance	540,868	530,148	484,473	478,924
Interstate patient outflows	461,596	365,032	461,596	365,032
Isolated patient travel accommodation assistance	55,051	49,302	-	-
Legal services	25,011	20,780	8,823	7,076
Maintenance (see (a) below)	770,370	666,989	14,409	5,978
Medical and surgical supplies (including prostheses)	1,137,511	1,082,012	6,874	8,380
Motor vehicle expenses	66,515	64,674	160	237
Occupancy agreement expenses - Property and				
Development NSW	55,660	49,847	23,417	22,642
Office expenses	92,837	96,778	2,548	2,886
Outsourced patient services	460,583	571,023	6,843	4,251
Patient transport costs	65,402	56,000	103	123
Pharmaceutical supplies	1,034,890	1,060,016	222,575	163,503
Professional services (excluding consultants)	53,803	79,965	17,545	18,059
Specialised health services	649,964	594,741	41,883	39,124
Staff related costs	92,140	75,740	2,539	1,505
Travel expenses	140,704	146,975	1,544	1,866
Visiting medical officers	1,317,343	1,194,677	-	-
Warehousing expenses	22,942	23,965	-	-
Works performed for entities controlled by the				
ultimate parent	45,237	9,476	-	-
General expenses	168,979	238,057	21,557	259,617
	9,047,365	8,858,313	1,423,176	1,490,349

The majority of the costs in relation to food supplies, medical and surgical supplies and pharmaceutical supplies relate to the consumption of inventory held by the consolidated entity.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 3. Operating expenses (continued)

General expenses of \$168.98 million (2024: \$238.06 million) for the consolidated entity relates to advertising, marketing, courier, freight, taxes, rates and related charges, security services and other miscellaneous expenses.

In 2024, general expenses of \$259.62 million for the parent entity included \$229.80 million for JMO litigation settlement expense.

#### (a) Reconciliation of total maintenance expense

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Corrective maintenance	229,986	172,073	2,292	2,188
Planned maintenance	331,713	296,139	2,152	1,891
New / replacement equipment not capitalised	197,721	198,178	2,322	1,857
Other	10,950	599	7,643	42
Maintenance expense - contracted labour and	770,370	666,989	14,409	5,978
other (non-employee related), as above				
Employee related maintenance expense*	69,330	65,897	-	-
Total maintenance expenses	839,700	732,886	14,409	5,978

<sup>\*</sup> This balance consists of employees who have been classified as providing maintenance services for the consolidated entity and the expense is included in employee related expenses in Note 2.

# 4. Depreciation and amortisation

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Depreciation - buildings	963,281	883,909	9,409	9,414
Depreciation - plant and equipment	292,311	272,030	1,211	1,247
Depreciation - infrastructure systems	41,013	38,595	137	123
Depreciation - right-of-use land and buildings	68,019	74,286	-	133
Depreciation - right-of-use plant and equipment	103,434	96,787	63	45
Amortisation - intangible assets	109,482	112,247	886	458
	1,577,540	1,477,854	11,706	11,420

Refer to Note 23 Property, plant and equipment, Note 24 Leases and Note 25 Intangible assets for recognition and measurement policies on depreciation and amortisation.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 5. Grants and subsidies

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Payments to entities controlled by the Ministry	-	-	26,002,413	24,722,659
Payments to Affiliated Health Organisations	912,059	860,026	536,316	501,307
Payments to other public health services not				
controlled by the Ministry	161,721	141,149	161,721	141,149
Grants provided to support:				
- Community packages	51,148	51,385	1,701	731
- Grants to research organisations	89,335	104,491	66,127	76,489
- Non-Government organisations	210,014	206,568	104,506	100,610
Grants to entities controlled by the ultimate parent	65,949	60,907	62,773	58,594
Other grants	388,897	417,667	349,429	379,636
	1,879,123	1,842,193	27,284,986	25,981,175

Other grants consist of various grants provided to external organisations to support health related objectives and activities. It also includes \$166.79 million (2024: \$169.95 million) towards various mental health programs which includes \$96.89 million (2024: \$93.30 million) towards the Mental Health Housing and Accommodation Support Initiative (HASI) and Community Living Supports (CLS) program in the consolidated and parent entity.

#### **Recognition and Measurement**

Grants and subsidies generally comprise contributions in cash or in kind to controlled entities of the Ministry (from the parent entity), affiliated health organisations, various local government authorities and not-for-profit community organisations to support their health-related objectives and activities. Expenses are recognised on an accruals basis when the reporting entity has a present obligation under a contract to make the payment or upon the transfer of the cash or assets. The transferred assets are measured at their fair value.

#### 6. Finance costs

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Interest expense from lease liabilities	31,121	22,856	7	17
Interest expense from financial liabilities at				
amortised cost	105,569	103,610	-	-
Other interest and charges	24	48	-	_
	136,714	126,514	7	17

# **Recognition and Measurement**

Finance costs consist of interest and other costs incurred in connection with the borrowing of funds. Finance costs are recognised as expenses in the period in which they are incurred, in accordance with NSW Treasury's mandate to not-for-profit NSW General Government Sector entities.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 7. Appropriations and transfers to The Crown in right of the State of New South Wales (Crown)

#### Summary of compliance at a lead minister level

	2025 \$000	2024 \$000
Original budget per Appropriation Act	20,367,312	19,612,662
Other appropriations / expenditure:		
Variations made to appropriations during the financial year		
- Section 4.9 GSF Act (transfer of functions between GSF agencies)	-	4,500
- Section 4.11 GSF Act (variations of annual appropriations for Commonwealth		
grants)	15,078	4,229
- Special appropriations (per Section 39 (1)(b) of the Appropriations Act)	3,382	-
Total spending authority from parliamentary appropriations, other than deemed		
appropriations	20,385,772	19,621,391
Add:		
The spending authority from deemed appropriations during the year	14,461,999	13,709,915
The unutilised spending authority from deemed appropriations in prior years	2,781,242	2,470,125
Total	37,629,013	35,801,431
Less: total expenditure out of the Consolidated Fund	(33,962,443)	(32,537,753)
Variance	3,666,570	3,263,678
Less:		
The spending authority from appropriations lapsed at 30 June	(526,764)	(482,436)
Deemed appropriations balance carried forward to following years	3,139,806	2,781,242
	2025	2024
	\$000	\$000
Appropriations (per Statement of Comprehensive Income)	19,859,008	19,138,955
Total amount drawn down against Annual Appropriations:	19,859,008	19,138,955

The Appropriation Act 2024 (Appropriations Act) (and the subsequent variations, if applicable) appropriates the sum of \$20,367.31 million to the Minister for Health out of the Consolidated Fund for the services of the Ministry of Health for the year 2025. The spending authority of the Minister from the Appropriations Act has been delegated or subdelegated to officers of the Ministry of Health and entities that it is administratively responsible for, listed in Note 1 to the financial statements, with separate instruments of delegation issued to portfolio agencies Mental Health Commission of New South Wales and Health Care Complaints Commission.

The lead Minister for each entity above, being the Minister for Health, is taken to have been given an appropriation out of the Consolidated Fund under the authority of section 4.7 of the GSF Act, at the time the entity receives or recovers any deemed appropriation money, for an amount equivalent to the money that is received or recovered by the entity. These deemed appropriations are taken to have been given for the services of the Ministry of Health.

In addition, government money that a GSF agency receives or recovers, from another GSF agency, of a kind prescribed by the GSF regulations that forms part of the Consolidated Fund, is also deemed appropriation moneys where the receiving agency has a different lead Minister to the agency making the payment, or one or both of the agencies is a special office (as defined in section 4.7(8)).

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 7. Appropriations and transfers to The Crown in right of the State of New South Wales (Crown) (continued)

## Summary of compliance at a lead minister level (continued)

The delegation / sub-delegations for 2025 and 2024, authorising officers to spend Consolidated Fund money, impose limits to the amounts of individual transactions, but do not specify an aggregate expenditure limit for the respective entities. However, as it relates to expenditure in reliance on a sum appropriated through an annual Appropriations Act, the delegation / sub-delegations are referrable to the overall authority to spend set out in the relevant Appropriations Act. The individual transaction limits have been properly observed. The information in relation to the limit from the Appropriations Act is disclosed in the summary of compliance table above.

The summary of compliance has been prepared on the basis of aggregating the spending authorities of both the Minister for Health for the services of the Ministry of Health and the lead Ministers for the services of the entities listed above that receives or recovers deemed appropriation money. It reflects the status at the point in time this disclosure statement is being made.

#### **Recognition and Measurement**

Parliamentary appropriations other than deemed appropriations

Income from appropriations, other than deemed appropriations (of which the accounting treatment is based on the underlying transaction), does not contain enforceable and sufficiently specific performance obligations as defined by AASB 15 *Revenue from Contracts with Customers* (AASB 15). Therefore, appropriations (other than deemed appropriations) are recognised as income when the entity obtains control over the asset comprising the appropriations. Control over appropriations is normally obtained upon the receipt of cash.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 8. Sale of goods and services from contracts with customers

· ·	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Sale of goods				
Sale of inventories	7,854	2,414	-	-
Sales and recoveries of pharmaceutical supplies	389,380	443,980	-	-
Sales of prostheses	63,714	63,592	-	-
Other	31,499	31,512	1,464	<u>-</u>
	492,447	541,498	1,464	-
Rendering of services				
Patients				
Fees for clinical services	74,449	66,670	-	-
Fees for medical services rendered	1,320,955	1,199,446	10,343	9,891
Interstate patient inflows	152,998	101,939	152,998	101,939
Motor accident third party insurance covered	222,903	192,029	-	-
Patient transport fees	90,724	84,341	-	-
Other patient fees	101,264	91,172	-	-
General Community				
Car parking fees	86,894	51,691	28	6
Commercial activities	55,213	50,478	-	-
Fees for non-medical services	4,570	4,169	-	-
Non-NSW Health entities				
Services provided to non NSW Health organisations	42,334	40,713	-	-
Entities controlled by the ultimate parent				
Fees for capital works performed	45,237	9,476	-	-
Other				
Fees for private usage of hospital's facilities	9,555	9,489	-	-
Infrastructure fees - monthly facility charge	366,041	338,258	-	-
Infrastructure fees - annual charge	119,290	95,459	-	-
General user charges fees	55,213	53,686	227	1,051
Personnel service fees recharged	33,447	30,619	33,447	30,619
Other services	42,917	38,027	900	53
	2,824,004	2,457,662	197,943	143,559
	3,316,451	2,999,160	199,407	143,559

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 8. Sale of goods and services from contracts with customers (continued) Recognition and Measurement

# Sales of goods

Revenue from sale of goods is recognised when the consolidated entity satisfies the performance obligation by transferring the promised goods.

Type of good	Nature of timing of satisfaction of performance obligations, including significant payment terms	Revenue recognition policies
Sales of inventories and sale and recoveries of pharmaceutical supplies	The performance obligation of transferring inventories and pharmaceutical products is typically satisfied at the point in time when the products are dispensed to customers, which denotes acceptance by the customer, and therefore deemed as the point in time when the control is transferred to the customer. The payments are typically due within 30 days after the invoice date.	Revenue from these sales is recognised based on the price specified on the invoice, and revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. No element of financing is deemed present as the sales are made with a short credit term. No volume discount or warranty is provided on the sale.
Sales of prostheses	Relates to revenue generated for surgically implanted prostheses and medical devices. The performance obligation of transferring these products is typically satisfied at the point in time when the products are implanted in the body of the patient, which denotes acceptance by the customer, and therefore deemed as the point in time when the control is transferred to the customer. The payments are typically due within 30 days after the invoice date.	Revenue from these sales is recognised based on the price specified on the invoice, and revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. No element of financing is deemed present as the sales are made with a short credit term. No volume discount or warranty is provided on the sale.
Other	Relates to sale of various products including the sale of low value medical equipment, schedule 3 medical equipment, sale of publications, old wares and refuse and other general goods. The performance obligation of transferring these products is typically satisfied at the point in time when the products are purchased by the customer and takes delivery, which denotes acceptance by the customer, and therefore deemed as the point in time when the control is transferred to the customer. The payments are typically due within 30 days after the invoice date.	Revenue from these sales is recognised based on the price specified on the invoice, and revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. No element of financing is deemed present as the sales are made with a short credit term. No volume discount or warranty is provided on the sale.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 8. Sale of goods and services from contracts with customers (continued) Recognition and Measurement (continued)

#### Rendering of services

Revenue from rendering of services is recognised when the consolidated entity satisfies the performance obligation by transferring the promised services.

# Nature of timing of satisfaction of performance obligations, including significant payment terms

#### Type of service

# Patient services Patient transport fees, clinical and medical services, interstate patient flows and motor accident third party insurance

The performance obligations in relation to patient services are typically satisfied as the health services are delivered to the chargeable inpatients and non-inpatients. Public patients are not charged for health services provided at public hospitals. Chargeable patients, including Medicare ineligible patients, privately insured patients, eligible veterans and compensable patients are billed for health services provided under various contractual arrangements. Billings are typically performed upon patient discharge and are based on the rates specified by the Ministry of Health. The payments are typically due within 30 days

Non-patient services provided to the General community, non-NSW Health entities and entities controlled by the ultimate parent Various non-patient related services are provided to the general community, non-NSW health entities and entities controlled by the ultimate parent. The performance obligations for these services are typically satisfied by transferring the promised services to its respective customers. The payments are typically due within 30 days after the invoice date.

after the invoice date.

## Revenue recognition policies

Revenue is recognised on an accrual basis when the service has been provided to the patient. In limited circumstances the price is not fully recovered, e.g. due to inadequate insurance policies, overseas patients returning to their home country before paying, etc. The likelihood of occurrences is considered on a case by case basis. In most instances revenue is initially recognised at full amounts and subsequently adjusted when more information is provided. No element of financing is deemed present as majority of the services are made with a short credit term.

Revenue is recognised when promised services are delivered. No element of financing is deemed present as the services are made with a short credit term.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 8. Sale of goods and services from contracts with customers (continued) Recognition and Measurement (continued)

Rendering of services (continued)

	Nature of timing of satisfaction of					
	performance obligations, including					
Type of service	significant payment terms	Revenue recognition policies				
Fees for private usage	Specialist doctors with rights of private	Revenue is recognised when promised				
of hospital's facilities	practice are subject to an infrastructure	services are delivered. No element of				
	charge, including service charges where	financing is deemed present as the				
	applicable for the use of hospital facilities at	services are made with a short credit				
	rates determined by the Ministry of Health. The	term.				
	performance obligations for these services are					
	typically satisfied when the hospital facilities					
	are made available and used by the doctors					
	and staff specialists. The payments are					
	typically due when monies are collected from					
	patient billings for services provided under the					
	arrangement.					
Other	Various other services are provided for general	Revenue is recognised when promised				
	user charges, personnel services recharged	services are delivered. No element of				
	and other small services. The performance	financing is deemed present as the				
	obligations for these services are satisfied by	services are made with a short credit				
	transferring the promised services to its	term.				
	respective customers. Prices are determined					
	by the Ministry of Health and billed once					
	services have been provided. The payments are					
	typically due within 30 days after the invoice					
	date.					

Refer to Note 29 for the disclosure of the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period, and when the consolidated entity expects to recognise the unsatisfied portion as revenue.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 9. Investment revenue

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Interest income from financial assets at amortised		_		_
cost	105,938	103,123	20,858	18,606
Finance income on the net investment in the lease	2,304	2,230	-	-
Net gain / (loss) from TCorpIM Funds measured at fair				
value through profit or loss	6,940	7,856	-	-
Royalties	66	25	-	-
Dividends	11	171	-	-
Other	115	229	-	<u>-</u>
	115,374	113,634	20,858	18,606

# **Recognition and Measurement**

# Net gain / (loss) from TCorpIM Funds measured at fair value through profit or loss

Net gain / (loss) from TCorpIM Funds measured at fair value through profit or loss includes distributions received as well as movements in the fair value.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 10. Grants and other contributions

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Grants to acquire / construct a recognisable non-				
financial asset to be controlled by the entity				
Grants to acquire / construct non-financial asset	34,614	25,203	413	47
Grants with sufficiently specific performance				
obligations				
Commonwealth National Health Reform Funding	7,576,324	7,106,916	7,576,324	7,106,916
Commonwealth National Partnership Agreement				
for Priority Groups COVID-19 Testing and				
Vaccination				
- PCR testing payment	-	40,111	-	40,111
- Vaccination dose delivery payment	-	58	-	58
Commonwealth Government grants for community				
based services	87,505	82,822	-	-
Commonwealth Government grants - other	67,604	41,281	42,176	7,937
Clinical drug trials and research grants	109,849	89,543	-	-
Grants from entities controlled by the ultimate				
parent	8,829	10,428	697	-
Other grants	93,117	93,436	-	1,407
Grants without specific performance obligations				
Commonwealth National Health Reform Funding	1,320,300	1,232,659	1,320,300	1,232,659
Commonwealth Government COVID-19 vaccines	1,201	2,104	-	-
Commonwealth Government grants - other	252,442	289,743	247,327	215,185
Clinical drug trials and research grants	19,205	15,126	-	-
Grants from entities controlled by the ultimate				
parent	174,699	153,026	173,845	101,629
Other grants	52,219	78,554	44,263	11,190
Donations				
Donations	81,443	81,282	-	
	9,879,351	9,342,292	9,405,345	8,717,139

Commonwealth National Health Reform Funding revenue includes adjustments from the reconciliation of the prior year activity performed by the National Health Funding Pool Administrator as required under Section 238(1)(a) of the *National Health Reform Act 2011.* The adjustments include an increase of \$3.9 million (2024: decrease of \$6.5 million) revenue recognised under the 'Commonwealth National Health Funding Reform Funding'.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 10. Grants and other contributions (continued) Recognition and Measurement

Income from grants to acquire / construct a recognisable non-financial asset to be controlled by the consolidated entity is recognised when the consolidated entity satisfies its obligations under the transfer. The consolidated entity satisfies the performance obligation under the transfer over time as the non-financial assets are being constructed. The percentage of cost incurred is used to recognise income, because this most closely reflects the progress to completion.

Revenue from grants with sufficiently specific performance obligations are recognised when the consolidated entity satisfies a performance obligation by transferring the promised goods or services.

The consolidated entity typically receives grants in respect of:

- Commonwealth government funded grant under the National Health Reform Agreement to improve the state's health outcomes and ensure sustainability of the health system;
- Commonwealth government funded vaccinations, including COVID-19 vaccinations, which are provided free of charge to the community; and
- Other various grants in respect of research, clinical drug trials and other community, health and wellbeing related projects.

Since 2020, the consolidated entity has also received various COVID-19 funding from Commonwealth Government. The most recent agreement, National Partnership Agreement for Priority Groups COVID-19 Testing and Vaccination, ended on 31 December 2023.

The consolidated entity uses various methods to recognise revenue over time, depending on the nature and terms and conditions of the grant contract. The payments are typically based on an agreed timetable or on achievement of different milestones set up in the contract. Revenue is recognised as follows:

- Commonwealth National Health Reform consists of Activity Based Funding, Public Health Funding and Block Funding. Activity Based Funding is recognised under AASB 15, while Public Health and Block Funding is recognised under AASB 1058 Income of Not-for-Profit Entities (AASB 1058) due to lack of specific performance obligations. Revenue for Activity Based Funding is recognised when the hospital activities are performed. The revenue is calculated by the activity multiplied by the agreed National Weighted Activity Unit price. The Commonwealth undertakes an annual reconciliation of reported activity (revenue) against funding payments made for that year. Any differences arising from the reported activity (revenue) in previous years, is adjusted in the current year annual reconciliation.
- Commonwealth National Partnership Agreement for Priority Groups COVID-19 Testing and Vaccination (1 January 2023 to 31 December 2023) - consisted of two financial arrangements:
  - PCR Testing Payment: The Commonwealth shared the funding equally (pays for 50 per cent of costs) with the state government for costs incurred by states and territories for PCR testing for COVID-19. Revenue was recognised when the actual testing cost was incurred as a PCR testing payment.
  - Vaccination Dose Delivery Payment: The Commonwealth government provided states and territories a 50 per cent contribution to the agreed price per COVID-19 vaccine dose delivered. Revenue was recognised when the vaccine doses were delivered as a vaccination dose delivery payment.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 10. Grants and other contributions (continued) Recognition and Measurement (continued)

Other grants and contributions - consist of various types of grants and contributions received. The performance
obligations are typically satisfied when the specified activities / milestones agreed in the grant contract are
completed/met. Where there are no specific performance obligations, revenue is recognised on receipt of funding
under AASB 1058. The payments are typically made in advance or based on an agreed timetable.

Revenue from these grants is recognised based on the grant amount specified in the funding agreement / funding approval, and revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. No element of financing is deemed present as funding payments are usually received in advance or shortly after the relevant obligation is satisfied.

Refer to Note 29 for the transaction price allocated to the performance obligations that have not been satisfied at the end of the year and when it is expected to be recognised as revenue.

Income from grants without sufficiently specific performance obligations is generally recognised when the consolidated entity obtains control over the granted assets (e.g. cash).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 11. Acceptance by The Crown in right of the State of New South Wales (Crown) of employee benefits

The following liabilities and / or expenses have been assumed by the Crown:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Superannuation - defined benefit plan	40,968	40,405	406	514
Long service leave provision	472,651	549,535	9,713	10,136
Payroll tax	22	31	22	31
	513,641	589,971	10,141	10,681

#### 12. Other income

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Other income comprises the following:		_		
Commissions	1,892	1,953	-	-
Discounts	5,478	2,648	-	-
Insurance refunds	23,549	10,635	186	32
Rental income				
- rental income from subleasing right-of-use				
assets	138	27	-	-
- other rental income	45,242	41,402	14,839	12,902
Revenue related to service concession arrangements	9,646	9,903	-	-
Property not previously recognised	1,215	-	-	-
Other	10,587	34,293	5,368	6,984
	97,747	100,861	20,393	19,918

## **Recognition and Measurement**

## Insurance refunds

Insurance activities are conducted through the NSW Treasury Managed Fund (TMF) Scheme of self insurance for Government entities. Insurance refunds are recognised when TMF accepts the insurance claim.

#### Rental income

Rental income is accounted for on a straight-line basis over the lease term. The rental income is incidental to the purpose for holding the property.

# Revenue related to service concession arrangements

Revenue reflects the progressive unwinding of the 'grant of right to operate liability' (Note 32) over the remaining period of the arrangement.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 13. Gains / (losses) on disposal

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Gains / (losses) on disposal of:		_		
Property, plant and equipment				
Written down value of assets disposed	73,559	15,682	4,020	5
Less: Proceeds from disposal	(6,507)	(5,333)	(4,017)	-
Less: Proceeds received in advance for disposal*	(51,403)		-	-
Net gains / (losses) on disposal	(15,649)	(10,349)	(3)	(5)
Right-of-use assets				
Written down value of assets disposed	12,569	13,377	559	-
Less: lease liabilities extinguished	(9,111)	(14,104)	(598)	-
Less: Finance lease receivable	(4,616)	-	-	-
Net gains / (losses) on disposal	1,158	727	39	-
Intangible assets				
Written down value of assets disposed	3,120	2,125	53	-
Net gains / (losses) on disposal	(3,120)	(2,125)	(53)	-
Financial assets				
Written down value of financial assets	-	36,581	-	-
Less: Proceeds from sale of financial assets	-	36,581	-	-
Net gains / (losses) on disposal	-		-	-
Total gains / (losses) on disposal	(17,611)	(11,747)	(17)	(5)

<sup>\*</sup> Proceeds received in advance for disposal relate to upfront payments from the University of NSW in prior years for the construction of the integrated space at Prince of Wales Hospital, Randwick. In the current year, the integrated space was derecognised as a finance lease, and all upfront payments have been accounted for as proceeds from the asset disposal.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 14. Other gains / (losses)

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Inventory write down				
- Medical and surgical supplies	(10,806)	(84,987)	(4,590)	-
- Drug supplies	(15,282)	(7,101)	(1,701)	-
- Other	(1,087)	-	-	-
Gains / (losses) on derivative financial instruments at				
fair value through profit or loss	1,067	77	-	-
Foreign exchange gains / (losses)	292	55	45	(47)
Onerous contract costs	-	(166)	-	
	(25,816)	(92,122)	(6,246)	(47)

## 15. Conditions on restrictions on income of not-for-profit entities

The consolidated entity receives various types of grants and donations from different grantors / donors, some of which may not have enforceable performance obligations. The consolidated entity determines the grantor / donor expectations in determining the externally imposed restrictions and discloses them in accordance with different types of restrictions. The types of restrictions and income earned with restrictions are detailed in Note 27 Restricted assets.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 16. Disaggregated disclosure statements of the consolidated entity

CONSOLIDATED ENTITY EXPENSES	Service	area 1 *	Service	area 2 *	Service	area 3 *	Service	area 4 *	Service a	rea 5 *	Service a	area 6 *	Not Attrik	outable **	To	tal
AND INCOME	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000	\$000
Continuing operations																
Expenses excluding losses																
Employee related expenses	669,259	624,009	4,790,170	4,549,021	3,167,330	2,895,424	10,455,161	10,092,346	480,420	463,636	289,454	276,797	-	-	19,851,794	18,901,233
Operating expenses	556,609	490,861	2,059,737	1,981,882	1,179,676	1,173,446	4,981,731	4,953,270	171,358	170,155	98,254	88,699	-	-	9,047,365	8,858,313
Depreciation and amortisation	42,532	41,788	402,119	384,742	276,503	243,187	817,927	771,690	23,945	22,349	14,514	14,098	-	-	1,577,540	1,477,854
Grants and subsidies	71,019	52,961	816,223	733,312	91,004	95,012	743,419	792,998	40,059	45,037	117,399	122,873	-	-	1,879,123	1,842,193
Finance costs	2,633	2,695	34,502	35,103	27,809	20,530	66,486	62,817	3,324	3,376	1,960	1,993	-	-	136,714	126,514
Total expenses excluding losses	1,342,052	1,212,314	8,102,751	7,684,060	4,742,322	4,427,599	17,064,724	16,673,121	719,106	704,553	521,581	504,460	-	-	32,492,536	31,206,107
Revenue																
Appropriations **	-	-	-	-	-	-	-	-	-	-	-	-	19,859,008	19,138,955	19,859,008	19,138,955
Acceptance by the Crown of																
employee benefits and other liabilities	18,612	22,618	134,926	156,345	79,477	84,379	261,326	303,660	11,965	13,873	7,335	9,096	-	-	513,641	589,971
Sale of goods and services from																
contracts with customers	16,197	14,258	880,238	837,459	279,516	187,014	2,097,142	1,950,496	35,042	9,933	8,316	-	-	-	3,316,451	2,999,160
Investment revenue	3,215	3,207	27,108	27,036	11,585	10,120	69,607	69,422	3,859	3,849	-	-	-	-	115,374	113,634
Grants and other contributions	407,499	286,038	2,023,221	1,814,964	1,179,177	1,031,396	5,854,659	5,836,339	321,105	276,324	93,690	97,231	-	-	9,879,351	9,342,292
Other income	2,458	2,839	20,739	23,928	18,317	8,957	53,281	61,731	2,952	3,406	-	-	-	-	97,747	100,861
Total revenue	447,981	328,960	3,086,232	2,859,732	1,568,072	1,321,866	8,336,015	8,221,648	374,923	307,385	109,341	106,327	19,859,008	19,138,955	33,781,572	32,284,873
Gains / (losses) on disposal	-	-	-	-	-	-	-	-	-	-	-	-	(17,611)	(11,747)	(17,611)	(11,747)
Impairment losses on financial assets	-	-	-	-	-	-	-	-	-	-	-	-	(111,613)	(84,680)	(111,613)	(84,680)
Other gains / (losses)	-	-	-	-	-	-	-	-	-	-	-	-	(25,816)	(92,122)	(25,816)	(92,122)
Net result from continuing operations	(894,071)	(883,354)	(5,016,519)	(4,824,328)	(3,174,250)	(3,105,733)	(8,728,709)	(8,451,473)	(344,183)	(397,168)	(412,240)	(398,133)	19,703,968	18,950,406	1,133,996	890,217
Net result from discontinued																
operations	-	-	-	-	-	-	-	-	_	-	-	-	-	-	-	-
Net result	(894,071)	(883,354)	(5,016,519)	(4,824,328)	(3,174,250)	(3,105,733)	(8,728,709)	(8,451,473)	(344,183)	(397,168)	(412,240)	(398,133)	19,703,968	18,950,406	1,133,996	890,217
Other comprehensive income																
·																
Items that will not be reclassified to																
net result in subsequent periods Changes in revaluation surplus of																
property, plant and equipment	31,842	33,661	301,059	309,912	207,013	195,889	612,368	621,601	17,927	18,002	10,866	11,356	_	_	1,181,078	1,190,421
Total other comprehensive income	31,842	33,661	301,059	309,912	207,013	195,889	612,368	621,601	17,927	18,002	10,866	11,356		_	1,181,078	1,190,421
Total comprehensive income	(862,229)		(4,715,460)		(2,967,237)			(7,829,872)		(379,166)			19,703,968	18,950,406	2,315,074	2,080,638

<sup>\*</sup> The name and purpose of each service area is summarised in Note 16 (a).

<sup>\*\*</sup> Appropriations are made on an entity basis and not to individual service area. Consequently, appropriations are included in the 'Not Attributable' column.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 16. Disaggregated disclosure statements of the consolidated entity (continued)

CONSOLIDATED ENTITY ASSETS	Service	area 1 *	Service a	area 2 *	Service	area 3 *	Service	area 4 *	Service a	rea 5 *	Service a	area 6 *	Not Attr	ibutable	То	tal
AND LIABILITIES	2025 \$000	2024 \$000														
ASSETS																
Current assets																
Cash and cash equivalents	129,684	108,046	782,970	684,832	458,251	394,604	1,648,967	1,485,970	69,487	62,792	50,400	44,959	-	-	3,139,759	2,781,203
Receivables	6,934	6,026	376,747	353,924	119,634	79,035	897,589	824,313	14,998	4,198	3,559	-	-	-	1,419,461	1,267,496
Contract assets	38	12	2,082	748	661	167	4,959	1,741	83	9	20	-	-		7,843	2,677
Inventories	17,938	18,011	66,385	72,721	38,021	43,057	160,560	181,749	5,523	6,243	3,167	3,255	-	-	291,594	325,036
Financial assets at fair value	3,081	2,662	18,603	16,872	10,888	9,722	39,180	36,610	1,651	1,547	1,198	1,108	-	-	74,601	68,521
Other financial assets	16	-	97	-	57	-	204	-	9	-	6	-	-	-	389	-
Non-current assets held for sale	-	8	-	79	-	50	-	159	-	5	-	3	-	-	-	304
Total current assets	157,691	134,765	1,246,884	1,129,176	627,512	526,635	2,751,459	2,530,542	91,751	74,794	58,350	49,325	-	-	4,933,647	4,445,237
Non-current assets																
Receivables	673	575	36,530	33,766	11,600	7,540	87,033	78,643	1,454	400	345	-	-	-	137,635	120,924
Financial assets at fair value	235	247	1,418	1,564	830	901	2,986	3,393	126	143	91	103	-	-	5,686	6,351
Other financial assets	4,017	3,527	24,252	22,351	14,194	12,879	51,076	48,498	2,152	2,049	1,561	1,467	-	-	97,252	90,771
Property, plant and equipment																
- Land and buildings	807,727	790,205	7,636,425	7,275,365	5,250,927	4,598,601	15,532,822	14,592,436	454,728	422,610	275,626	266,586	-	-	29,958,255	27,945,803
- Plant and equipment	45,274	45,813	428,034	421,782	294,323	266,599	870,639	845,982	25,488	24,500	15,449	15,455	-	-	1,679,207	1,620,131
- Infrastructure systems	24,598	24,076	232,560	221,661	159,912	140,107	473,036	444,593	13,848	12,876	8,394	8,122	-	-	912,348	851,435
Right-of-use assets	19,075	20,895	180,336	192,376	124,002	121,597	366,812	385,855	10,739	11,175	6,509	7,049	-	-	707,473	738,947
Intangible assets	28,972	27,874	273,915	256,628	188,348	162,209	557,154	514,728	16,311	14,907	9,887	9,403	-	-	1,074,587	985,749
Total non-current assets	930,571	913,212	8,813,470	8,425,493	6,044,136	5,310,433	17,941,558	16,914,128	524,846	488,660	317,862	308,185	-	-	34,572,443	32,360,111
TOTAL ASSETS	1,088,262	1,047,977	10,060,354	9,554,669	6,671,648	5,837,068	20,693,017	19,444,670	616,597	563,454	376,212	357,510	-	-	39,506,090	36,805,348
LIABILITIES																
Current liabilities																
Payables	152,153	115,520	563,045	466,416	322,474	276,159	1,361,794	1,165,703	46,842	40,044	26,858	20,875	-	-	2,473,167	2,084,717
Contract liabilities	1,621	1,127	8,051	7,146	4,692	4,061	23,296	22,980	1,278	1,088	373	383	-	-	39,311	36,785
Borrowings	8,150	7,260	49,206	46,015	28,799	26,514	103,630	99,846	4,367	4,219	3,167	3,021	-	-	197,320	186,875
Provisions	122,449	114,542	876,421	835,007	579,502	531,477	1,912,902	1,852,527	87,899	85,104	52,959	50,808	-	-	3,632,133	3,469,465
Other current liabilities	2,090	3,992	12,614	25,302	7,383	14,579	26,566	54,901	1,119	2,320	812	1,661	-	-	50,584	102,755
Total current liabilities	286,463	242,441	1,509,337	1,379,886	942,850	852,790	3,428,188	3,195,957	141,505	132,775	84,169	76,748	-	-	6,392,515	5,880,597
Non-current liabilities																
Payables	4,441	5,896	16,434	23,804	9,412	14,094	39,747	59,493	1,367	2,044	784	1,065	-	-	72,185	106,396
Contract liabilities	3	6	17	38	10	22	49	124	3	6	1	2	-	-	83	198
Borrowings	61,864	60,637	373,494	384,330	218,596	221,453	786,593	833,932	33,147	35,239	24,042	25,231	-	-	1,497,733	1,560,822
Provisions	2,665	2,567	19,067	18,719	12,608	11,914	41,617	41,529	1,912	1,908	1,152	1,139	-	-	79,021	77,776
Other non-current liabilities	12,419	12,062	74,985	76,459	43,886	44,056	157,921	165,904	6,655	7,011	4,827	5,020	-	-	300,693	310,512
Total non-current liabilities	81,392	81,168	483,997	503,350	284,512	291,539	1,025,927	1,100,982	43,084	46,208	30,806	32,457	-	-	1,949,715	2,055,704
TOTAL LIABILITIES	367,855	323,609	1,993,334	1,883,236	1,227,362	1,144,329		4,296,939	184,589	178,983	114,975	109,205		-	8,342,230	7,936,301
NET ASSETS	720,407	724,368	8,067,020	7,671,433	5,444,286	4,692,739	16,238,902	15,147,731	432,008	384,471	261,237	248,305	-	-	31,163,860	28,869,047

<sup>\*</sup> The name and purpose of each service area is summarised in Note 16 (a).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 16. Disaggregated disclosure statements of the consolidated entity (continued)

# (a) Disaggregated disclosure name and purpose of the consolidated entity

Disaggregated information has been presented on the same basis as 2023-24.

Service area	Purpose
Service area 1 - Population health services	Population health services reflects preventive and population health and is critical to keeping people healthier. It covers a range of functions
	NSW Health is responsible for including to protect and promote public health, control infectious diseases, reduce preventive diseases and death, help people manage their own health, and promote equitable health outcomes in the community.
Service area 2 -	Community health services reflects that healthcare extends beyond the
Community health services	hospital and needs to connect across settings to reduce the burden of chronic disease, assist people with conditions to live well and avoid complications, support people to recover from illness and injury, and prevent avoidable hospitalisations. NSW Health services funded to achieve this outcome include non-admitted and community-based services, sub-acute services, hospital in the home, and dental services.
Service area 3 -	NSW Health often provides the first point of contact for those needing
Emergency services	access to emergency healthcare and is responsible for managing and administering ambulance and emergency services.
Service area 4 -	Admitted health service reflect the state's responsibility to manage and
Admitted health services	administer public hospitals. When people are admitted to a hospital in NSW, they can expect world-class medical and surgical care within clinically recommended timeframes.
Service area 5 -	Teaching and training reflects the requirement that a skilled workforce
Teaching and training	with access to world leading education and training is essential to deliver safe, reliable person-centred care driving the best outcomes and experiences.
Service area 6 -	Health and medical research reflects the requirement that clinical
Health and medical research	service delivery continues to transform through health and medical research, digital technologies, and data analytics.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 17. Cash and cash equivalents

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Cash at bank and on hand	3,139,759	2,781,203	931,805	572,108
Cash at bank - held by HealthShare NSW	-	<u>-</u>	138,997	111,453
	3,139,759	2,781,203	1,070,802	683,561

Cash at bank - held by HealthShare NSW represents the balance of cash held by HealthShare NSW in a central bank account, on behalf of the parent entity for its operating and investing activities. It is an operational bank account that earns interest on daily bank balances.

Refer to Note 41 for details regarding credit risk and market risk arising from financial instruments.

Cash and cash equivalents includes restricted cash of \$1,963.88 million (2024: \$1,883.58 million) for the consolidated entity and \$139.00 million (2024: \$111.45 million) for the parent entity. Refer to Note 27 for details of restricted assets which consists of cash and cash equivalents and TCorpIM fund investments.

HealthShare NSW, a controlled entity of the parent entity manages accounts payable and employee related payments on behalf of the parent entity for payments to suppliers and employees. HealthShare NSW makes payments after the parent has submitted correctly rendered invoices and exception based approved payroll reports are received. These payments are reported as expenditures and cash outflows in the financial statements of the parent entity.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 18. Receivables

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				
Trade receivables from contracts with customers	999,122	874,190	205,686	215,006
Receivables from controlled health entities	-	-	27,318	76,766
Goods and Services Tax	164,948	139,068	20,301	12,652
Other receivables	119,773	106,498	25,981	11,297
	1,283,843	1,119,756	279,286	315,721
Less: allowance for expected credit losses*		_		_
- Trade receivables from contracts with customers	(178,146)	(127,816)	-	-
- Other receivables	(8,294)	(4,489)	(1,888)	(468)
	1,097,403	987,451	277,398	315,253
Prepayments	322,058	280,045	5,894	3,646
Total current receivables	1,419,461	1,267,496	283,292	318,899
Non-current				
Trade receivables from contracts with customers	295	142	-	-
Other receivables	7,171	6,163	6,700	5,903
	7,466	6,305	6,700	5,903
Less: allowance for expected credit losses*				
- Trade receivables from contracts with customers	(277)	(142)	-	-
- Other receivables	(32)	(6)	-	<u> </u>
	7,157	6,157	6,700	5,903
Prepayments	130,478	114,767	-	-
Total non-current receivables	137,635	120,924	6,700	5,903

<sup>\*</sup> Movement in the allowance for expected credit losses

Trade receivables from contracts with customers and other receivables

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Balance at the beginning of the year	(132,453)	(152,536)	(468)	(595)
Amounts written off during the year	57,317	104,763	-	7
(Increase) / decrease in allowance recognised in net				
result <sup>1</sup>	(111,613)	(84,680)	(1,420)	120
Balance at the end of the year	(186,749)	(132,453)	(1,888)	(468)

<sup>&</sup>lt;sup>1</sup> Includes impairment loss recognised of \$106.85 million (2024: \$80.18 million) in the consolidated entity and \$Nil (2024: \$Nil) in the parent entity on trade receivables from contracts with customers.

Details regarding credit risk of receivables that are neither past due nor impaired, are disclosed in Note 41.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 18. Receivables (continued)

#### **Recognition and Measurement**

Receivables are initially recognised at fair value plus any directly attributable transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price.

#### Subsequent measurement

The consolidated entity holds receivables with the objective to collect the contractual cash flows and therefore measures them at amortised cost using the effective interest method, less any impairment. Changes are recognised in the net result for the year when impaired, derecognised or through the amortisation process.

#### **Impairment**

For trade receivables, the consolidated entity applies a simplified approach in calculating expected credit losses (ECLs). The consolidated entity recognises a loss allowance based on lifetime ECLs at each reporting date. The consolidated entity has established a provision matrix based on its historical credit loss experience for trade receivables, adjusted for forward looking factors specific to the receivable.

#### 19. Contract assets

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				
Contract assets	7,843	2,677	6,301	636
	7,843	2,677	6,301	636

The contract asset balance has increased in the consolidated and parent entity during the year due to the varying billing arrangements from contracts existing at different reporting dates.

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Contract receivables (included in Note 18)	999,417	874,332	233,004	291,772
	999,417	874,332	233,004	291,772

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 20. Inventories

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				_
Held-for-distribution				
Drug supplies	152,056	166,298	98,845	37,369
Medical and surgical supplies	161,427	192,114	-	1,439
Food and hotel supplies	3,171	3,072	-	-
Other	5,425	7,351	-	-
	322,079	368,835	98,845	38,808
Less: Allowance for impairment		_		
- Drug supplies	(1,701)	(6,457)	(1,701)	-
- Medical and surgical supplies	(28,784)	(37,342)	-	<u> </u>
	291,594	325,036	97,144	38,808

The majority of the inventory held-for-distribution is held for consumption in the ordinary activities of the consolidated entity and upon consumption, are expensed in food supplies, medical and surgical supplies and pharmaceutical supplies (Note 3).

#### **Recognition and Measurement**

All inventories are held for distribution (consumed in the ordinary activities of the consolidated entity). Inventories held for distribution are stated at cost, adjusted when applicable, for any loss of service potential. A loss of service potential is identified and measured based on the existence of a current replacement cost that is lower than the carrying amount or any loss of operating capacity due to obsolescence. Costs are assigned to individual items of stock mainly on the basis of weighted average costs.

In 2025, the consolidated entity wrote off \$40.49 million of inventories. Following the write-off, the allowance for impairment was reassessed and a reduction in impairment of \$13.31 million was recognised mainly due to large write-off of expired inventory items. The write-off and additional allowance for impairment expensed under other gains / (losses) (Note 14) is \$27.18 million.

The cost of inventories acquired at no cost or for nominal consideration is the current replacement cost as at the date of acquisition. Current replacement cost is the cost the consolidated entity would incur to acquire the asset. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Obsolete items are disposed of in accordance with instructions issued by the Ministry.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 21. Financial assets at fair value

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				_
Derivatives	1,587	2,447	-	-
TCorpIM Funds Investment facilities	73,014	66,074	-	
	74,601	68,521	-	-
Non-current				
Derivatives	5,686	6,351	-	-
	5,686	6,351	-	-

Refer to Note 41 for further information regarding fair value measurement, credit risk, and market risk arising from financial instruments.

#### **Recognition and Measurement**

Classification and measurement

The consolidated entity's financial assets at fair value are classified, at initial recognition, at fair value through profit or loss.

Transaction costs of financial assets carried at fair value through profit or loss are expensed in net results.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss include financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value under AASB 9 Financial Instruments (AASB 9).

Financial assets are held for trading if acquired for the purpose of selling or repurchasing in the near term. Derivatives are economic hedges classified as fair value through profit or loss unless they are designated as effective hedging instruments.

Derivative contracts are carried as financial assets when their fair value at the reporting date is positive. Derivative contracts maturing less than 12 months are classified as current and all other contracts as non-current.

The consolidated entity has elected not to apply hedge accounting to the economic hedges.

Financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. TCorpIM Funds are managed and their performance is evaluated on a fair value basis and therefore the business model is neither to hold to collect contractual cash flows or sell the financial asset. Hence these investments are mandatorily required to be measured at fair value through profit or loss.

Notwithstanding the criteria to be classified at amortised cost or at fair value through other comprehensive income, financial assets may be designated at fair value through profit or loss on initial recognition if doing so eliminates, or significantly reduces, an accounting mismatch.

A gain or loss on a financial asset that is subsequently measured at fair value through profit or loss is recognised in net results and presented net within other gains / (losses), except for TCorpIM Funds that are presented in 'investment revenue' in the period in which it arises.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 22. Other financial assets

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				_
Receivables on finance leases as lessor (Note 24)	389	-	-	-
Intra health loans receivable	-	<u>-</u>	184,620	281,133
	389	_	184,620	281,133
Non-current				
Receivables on finance leases as lessor (Note 24)	97,252	90,771	_	-
	97,252	90,771	-	-

The current intra health loans receivable balance within the parent entity includes \$184.62 million (2024: \$281.13 million) of cash advances provided to HealthShare NSW to make all payments to employees, suppliers of goods and services and grants and subsidies.

Refer to Note 41 for further information regarding fair value measurement, credit risk, and market risk arising from financial instruments.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025  $\,$ 

# 23. Property, plant and equipment (a) Total property, plant and equipment CONSOLIDATED

	Land and	Plant and Infrastructure		
	Buildings	Equipment	systems	Total
	\$000	\$000	\$000	\$000
At 1 July 2023 - fair value				
Gross carrying amount	38,802,773	3,369,330	1,539,535	43,711,638
Less: accumulated depreciation and impairment	(12,763,020)	(1,847,933)	(657,870)	(15,268,823)
Net carrying amount	26,039,753	1,521,397	881,665	28,442,815
Year ended 30 June 2024				
Net carrying amount at beginning of year	26,039,753	1,521,397	881,665	28,442,815
Additions	1,587,613	412,507	97	2,000,217
Reclassifications to intangibles	-	(2,640)	-	(2,640)
Reclassification to inventory	-	(3,228)	-	(3,228)
Disposals	(5,026)	(10,656)	-	(15,682)
Net revaluation increment less revaluation decrements	1,159,175	205	31,041	1,190,421
Depreciation expense	(883,909)	(272,030)	(38,595)	(1,194,534)
Other reclassifications within property, plant and				
equipment	48,197	(25,424)	(22,773)	-
Net carrying amount at end of year	27,945,803	1,620,131	851,435	30,417,369

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 23. Property, plant and equipment (continued)(a) Total property, plant and equipment (continued)CONSOLIDATED

	Land and	Plant and Infrastructure		
	Buildings	Equipment	systems	Total
	\$000	\$000	\$000	\$000
At 1 July 2024 - fair value				
Gross carrying amount	41,765,112	3,577,809	1,553,942	46,896,863
Less: accumulated depreciation and impairment	(13,819,309)	(1,957,678)	(702,507)	(16,479,494)
Net carrying amount	27,945,803	1,620,131	851,435	30,417,369
Year ended 30 June 2025				
Net carrying amount at beginning of year	27,945,803	1,620,131	851,435	30,417,369
Additions	1,983,234	357,307	1,122	2,341,663
Reclassifications to intangibles	-	(235)	-	(235)
Reclassification from right-of-use assets	56	-	-	56
Reclassification from assets held for sale	304	-	-	304
Disposals	(67,549)	(6,010)	-	(73,559)
Equity transfers out <sup>(i)</sup>	(15,947)	(4,314)	-	(20,261)
Net revaluation increment less revaluation decrements	1,148,353	-	32,725	1,181,078
Depreciation expense	(963,281)	(292,311)	(41,013)	(1,296,605)
Other reclassifications within property, plant and				
equipment	(72,718)	4,639	68,079	-
Net carrying amount at end of year	29,958,255	1,679,207	912,348	32,549,810
At 30 June 2025 - fair value				
	45.040.005	0.700.040	4.070.004	E0 4E0 0E0
Gross carrying amount	45,012,205	3,768,043	1,676,604	50,456,852
Less: accumulated depreciation and impairment	(15,053,950)	(2,088,836)	(764,256)	(17,907,042)
Net carrying amount	29,958,255	1,679,207	912,348	32,549,810

<sup>(</sup>i) Further details regarding equity transfers are disclosed in Note 33(a).

The net carrying amount of service concession assets included in each class of property, plant and equipment as at 30 June 2025:

- land and buildings \$718.59 million (2024: \$804.72 million)
- plant and equipment \$10.22 million (2024: \$16.18 million)
- infrastructure systems \$25.69 million (2024: \$26.34 million)

During the current period, the net carrying amount of \$94.47 million (2024: \$55.49 million) for service concession assets of the consolidated entity has been reclassified to normal property, plant and equipment.

Further details regarding fair value measurement of property, plant and equipment are disclosed in Note 26(b).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

# (b) Property, plant and equipment held and used by the consolidated entity $\label{eq:consolidated} \textbf{CONSOLIDATED}$

	Land and	Plant and Infrastructure		
	Buildings	Equipment	systems	Total
	\$000	\$000	\$000	\$000
At 1 July 2023 - fair value				
Gross carrying amount	38,413,521	3,369,330	1,538,973	43,321,824
Less: accumulated depreciation and impairment	(12,578,968)	(1,847,933)	(657,540)	(15,084,441)
Net carrying amount	25,834,553	1,521,397	881,433	28,237,383
Year ended 30 June 2024				
Net carrying amount at beginning of year	25,834,553	1,521,397	881,433	28,237,383
Additions	1,586,863	412,507	97	1,999,467
Reclassifications to intangibles	-	(2,640)	-	(2,640)
Reclassification from inventory	-	(3,228)	-	(3,228)
Disposals	(2,714)	(10,656)	-	(13,370)
Net revaluation increment less revaluation decrements	1,147,330	205	31,030	1,178,565
Depreciation expense	(873,876)	(272,030)	(38,582)	(1,184,488)
Other reclassifications within property, plant and				
equipment	51,429	(25,424)	(22,773)	3,232
Net carrying amount at end of year	27,743,585	1,620,131	851,205	30,214,921

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

(b) Property, plant and equipment held and used by the consolidated entity (continued) CONSOLIDATED

	Land and	Plant and Infrastructure		
	Buildings	Equipment .	systems	Total
	\$000	\$000	\$000	\$000
At 1 July 2024 - fair value				
Gross carrying amount	41,376,763	3,577,809	1,553,352	46,507,924
Less: accumulated depreciation and impairment	(13,633,178)	(1,957,678)	(702,147)	(16,293,003)
Net carrying amount	27,743,585	1,620,131	851,205	30,214,921
v				
Year ended 30 June 2025	07740505	1 000 101	054.005	00.014.001
Net carrying amount at beginning of year	27,743,585	1,620,131	851,205	30,214,921
Additions	1,974,951	357,307	1,122	2,333,380
Reclassifications to intangibles	-	(235)	-	(235)
Reclassification from right-of-use assets	56	-	-	56
Reclassification to assets held for sale	304	-	-	304
Disposals	(67,500)	(6,010)	-	(73,510)
Equity transfers out <sup>(i)</sup>	(15,947)	(4,314)	-	(20,261)
Net revaluation increment less revaluation decrements	1,106,213	-	32,716	1,138,929
Depreciation expense	(945,746)	(292,311)	(40,998)	(1,279,055)
Other reclassifications within property, plant and				
equipment	(75,299)	4,639	68,079	(2,581)
Net carrying amount at end of year	29,720,617	1,679,207	912,124	32,311,948
A+ 00 long 0005 follows				
At 30 June 2025 - fair value	44 500 700	0.700.040	4 075 000	40.070.001
Gross carrying amount	44,529,798	3,768,043	1,675,990	49,973,831
Less: accumulated depreciation and impairment	(14,809,181)	(2,088,836)	(763,866)	(17,661,883)
Net carrying amount	29,720,617	1,679,207	912,124	32,311,948

<sup>(</sup>i) Further details regarding equity transfers are disclosed in Note 33(a).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025  $\,$ 

## 23. Property, plant and equipment (continued)

(c) Property, plant and equipment where the consolidated entity is the lessor under operating leases  ${\bf CONSOLIDATED}$ 

	Land and	Plant and In	frastructure	
	Buildings	Equipment	systems	Total
A.4.1. 0000 ( ; )	\$000	\$000	\$000	\$000
At 1 July 2023 - fair value	222.252		500	000.014
Gross carrying amount	389,252	-	562	389,814
Less: accumulated depreciation and impairment	(184,052)	-	(330)	(184,382)
Net carrying amount	205,200	-	232	205,432
Year ended 30 June 2024				
Net carrying amount at beginning of year	205,200	-	232	205,432
Additions	750	-	-	750
Disposals	(2,312)	-	-	(2,312)
Net revaluation increment less revaluation decrements	11,845	-	11	11,856
Depreciation expense	(10,033)	-	(13)	(10,046)
Other reclassifications within property, plant and				
equipment	(3,232)	-	-	(3,232)
Net carrying amount at end of year	202,218	-	230	202,448
Add hely 2024 fair value				
At 1 July 2024 - fair value	200 240		590	388,939
Gross carrying amount	388,349 (186,131)	<del>-</del>	(360)	
Less: accumulated depreciation and impairment		<del>-</del>		(186,491)
Net carrying amount	202,218	-	230	202,448
Year ended 30 June 2025				
Net carrying amount at beginning of year	202,218	-	230	202,448
Additions	8,283	-	-	8,283
Disposals	(49)	-	-	(49)
Net revaluation increment less revaluation decrements	42,140	-	9	42,149
Depreciation expense	(17,535)	-	(15)	(17,550)
Other reclassifications within property, plant and				
equipment	2,581	-	-	2,581
Net carrying amount at end of year	237,638	-	224	237,862
At 30 June 2025 - fair value				
Gross carrying amount	482,407		614	483,021
Less: accumulated depreciation and impairment	(244,769)	_	(390)	(245,159)
Net carrying amount	237,638		224	237,862
Hot our ying amount	201,000	_	<i>LL</i> =	201,002

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 23. Property, plant and equipment (continued) (a) Total property, plant and equipment PARENT

	Land and	Plant and In	frastructure	
	Buildings \$000	Equipment \$000	systems \$000	Total \$000
At 1 July 2023 - fair value				
Gross carrying amount	347,575	23,184	4,901	375,660
Less: accumulated depreciation and impairment	(178,184)	(5,043)	(3,960)	(187,187)
Net carrying amount	169,391	18,141	941	188,473
Year ended 30 June 2024				
Net carrying amount at beginning of year	169,391	18,141	941	188,473
Additions	330	262	-	592
Disposals	-	(5)	-	(5)
Transfers from NSW Health entities	-	4	-	4
Net revaluation increment less revaluation decrements	5,638	-	35	5,673
Depreciation expense	(9,414)	(1,247)	(123)	(10,784)
Net carrying amount at end of year	165,945	17,155	853	183,953
At 1 July 2024 - fair value				
Gross carrying amount	361,589	22,494	5,107	389,190
Less: accumulated depreciation and impairment	(195,644)	(5,339)	(4,254)	(205,237)
Net carrying amount	165,945	17,155	853	183,953
Year ended 30 June 2025				
Net carrying amount at beginning of year	165,945	17,155	853	183,953
Additions	-	656	-	656
Disposals	(4,017)	(3)	-	(4,020)
Equity transfers in <sup>(i)</sup>	4,017	-	-	4,017
Transfers to NSW Health entities	-	(678)	-	(678)
Net revaluation increment less revaluation decrements	43,302	-	388	43,690
Depreciation expense	(9,409)	(1,211)	(137)	(10,757)
Net carrying amount at end of year	199,838	15,919	1,104	216,861
As at 30 June 2025				
Gross carrying amount	354,964	21,756	6,011	382,731
Less: accumulated depreciation and impairment	(155,126)	(5,837)	(4,907)	(165,870)
Net carrying amount	199,838	15,919	1,104	216,861

<sup>(</sup>i) Further details regarding equity transfers are disclosed in Note 33(a).

The parent entity does not have any service concession assets for the periods ended 30 June 2025 and 30 June 2024.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

# (b) Property, plant and equipment held and used by the parent entity $\ensuremath{\mathsf{PARENT}}$

	Plant and I	nfrastructure	
At 1 July 2023 - fair value Gross carrying amount 223,048 Less: accumulated depreciation and impairment (87,529)  Net carrying amount 135,519  Year ended 30 June 2024  Net carrying amount at beginning of year 135,519  Additions 97 Disposals - Transfers from NSW Health entities - Net revaluation increment less revaluation decrements 1,060 Depreciation expense (7,605) Other reclassifications within property, plant and equipment 7,088  Net carrying amount at end of year 136,159  At 1 July 2024 - fair value Gross carrying amount 265,425 Less: accumulated depreciation and impairment (129,266)  Net carrying amount at beginning of year 136,159  Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017) Equity transfers in 4,017 Transfers to NSW Health entities - Disposals (4,017) Equity transfers in 5,037 Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430) Net carrying amount at end of year (1,430) Net carrying amount at end of year (1,430) Net carrying amount at end of year (1,430)	quipment	systems	Total
Gross carrying amount Less: accumulated depreciation and impairment  Net carrying amount  Year ended 30 June 2024  Net carrying amount at beginning of year  Additions  Disposals  Transfers from NSW Health entities  Net revaluation increment less revaluation decrements  Other reclassifications within property, plant and equipment  At 1 July 2024 - fair value  Gross carrying amount  Less: accumulated depreciation and impairment  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  Less: accumulated depreciation and impairment  Transfers to NSW Health entities  Lequity transfers in (4,017)  Equity transfers to NSW Health entities  Net revaluation increment less revaluation decrements  Net revaluation increment less revaluation decrements  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  165,091	\$000	\$000	\$000
Less: accumulated depreciation and impairment       (87,529)         Net carrying amount       135,519         Year ended 30 June 2024       Pear ended 30 June 2024         Net carrying amount at beginning of year       135,519         Additions       97         Disposals       -         Transfers from NSW Health entities       -         Net revaluation increment less revaluation decrements       1,060         Depreciation expense       (7,605)         Other reclassifications within property, plant and equipment       7,088         Net carrying amount at end of year       136,159         At 1 July 2024 - fair value       265,425         Less: accumulated depreciation and impairment       (129,266)         Net carrying amount       136,159         Year ended 30 June 2025       Year ended 30 June 2025         Net carrying amount at beginning of year       136,159         Additions       -         Disposals       (4,017)         Equity transfers in (6)       4,017         Transfers to NSW Health entities       -         Net revaluation increment less revaluation decrements       38,037         Depreciation expense       (7,675)         Other reclassifications within property, plant and equipment       (1,430)     <			
Net carrying amount       135,519         Year ended 30 June 2024       135,519         Net carrying amount at beginning of year       135,519         Additions       97         Disposals       -         Transfers from NSW Health entities       -         Net revaluation increment less revaluation decrements       1,060         Depreciation expense       (7,605)         Other reclassifications within property, plant and equipment       7,088         Net carrying amount at end of year       136,159         At 1 July 2024 - fair value       (129,266)         Gross carrying amount       (265,425)         Less: accumulated depreciation and impairment       (129,266)         Net carrying amount       136,159         Vear ended 30 June 2025       (129,266)         Net carrying amount at beginning of year       136,159         Additions       -         Disposals       (4,017)         Equity transfers in (6)       4,017         Transfers to NSW Health entities       -         Net revaluation increment less revaluation decrements       38,037         Depreciation expense       (7,675)         Other reclassifications within property, plant and equipment       (1,430)         Net carrying amount at end	23,184	4,901	251,133
Year ended 30 June 2024  Net carrying amount at beginning of year 135,519  Additions 97  Disposals	(5,043)	(3,960)	(96,532)
Net carrying amount at beginning of year  Additions  Disposals  Transfers from NSW Health entities  Net revaluation increment less revaluation decrements  1,060 Depreciation expense  (7,605) Other reclassifications within property, plant and equipment  7,088  Net carrying amount at end of year  136,159  At 1 July 2024 - fair value Gross carrying amount  Less: accumulated depreciation and impairment  (129,266)  Net carrying amount  136,159  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  - Disposals  (4,017) Equity transfers in (0)  Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  38,037 Depreciation expense  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  165,091	18,141	941	154,601
Net carrying amount at beginning of year  Additions  Disposals  Transfers from NSW Health entities  Net revaluation increment less revaluation decrements  1,060 Depreciation expense  (7,605) Other reclassifications within property, plant and equipment  7,088  Net carrying amount at end of year  136,159  At 1 July 2024 - fair value Gross carrying amount  Less: accumulated depreciation and impairment  (129,266)  Net carrying amount  136,159  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  - Disposals  (4,017) Equity transfers in (0)  Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  38,037 Depreciation expense  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  165,091			
Additions 97 Disposals	18,141	941	154,601
Disposals Transfers from NSW Health entities Net revaluation increment less revaluation decrements 1,060 Depreciation expense (7,605) Other reclassifications within property, plant and equipment 7,088  Net carrying amount at end of year 136,159  At 1 July 2024 - fair value Gross carrying amount Less: accumulated depreciation and impairment (129,266) Net carrying amount 136,159  Year ended 30 June 2025 Net carrying amount at beginning of year Additions - Disposals (4,017) Equity transfers in (0) Transfers to NSW Health entities Net revaluation increment less revaluation decrements 38,037 Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430) Net carrying amount at end of year 165,091	262	_	359
Transfers from NSW Health entities  Net revaluation increment less revaluation decrements  1,060  Depreciation expense  (7,605)  Other reclassifications within property, plant and equipment  7,088  Net carrying amount at end of year  136,159  At 1 July 2024 - fair value  Gross carrying amount  265,425  Less: accumulated depreciation and impairment  (129,266)  Net carrying amount  136,159  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  - Disposals  (4,017)  Equity transfers in (i)  4,017  Transfers to NSW Health entities  - Net revaluation increment less revaluation decrements  Depreciation expense  (7,675)  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  165,091	(5)	_	(5)
Depreciation expense Other reclassifications within property, plant and equipment 7,088  Net carrying amount at end of year 136,159  At 1 July 2024 - fair value Gross carrying amount Less: accumulated depreciation and impairment (129,266) Net carrying amount 136,159  Year ended 30 June 2025 Net carrying amount at beginning of year Additions Disposals (4,017) Equity transfers in (1) Transfers to NSW Health entities Net revaluation increment less revaluation decrements 38,037 Depreciation expense Other reclassifications within property, plant and equipment (1,430) Net carrying amount at end of year 165,091	4	_	4
Other reclassifications within property, plant and equipment 7,088  Net carrying amount at end of year 136,159  At 1 July 2024 - fair value Gross carrying amount 265,425 Less: accumulated depreciation and impairment (129,266)  Net carrying amount 136,159  Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017) Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037 Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	-	35	1,095
Other reclassifications within property, plant and equipment 7,088  Net carrying amount at end of year 136,159  At 1 July 2024 - fair value Gross carrying amount 265,425 Less: accumulated depreciation and impairment (129,266)  Net carrying amount 136,159  Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017) Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037 Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	(1,247)	(123)	(8,975)
equipment7,088Net carrying amount at end of year136,159At 1 July 2024 - fair valueGross carrying amount265,425Less: accumulated depreciation and impairment(129,266)Net carrying amount136,159Additions-Disposals(4,017)Equity transfers in (i)4,017Transfers to NSW Health entities-Net revaluation increment less revaluation decrements38,037Depreciation expense(7,675)Other reclassifications within property, plant and equipment(1,430)Net carrying amount at end of year165,091	, , ,	,	, , ,
Net carrying amount at end of year  At 1 July 2024 - fair value Gross carrying amount 265,425 Less: accumulated depreciation and impairment (129,266)  Net carrying amount 136,159  Year ended 30 June 2025 Net carrying amount at beginning of year 136,159 Additions - Disposals (4,017) Equity transfers in (1) 4,017 Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037 Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430) Net carrying amount at end of year 165,091	_	_	7,088
At 1 July 2024 - fair value Gross carrying amount 265,425 Less: accumulated depreciation and impairment (129,266)  Net carrying amount 136,159  Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017)  Equity transfers in (i) 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037  Depreciation expense (7,675)  Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	17,155	853	154,167
Gross carrying amount  Less: accumulated depreciation and impairment  (129,266)  Net carrying amount  136,159  Year ended 30 June 2025  Net carrying amount at beginning of year  Additions  Disposals  (4,017)  Equity transfers in (i)  Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  Net revaluation expense  (7,675)  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  136,159  (4,017)  4,017  Transfers to NSW Health entities  (7,675)  Other reclassifications within property, plant and equipment  (1,430)	17,100		10-1,101
Less: accumulated depreciation and impairment (129,266)  Net carrying amount 136,159  Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017)  Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037  Depreciation expense (7,675)  Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091			
Net carrying amount136,159Year ended 30 June 2025136,159Net carrying amount at beginning of year136,159Additions-Disposals(4,017)Equity transfers in (i)4,017Transfers to NSW Health entities-Net revaluation increment less revaluation decrements38,037Depreciation expense(7,675)Other reclassifications within property, plant and equipment(1,430)Net carrying amount at end of year165,091	22,494	5,107	293,026
Year ended 30 June 2025  Net carrying amount at beginning of year 136,159  Additions - Disposals (4,017)  Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037  Depreciation expense (7,675)  Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	(5,339)	(4,254)	(138,859)
Net carrying amount at beginning of year  Additions  Disposals  (4,017)  Equity transfers in <sup>(i)</sup> Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  Depreciation expense  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  136,159  4,017  7,017  14,017  17,017  18,017  18,017  18,017  18,017  18,017  18,017  18,017  18,017  18,017	17,155	853	154,167
Additions - Disposals (4,017)  Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities - Net revaluation increment less revaluation decrements 38,037  Depreciation expense (7,675)  Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091			
Disposals  Equity transfers in <sup>(i)</sup> 4,017  Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  38,037  Depreciation expense  (7,675)  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  (4,017)  4,017  (7,675)  (7,675)  (7,675)	17,155	853	154,167
Equity transfers in <sup>(i)</sup> Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  Depreciation expense  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  4,017  4,017  4,017  (7,675)  (1,430)	656	-	656
Transfers to NSW Health entities  Net revaluation increment less revaluation decrements  38,037  Depreciation expense  (7,675)  Other reclassifications within property, plant and equipment  (1,430)  Net carrying amount at end of year  165,091	(3)	-	(4,020)
Net revaluation increment less revaluation decrements 38,037  Depreciation expense (7,675)  Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	-	-	4,017
Depreciation expense (7,675) Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	(678)	-	(678)
Other reclassifications within property, plant and equipment (1,430)  Net carrying amount at end of year 165,091	-	388	38,425
equipment (1,430)  Net carrying amount at end of year 165,091	(1,211)	(137)	(9,023)
Net carrying amount at end of year 165,091			
	-	-	(1,430)
At 30 June 2025 - fair value	15,919	1,104	182,114
Gross carrying amount 213,733	21,756	6,011	241,500
Less: accumulated depreciation and impairment (48,642)	(5,837)	(4,907)	(59,386)
Net carrying amount 165,091	15,919	1,104	182,114

<sup>(</sup>i) Further details regarding equity transfers are disclosed in Note 33(a).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025  $\,$ 

## 23. Property, plant and equipment (continued)

(c) Property, plant and equipment where the parent entity is the lessor under operating leases PARENT

	Land and	Plant and Infrastructure		
	Buildings \$000	Equipment \$000	systems \$000	Total \$000
At 1 July 2023 - fair value				
Gross carrying amount	124,527	-	-	124,527
Less: accumulated depreciation and impairment	(90,655)	-	-	(90,655)
Net carrying amount	33,872	-	-	33,872
Year ended 30 June 2024				
Net carrying amount at beginning of year	33,872	-	-	33,872
Additions	233	-	-	233
Net revaluation increment less revaluation decrements	4,578	-	-	4,578
Depreciation expense	(1,809)	-	-	(1,809)
Other reclassifications within property, plant and				
equipment	(7,088)	-	-	(7,088)
Net carrying amount at end of year	29,786	-	-	29,786
At 1 July 2024 - fair value				
Gross carrying amount	96,164	-	-	96,164
Less: accumulated depreciation and impairment	(66,378)	-	-	(66,378)
Net carrying amount	29,786	-	-	29,786
Year ended 30 June 2025				
Net carrying amount at beginning of year	29,786	-	-	29,786
Net revaluation increment less revaluation decrements	5,265	-	-	5,265
Depreciation expense	(1,734)	-	-	(1,734)
Other reclassifications within property, plant and				
equipment	1,430	-	-	1,430
Net carrying amount at end of year	34,747	-	-	34,747
At 30 June 2025 - fair value				
Gross carrying amount	141,231	-	-	141,231
Less: accumulated depreciation and impairment	(106,484)	-	-	(106,484)
Net carrying amount	34,747	-	-	34,747

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 23. Property, plant and equipment (continued)

#### **Recognition and Measurement**

#### Acquisition of property, plant and equipment

Property, plant and equipment acquired are initially recognised at cost and subsequently revalued at fair value less accumulated depreciation and impairment.

Assets acquired at no cost, or for nominal consideration, are initially recognised at their fair value at the date of acquisition.

Land and buildings which are owned by the Health Administration Corporation or the State and operated by the parent or its controlled entities are deemed to be controlled by the parent and its controlled entities and are recognised as such in the financial statements.

#### Capitalisation thresholds

Property, plant and equipment costing \$10,000 and above individually (or forming part of a group costing more than \$100,000) are capitalised.

#### Depreciation of property, plant and equipment

Except for certain non-depreciable assets, depreciation is provided for on a straight-line basis so as to write off the depreciable amount of each asset as it is consumed over its useful life to the consolidated entity.

All material identifiable components of assets are depreciated separately over their useful lives.

Land is not a depreciable asset. Certain artworks and collections may not have a limited useful life because appropriate curatorial and preservation policies are adopted. Such assets are not subject to depreciation. The decision not to recognise depreciation for these assets is reviewed annually.

Details of useful lives initially applied for major asset categories are as follows:

	Usetul lives
Buildings	30-70 years
Buildings - leasehold improvements	3-10 years
Plant and equipment	4-20 years
Infrastructure systems	40 years

Plant and equipment comprises, among others, medical, computer and office equipment, motor vehicles, furniture and fittings and PODS (a detachable or self-contained unit on ambulances used for patient treatment).

Infrastructure systems comprises public facilities which provide essential services and enhance the productive capacity of the economy including roads, bridges, water infrastructure and distribution works, sewerage treatment plants, seawalls and water reticulation systems.

The estimated useful lives, residual values and depreciation methods are reviewed at the end of each reporting period and adjusted if appropriate.

#### Right-of-Use Assets acquired by lessees

AASB 16 *Leases* (AASB 16) requires a lessee to recognise a right-of-use asset for most leases. The consolidated entity has elected to present right-of-use assets separately in the Statement of Financial Position.

Further information on leases is contained at Note 24.

#### Service concession assets

Service concession arrangements (SCAs) are contracts between a grantor and an operator where an operator provides public services related to a service concession asset on behalf of a public sector grantor for a specified period of time and manages at least some of those services.

Based on the consolidated entity's assessment, the following arrangements fall in scope of AASB 1059:

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

**Recognition and Measurement (continued)** 

Service concession assets (continued)

Description	Public Hospitals				
Name and description of the SCA	Northern Beaches Hospital and Hawkesbury Hospital are two public hospitals built under two separate Public Private Partnership (PPP) arrangements that are treated as part of service concession arrangements.				
Period of arrangement	Northern Beaches Public Hospital Northern Beaches Car Park Hawkesbury Hospital	20 years (2018 - 2038) 40 years (2018 - 2058) 29 years (1994 - 2024)			
		ospital ended on 30 June 2024, following which operator were transferred to the consolidated			
Terms of the arrangement	Hospital) and St John of God Healt build, operate and manage the hosp arrangement. The construction of be entity. Northern Beaches Hospita construction works, while Hawkes financing arrangement with the construction payments. The Operate park, and the consolidated entity has generate revenue from that car par	HealthScope (Operator for Northern Beaches th Care (Operator for Hawkesbury Hospital) to pitals and the car park for the duration of the oth hospitals was funded by the consolidated at was paid upfront on completion of the abury Hospital was paid over time under a Operator. There are no remaining future for has fully funded the Northern Beaches car as granted rights to the Operator to operate and the caches Public Hospital with the Operator, which paid on a monthly basis.			
Rights and obligations	and the carpark. The operator is respublic patients at the hospital which under the annual service agreements is obligated to return all assets be Beaches Hospital, the consolidated facilities with the private operator expiry of the concession period. The notice outlining what shared service consolidated entity has the right	to provide HealthScope access to the hospital sponsible for the delivery of health services to the consolidated entity is obligated to pay for s. At the end of the arrangement, the operator ack to the consolidated entity. For Northern entity will be sharing a portion of the hospital for an additional term of 20 years after the he consolidated entity is required to issue a ses will be provided by different parties. The to extend the Northern Beaches Hospital by way of giving three years notice to the			
Changes in arrangement occurring during 2024	Nil				
Changes in arrangement occurring during 2025	transitioned from St John of God H	nd management of Hawkesbury Hospital has Health Care to Nepean Blue Mountains Local to Hawkesbury Hospital have been transferred			

out of service concession assets.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

**Recognition and Measurement (continued)** 

Service concession assets (continued)

Carrying amounts of public hospital service concession assets

	Land and	Plant and	Infrastructure	
	buildings	equipment	Systems	Total
	2024	2024	2024	2024
	\$000	\$000	\$000	\$000
Year ended 30 June 2024				_
Northern Beaches Public				
Hospital	596,424	14,261	25,309	635,994
Northern Beaches Car Park	57,356	-	-	57,356
Hawkesbury Hospital	81,520	1,916	980	84,416
Net carrying amount	735,300	16,177	26,289	777,766

	Land and buildings 2025 \$000	Plant and equipment 2025 \$000	Infrastructure Systems 2025 \$000	Total 2025 \$000
Year ended 30 June 2025				
Northern Beaches Public				
Hospital	601,565	10,216	25,616	637,397
Northern Beaches Car Park	58,541	-	-	58,541
Net carrying amount	660,106	10,216	25,616	695,938

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

**Recognition and Measurement (continued)** 

Service concession assets (continued)

Description	Hospital car parks			
Name and description of the SCA	Consist of two arrangements: - Multi-storey carparks at Royal North Shore Hospital, RNSH P1 and RNSH P2 - St George Hospital car parks			
Period of arrangement	RNSH P1 car park 26.5 years (2010 - 2036)  RNSH P2 car park 22 years (2014 - 2036)  St George hospital car park 25 years (1999 - 2024)			
Terms of the arrangement	The consolidated entity contracted Infrashore (Operator) to build RNSH P2 car park and manage both RNSH P1 and P2 car parks for the duration of the arrangement. The construction of the RNSH P2 car park is funded by the consolidated entity, paid in instalments under a financing arrangement for the duration of the term. RNSH P1 car park was an existing carpark of the consolidated entity. The St George hospital car park was funded by the International Parking Group (Operator) which was contracted by the consolidated entity to build, manage and operate the car park for the duration of the arrangement. For all these car parks, the consolidated entity has granted rights to the Operator to operate and generate revenue from the car parks. Upon grant of this right, the Operator has paid an upfront license fee to the consolidated entity.			
Rights and obligations	The consolidated entity is obliged to provide the operators with access to carparks and obligated to pay for the construction of the RNSH P2 car park until the financing arrangement with the Operator. The operators are responsible operating the car parks and at the end of the arrangement, return all assets back the consolidated entity. There are currently no provisions for extension of the term in the existing contract.			
Changes in arrangement occurring during 2024	Nil			
Changes in arrangement occurring during 2025	St George hospital car park arrangement has concluded and its assets were transferred out of service concession assets.			

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

**Recognition and Measurement (continued)** 

Service concession assets (continued)

Carrying amounts of hospital car park service concession assets

	Land and	Plant and	Infrastructure	
	buildings	equipment	Systems	Total
	2024	2024	2024	2024
	\$000	\$000	\$000	\$000
Year ended 30 June 2024				_
RNSH P1 Car Park	24,469	-	-	24,469
RNSH P2 Car Park	24,909	-	-	24,909
St George Hospital Car Park	10,230	-	-	10,230
Net carrying amount	59,608	-	-	59,608

	Land and buildings 2025 \$000	Plant and equipment 2025 \$000	Infrastructure Systems 2025 \$000	Total 2025 \$000
Year ended 30 June 2025 RNSH P1 Car Park	24,268			24,268
RNSH P2 Car Park	25,361	- -	- -	25,361
Net carrying amount	49,629	-	-	49,629

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 23. Property, plant and equipment (continued) Recognition and Measurement (continued)

Service concession assets (continued)

Description	Hospital facilities			
Name and description of the SCA	Mercy Care Centre Young - 26 bed purpose-built sub-acute rehabilitation are palliative care unit in Young that provides services to the people of Young are surrounding regions. The Mercy Care Centre Young is owned by the consolidate entity and operated by Mercy Health under a 20 year lease agreement and annu service agreements.			
Period of arrangement	Mercy Care Centre Young 20 years (2004 to 2024)			
Terms of the arrangement	The consolidated entity has contracted Mercy Health (Operator for Mercy C Centre Young) to manage the facility for the duration of the arrangement funding arrangement has also been agreed to compensate the operator managing the facility. The capital assets associated with the arrangement has been provided by the consolidated entity to the operators.			
Rights and obligations	The consolidated entity is obligated to provide the operator with access to the facility. The operator is responsible for the delivery of specified services to patients at the facility. The consolidated entity is obligated to pay for those services under the funding agreement. At the end of the arrangement, the operator is obliged to return all assets back to the consolidated entity. There is no provision for an extension of the terms, however they can be separately negotiated.			
Changes in arrangement occurring during 2024	The lease arrangement for Mercy Care Centre Young has expired in June 2024. The arrangement continued on a month to month basis, while negotiations were underway.			
Changes in arrangement occurring during 2025	The arrangement continues on a month to month basis and negotiations to extend the lease are still underway.			

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 23. Property, plant and equipment (continued)

**Recognition and Measurement (continued)** 

Service concession assets (continued)

Carrying amounts of hospital facility service concession assets

	Land and	Plant and	Infrastructure	
	buildings	equipment	Systems	Total
	2024	2024	2024	2024
	\$000	\$000	\$000	\$000
Year ended 30 June 2024				
Mercy Care Centre Young	9,815	-	50	9,865
Net carrying amount	9,815	-	50	9,865

	Land and	Plant and	Infrastructure	Takal
	buildings	equipment	Systems	Total
	2025	2025	2025	2025
	\$000	\$000	\$000	\$000
Year ended 30 June 2025				
Mercy Care Centre Young	8,857	-	73	8,930
Net carrying amount	8,857	-	73	8,930

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 23. Property, plant and equipment (continued)

#### **Recognition and Measurement (continued)**

#### Revaluations of property, plant and equipment

Physical non-current assets are valued in accordance with the 'Valuation of Physical Non-Current Assets at Fair Value' Policy and Guidelines Paper (TPP 21-09) and Treasurer's Direction, 'Valuation of Physical Non-Current Assets at Fair Value' (TD 21-05). TD 21-05 and TPP 21-09 adopt fair value in accordance with AASB 13 Fair Value Measurement and AASB 116 Property, Plant and Equipment.

Property, plant and equipment is measured at the highest and best use by market participants that is physically possible, legally permissible and financially feasible. The highest and best use must be available at a period that is not remote and takes into account the characteristics of the asset being measured, including any socio-political restrictions imposed by government. In most cases, after taking into account these considerations, the highest and best use is the existing use. In limited circumstances, the highest and best use may be a feasible alternative use, where there are no restrictions on use or where there is a feasible higher restricted alternative use.

Revaluations are made with sufficient regularity to ensure the carrying amount of each asset in the class does not differ materially from its fair value at reporting date. The consolidated entity conducts a comprehensive revaluation at least every three years on a rotational basis for its land and buildings and infrastructure. Interim desktop revaluations are conducted between comprehensive revaluations for those assets, where cumulative changes to indicators suggest fair value may differ materially from carrying value. The consolidated entity uses an independent professionally qualified valuer for such revaluations.

The last comprehensive revaluation for the parent entity was completed on 31 December 2024 and was based on an independent assessment.

Comprehensive revaluations are conducted in December for the controlled entities on a rolling basis and are based on an independent assessment. A schedule of revaluations has been developed which rolls over every three years. Interim or out of schedule revaluations are conducted where cumulative changes to indicators suggest fair value may differ materially from the carrying value.

Indices obtained from external professionally qualified valuers in 2025 and 2024 indicated a material cumulative increase in market prices for land and a material increase in construction and labour costs for building and infrastructure from the last comprehensive revaluation. Management has applied these indices to perform an interim revaluation and has recognised the resulting revaluation increment for land, building and infrastructure.

Non-specialised assets with short useful lives are measured at depreciated historical cost, as an approximation of fair value. The consolidated entity has assessed that any difference between fair value and depreciated historical cost is unlikely to be material.

For other assets valued using other valuation techniques, any balances of accumulated depreciation at the revaluation date in respect of those assets are credited to the asset accounts to which they relate. The net asset accounts are then increased or decreased by the revaluation increments or decrements.

Revaluation increments are recognised in other comprehensive income and credited to revaluation surplus in equity. However, to the extent that an increment reverses a revaluation decrement in respect of the same class of asset previously recognised as a loss in the net result, the increment is recognised immediately as a gain in the net result.

Revaluation decrements are recognised immediately as a loss in the net result, except to the extent that it offsets an existing revaluation surplus on the same class of assets, in which case, the decrement is debited directly to the revaluation surplus.

As a not-for-profit entity, revaluation increments and decrements are offset against one another within a class of non-current assets, but not otherwise.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 24. Leases

#### (a) Entity as a lessee

The consolidated entity leases various property, equipment and motor vehicles. Lease contracts are typically made for fixed periods of 1 to 40 years (parent entity: 1 to 4 years), but may have extension options. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants, but leased assets may not be used as security for borrowing purposes. The consolidated entity does not provide residual value guarantees in relation to leases.

Extension and termination options are included in a number of property and equipment leases. These terms are used to maximise operational flexibility in terms of managing contracts. The majority of extension and termination options held are exercisable only by the consolidated entity and not by the respective lessor. In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated). Potential future cash outflows of \$101.95 million (2024: \$141.78 million) (parent entity: \$Nil, 2024: \$Nil)) have not been included in the lease liability because it is not reasonably certain that the leases will be extended (or not terminated). The assessment is reviewed if a significant event or a significant change in circumstances occurs which affects this assessment and that is within the control of the lessee. During the current financial year, the financial effect of revising lease terms to reflect the effect of exercising extensions and termination options was an increase in recognised lease liabilities and right-of-use assets of \$35.27 million (2024: \$108.04 million) (parent entity: \$Nil, 2024: \$Nil).

AASB 16 *Leases* (AASB 16) requires a lessee to recognise a right-of-use asset and a corresponding lease liability for most leases.

The consolidated entity has elected to recognise payments for short-term leases and low value leases as expenses on a straight line basis, instead of recognising a right-of-use asset and lease liability. Short-term leases are leases with a lease term of 12 months or less. Low value assets are assets with a fair value of \$10,000 or less when new and comprise mainly of small office and medical equipment items.

All occupancy agreements entered into by the consolidated entity with Property and Development NSW (PDNSW), an entity of the ultimate parent, have a 'substitution right' clause added to the occupancy arrangements providing PDNSW with a substantive substitution right to relocate the consolidated entity during the term of the agreement. As a result of this clause, those agreements are not accounted for as a lease within the scope of AASB 16. These leases are recognised as an expense in Note 3 under 'Occupancy agreement expenses - Property and Development NSW' when incurred over the agreement duration.

#### Right-of-use assets under leases

The following table presents right-of-use assets that do not meet the definition of investment property. There are no right-of-use assets that meet the definition of investment property.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025  $\,$ 

## 24. Leases (continued)

(a) Entity as a lessee (continued) CONSOLIDATED

	Land and Buildings \$000	Plant and Equipment \$000	Total \$000
Balance at 1 July 2024	343,092	395,855	738,947
Additions	13,790	71,308	85,098
Reassessments - increase / (decrease)	18,244	49,262	67,506
Disposals	(10,774)	(1,795)	(12,569)
Depreciation expense	(68,019)	(103,434)	(171,453)
Reclassifications to property, plant and equipment	(56)	-	(56)
Balance at 30 June 2025	296,277	411,196	707,473
Balance at 1 July 2023	322,619	304,096	626,715
Additions	33,974	132,904	166,878
Reassessments - increase / (decrease)	73,012	56,792	129,804
Disposals	(12,227)	(1,150)	(13,377)
Depreciation expense	(74,286)	(96,787)	(171,073)
Balance at 30 June 2024	343,092	395,855	738,947
PARENT			
	Land and	Plant and	
	Buildings	Equipment	Total
	\$000	\$000	\$000
Balance at 1 July 2024	544	95	639
Additions	-	104	104
Reassessments - increase / (decrease)	-	(1)	(1)
Disposals	(544)	(15)	(559)
Depreciation expense	-	(63)	(63)
Balance at 30 June 2025	-	120	120
Balance at 1 July 2023	677	99	776
Additions	-	44	44
Reassessments - increase / (decrease)	_	(3)	(3)
Depreciation expense	(133)	(45)	(178)
Balance at 30 June 2024	544	95	639

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 24. Leases (continued)

## (a) Entity as a lessee (continued)

## Lease liabilities

The following table presents liabilities under leases:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Balance at 1 July	759,064	639,926	656	785
Additions	84,921	166,878	104	44
Interest expenses	31,121	22,856	7	17
Payments	(191,521)	(186,296)	(48)	(187)
Terminations / derecognition	(9,111)	(14,104)	(598)	-
Other adjustments	67,506	129,804	(1)	(3)
Balance at 30 June	741,980	759,064	120	656

Other adjustments for the consolidated entity include \$42.4 million (2024: \$108.0 million) of lease extensions recognised for aeromedical leases.

The following amounts were recognised in the Statement of Comprehensive Income during the period in respect of leases:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Depreciation expense of right-of-use assets	171,453	171,073	63	178
Interest expense on lease liabilities	31,121	22,856	7	17
Expenses relating to short-term leases	51,984	47,719	16	13
Expenses relating to leases of low-value assets	21,309	21,152	874	924
Income from subleasing right-of-use assets	(138)	(27)	-	-
(Gains) / losses on disposal	(1,158)	(727)	(39)	-
Total amount recognised in the statement of				
comprehensive income	274,571	262,046	921	1,132

The consolidated entity had total cash outflows for leases of \$264.81 million (parent entity: \$0.94 million) for the year ended 30 June 2025 (2024: \$255.17 million (parent entity: \$1.12 million)).

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 24. Leases (continued)

#### (a) Entity as a lessee (continued)

#### Leases at significantly below market terms and conditions principally to enable the entity to further its objectives

The consolidated entity entered into a number of leases, with lease terms ranging from 1 to 99 years with various organisations, including local councils, health charities, Catholic churches and other NSW State entities for the use of various community health buildings. There are also some leases for the use of various helipads across the state. These contracts generally specify lease payments of \$Nil or negligible amounts per annum, and the leased premises are used by the consolidated entity to provide different community health services and access to helipads. These community health buildings and helipads account for a small portion of similar assets used by the consolidated entity for the purposes of providing health services. Therefore, these lease arrangements do not have a significant impact on the consolidated entity's operations.

#### Recognition and measurement

The consolidated entity assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The consolidated entity recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets, except for short-term leases and leases of low-value assets.

#### i. Right-of-use assets

The right-of-use assets are subsequently measured at cost. They are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets, as follows:

Hooful lives

	Oseiul lives
Land and buildings	1 to 40 years
Plant and machinery	1 to 10 years
Motor vehicles	1 to 5 years
Aeromedical	1 to 15 years

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for real estate leases, the incremental borrowing rate is used. The consolidated entity does not borrow funds in the market. Instead it receives an allocation of the appropriations from the Crown and where the Crown needs additional funding, Treasury Corporation (TCorp) goes to the market to obtain these funds. As a result, the consolidated entity is using TCorp rates as its incremental borrowing rate. These rates are published by NSW Treasury on a regular basis.

#### ii. Short-term leases and leases of low-value assets

The consolidated entity applies the short-term lease recognition exemption to its short-term leases of buildings, machinery, motor vehicles and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low value assets are recognised as expense on a straight-line basis over the lease term.

iii. Leases that have significantly below-market terms and conditions principally to enable the entity to further its objectives

The initial and subsequent measurement of right-of-use assets under leases at significantly below-market terms and conditions that are entered into principally to enable the consolidated entity to further its objectives is the same as normal right-of-use assets. They are measured at cost, subject to impairment.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 24. Leases (continued)

#### (b) Entity as a lessor

#### Recognition and measurement

The consolidated entity leases some retail spaces located within the hospital precincts under operating leases with rental payable monthly. Lease payments generally contain uplift clauses to align to the market conditions.

The consolidated entity also leases land and buildings to non-government organisations (NGO's) and universities under operating leases arrangements. Generally there are no rental payments as the consolidated entity provides market rental assistance grants which offset the rental payments.

The consolidated entity also leases out certain areas and floors within its buildings on a long term basis, which are treated as finance leases. All lease payments are generally paid upfront and the asset gets derecognised from non-current assets.

#### Lessor for finance leases

Future minimum rentals receivable (undiscounted) under non-cancellable finance leases are as follows:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Within one year	600	-	-	-
One to two years	621	-	-	-
Two to three years	643	-	-	-
Three to four years	666	-	-	-
Four to five years	689	-	-	-
Later than five years	2,375	-	-	-
Total (excluding GST)	5,594	-	-	-

#### Reconciliation of net investment in leases

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Future undiscounted rentals receivable	5,594	-	-	-
Unguaranteed residual amounts - undiscounted	313,686	313,686	-	-
Less: unearned finance income	(221,639)	(222,915)	-	
Net investment in finance lease	97,641	90,771	-	-

#### Lessor for operating leases

Future minimum rental receivables (undiscounted) under non-cancellable operating leases as at 30 June are as follows:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Within one year	13,110	12,462	869	1,360
One to two years	11,323	10,996	890	1,322
Two to three years	10,992	10,185	820	1,372
Three to four years	10,140	9,446	699	1,358
Four to five years	9,907	9,214	720	1,320
Later than five years	95,121	97,171	3,269	8,036
Total (excluding GST)	150,593	149,474	7,267	14,768

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025  $\,$ 

# 25. Intangible assets

# CONSOLIDATED

	Software \$000	Total \$000
At 1 July 2023	3000	3000
Cost (gross carrying amount)	1,495,526	1,495,526
Less: accumulated amortisation and impairment	(763,480)	(763,480)
Net carrying amount	732,046	732,046
Year ended 30 June 2024		
Net carrying amount at beginning of year	732,046	732,046
Additions	365,435	365,435
Reclassifications from property, plant and equipment	2,640	2,640
Disposals	(2,125)	(2,125)
Amortisation (recognised in depreciation and amortisation)	(112,247)	(112,247)
Net carrying amount at the end of the year	985,749	985,749
At 1 July 2024		
Cost (gross carrying amount)	1,821,333	1,821,333
Less: accumulated amortisation and impairment	(835,584)	(835,584)
Net carrying amount	985,749	985,749
Year ended 30 June 2025		
Net carrying amount at beginning of year	985,749	985,749
Additions	201,205	201,205
Reclassifications from property, plant and equipment	235	235
Disposals	(3,120)	(3,120)
Amortisation (recognised in depreciation and amortisation)	(109,482)	(109,482)
Net carrying amount at the end of the year	1,074,587	1,074,587
At 30 June 2025		
Cost (gross carrying amount)	2,004,815	2,004,815
Less: accumulated amortisation and impairment	(930,228)	(930,228)
Net carrying amount	1,074,587	1,074,587

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 25. Intangible assets (continued)

#### **PARENT**

	Software	Total
	\$000	\$000
At 1 July 2023		
Cost (gross carrying amount)	8,362	8,362
Less: accumulated amortisation and impairment	(1,290)	(1,290)
Net carrying amount	7,072	7,072
Year ended 30 June 2024		
Net carrying amount at beginning of year	7,072	7,072
Additions	3,135	3,135
Amortisation (recognised in depreciation and amortisation)	(458)	(458)
Net carrying amount at the end of the year	9,749	9,749
At 1 July 2024		
Cost (gross carrying amount)	11,496	11,496
Less: accumulated amortisation and impairment	(1,747)	(1,747)
Net carrying amount	9,749	9,749
Year ended 30 June 2025		
Net carrying amount at beginning of year	9,749	9,749
Additions	6,370	6,370
Disposals	(53)	(53)
Amortisation (recognised in depreciation and amortisation)	(886)	(886)
Net carrying amount at the end of the year	15,180	15,180
At 30 June 2025		
Cost (gross carrying amount)	17,315	17,315
Less: accumulated amortisation and impairment	(2,135)	(2,135)
Net carrying amount	15,180	15,180

## **Recognition and Measurement**

The useful lives of intangible assets are assessed to be finite.

The consolidated entity's intangible assets are amortised using the straight-line method over a period of four to twenty years. Computer software developed or acquired by the consolidated entity are recognised as intangible assets.

The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 26. Fair value measurement of non-financial assets

#### Fair value measurement and hierarchy

When measuring fair value, the valuation technique used maximises the use of relevant observable inputs and minimises the use of unobservable inputs. Under AASB 13 Fair Value Measurement, the consolidated entity categorises, for disclosure purposes, the valuation techniques based on the inputs used in the valuation techniques as follows:

- Level 1 quoted (unadjusted) prices in active markets for identical assets / liabilities that the entity can access at the measurement date.
- Level 2 inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.
- Level 3 inputs that are not based on observable market data (unobservable inputs).

The consolidated entity recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

#### (a) Fair value hierarchy

CONSOLIDATED				Total Fair
	Level 1	Level 2	Level 3	Value
	\$000	\$000	\$000	\$000
2025				
Land and buildings	-	889,771	29,068,484	29,958,255
Infrastructure systems	-	222	912,126	912,348
	-	889,993	29,980,610	30,870,603
2024				
Land and buildings	-	814,418	27,131,385	27,945,803
Infrastructure systems	-	225	851,210	851,435
Non-current assets held for sale	-	304	-	304
	-	814,947	27,982,595	28,797,542

The above figures include leasehold improvements, work in progress and newly completed assets which are carried at cost. Cost for such assets are regarded as an approximation of fair value.

There were no transfers between Level 1 and 2 during the year ended 30 June 2025 and 2024.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 26. Fair value measurement of non-financial assets (continued)

#### (a) Fair value hierarchy (continued)

PARENT				Total Fair
	Level 1	Level 2	Level 3	Value
	\$000	\$000	\$000	\$000
2025				
Land and buildings	-	-	199,838	199,838
Infrastructure systems	-	-	1,104	1,104
	-	-	200,942	200,942
2024				
Land and buildings	-	-	165,945	165,945
Infrastructure systems	-	-	853	853
	-	-	166,798	166,798

The above figures include leasehold improvements, work in progress and newly completed assets which are carried at cost. Cost for such assets are regarded as an approximation of fair value.

There were no transfers between Level 1 and 2 during the year ended 30 June 2025 and 2024.

#### (b) Valuation techniques, inputs and processes

The consolidated entity obtains independent valuations for its non-financial assets at least every three years. The valuer used by the consolidated entity is independent of the respective entities.

At the end of each reporting period, the consolidated entity updates its assessment of the fair value of each category of non-financial assets, taking into account the most recent independent valuations. The best evidence of fair value is current prices in an active market for similar assets. Where such information is not available, the consolidated entity considers information from other sources, such as the indices provided by independent external valuers. These fair value adjustments are reflected in Note 23 Total property, plant and equipment reconciliation.

The valuations techniques used maximise the use of observable inputs where available and rely as little as possible on entity or asset specific estimates. The level in the fair value hierarchy is determined on the basis of the lowest level input that is significant to the measurement in its entirety. If significant inputs required to measure fair value of an asset are observable, the asset is included in level 2 of the fair value hierarchy. If one or more of the significant inputs is not based on observable market data, the asset is included in level 3 of the fair value hierarchy. All resulting fair value estimates for non-financial assets are included in level 3 with the exception of some land and buildings and non-current assets held for sale included in level 2.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 26. Fair value measurement of non-financial assets (continued)

#### (b) Valuation techniques, inputs and processes (continued)

The non-financial assets categorised in (a) above have been measured based on the following valuation techniques and inputs:

- For land, the valuation by the valuers is made on a market approach, comparing similar assets (not identical) and observable inputs. The most significant input is price per square metre. All commercial and non-restricted land is included in level 2 as these land valuations have a high level of observable inputs, although these lands are not identical. The majority of the restricted land has been classified as level 3 as, although observable inputs have been used, a significant level of professional judgement is required to adjust inputs in determining the land valuations. Certain parcels of land have zoning restrictions, for example hospital grounds, and values are adjusted accordingly.
- For buildings and infrastructure systems, many assets are of a specialised nature or use, and thus the most appropriate valuation method is depreciated replacement cost. These assets are included as level 3 as these assets have a high level of unobservable inputs. However, residential and commercial properties are valued on a market approach and are included in level 2.
- Non-current assets held for sale are a non-recurring item that is measured at the lesser of its carrying amount or fair value less cost to sell. These assets are categorised as level 2 except when an asset was a level 3 asset prior to transfer to non-current assets held for sale, and continues to be recognised as a level 3 asset where the carrying amount is less than the fair value (less cost) to sell.

#### Level 3 disclosures:

The fair value of buildings computed by suitably qualified independent valuers using a methodology known as the depreciated replacement cost valuation technique. The following table highlights the key unobservable (level 3) inputs assessed during the valuation process, the relationship to the estimated fair value and the sensitivity to changes in unobservable inputs.

	Valuation	
Assets	Techniques	Valuation Inputs
Land under specialised building(s)	Market approach	This valuation method involves comparing the subject property to comparable sale prices in similar location on a rate per square metre basis, adjusted for restrictions specific for the property (e.g. mandated use and / or zoning).
Specialised Buildings	Depreciated replacement cost approach	This valuation method involves establishing the current replacement cost of the modern equivalent asset for each type of building on a rate per square metre basis; depreciated to reflect the building's remaining useful life which is determined by a number of factors including asset condition and asset life.
Non-Specialised Buildings	Depreciated replacement cost approach	This valuation method involves establishing the current replacement cost of the modern equivalent asset for each type of building on a rate per square metre basis; depreciated to reflect the building's remaining useful life.
Infrastructure systems	Depreciated replacement cost approach	This valuation method involves establishing the current replacement cost of the modern equivalent infrastructure asset on a rate per square metre basis; depreciated to reflect the assets remaining useful life.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 26. Fair value measurement of non-financial assets (continued)

## (c) Reconciliation of recurring Level 3 fair value measurements

## CONSOLIDATED

	Land and	Infrastructure	Total Level 3
	Buildings	Systems	Recurring
	\$000	\$000	\$000
2025			
Fair value as at 1 July 2024	27,131,385	851,210	27,982,595
Additions	1,949,272	1,122	1,950,394
Revaluation increments / decrements recognised in other			
comprehensive income – included in line item 'Changes in			
revaluation surplus of property, plant and equipment'	1,100,867	32,714	1,133,581
Transfers from Level 2	4,474	-	4,474
Transfers to Level 2	(13,364)	-	(13,364)
Disposals	(63,908)	-	(63,908)
Depreciation expense	(953,786)	(40,999)	(994,785)
Equity transfers out - Note 33 (a)	(15,947)	-	(15,947)
Reclassification	(70,509)	68,079	(2,430)
Fair value as at 30 June 2025	29,068,484	912,126	29,980,610

#### **CONSOLIDATED**

	Land and Infrastructure		Total Level 3
	Buildings	Systems	Recurring
	\$000	\$000	\$000
2024			
Fair value as at 1 July 2023	25,291,915	882,158	26,174,073
Additions	1,582,922	97	1,583,019
Revaluation increments / decrements recognised in other			
comprehensive income – included in line item 'Changes in			
revaluation surplus of property, plant and equipment'	1,132,220	31,035	1,163,255
Transfers from Level 2	8,450	63	8,513
Transfers to Level 2	(73,371)	-	(73,371)
Disposals	(5,856)	=	(5,856)
Depreciation expense	(860,133)	(38,582)	(898,715)
Reclassification	55,238	(23,561)	31,677
Fair value as at 30 June 2024	27,131,385	851,210	27,982,595

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 26. Fair value measurement of non-financial assets (continued)

(c) Reconciliation of recurring Level 3 fair value measurements (continued)

## **PARENT**

	Land and Infrastructure		Total Level 3
	Buildings	Systems	Recurring
	\$000	\$000	\$000
2025			
Fair value as at 1 July 2024	165,945	853	166,798
Revaluation increments / decrements recognised in other			
comprehensive income – included in line item 'Changes in			
revaluation surplus of property, plant and equipment'	43,302	388	43,690
Depreciation expense	(9,409)	(137)	(9,546)
Fair value as at 30 June 2025	199,838	1,104	200,942

## **PARENT**

	Land and In	nfrastructure	Total Level 3
	Buildings	Systems	Recurring
	\$000	\$000	\$000
2024			
Fair value as at 1 July 2023	169,391	941	170,332
Additions	330	-	330
Revaluation increments / decrements recognised in other			
comprehensive income – included in line item 'Changes in			
revaluation surplus of property, plant and equipment'	5,638	35	5,673
Depreciation expense	(9,414)	(123)	(9,537)
Fair value as at 30 June 2024	165,945	853	166,798

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 27. Restricted assets

The financial statements include cash and cash equivalents and TCorpIM fund investments, the use of which is restricted for stipulated purposes and / or by externally imposed conditions, eg. donor requirements. The assets are only available for application in accordance with the terms of the donor restrictions.

## CONSOLIDATED

	2025 \$000	2024 \$000
Category	Ç	<del></del>
Community welfare	40,187	25,959
Facility improvements	769,317	793,944
Hold Funds in Perpetuity	14,722	14,487
Patient welfare	120,440	111,360
Private practice disbursements (No.2 Accounts)	583,525	539,601
Public contributions	76,122	71,192
Clinical trials	73,529	56,701
Research	258,880	234,098
Section 19(2) primary care - exemption initiative	5,984	5,132
Staff welfare	24,314	24,625
Training and education including conferences	98,262	94,670
Other	(28,390)	(22,111)
Total Restricted Assets	2,036,892	1,949,658
PARENT		
	2025	2024
	\$000	\$000
Category		
Facility improvements	110,817	85,083
Research	28,180	26,370
Total Restricted Assets	138,997	111,453

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 27. Restricted assets (continued)

Restricted assets are held for the following purpose and cannot be used for any other purpose.

Category	Purpose
Community welfare	Improvements to service access, health literacy, public and preventative health care.
Facility improvements	Repairs, maintenance, renovations and/or new equipment or building related expenditure.
Hold funds in perpetuity	Donor has explicitly requested funds be invested permanently and not otherwise expended.
Patient welfare	Improvements such as medical needs, financial needs and standards for patients' privacy and dignity.
Private practice disbursements	Staff specialists' private practice arrangements to improve the level of clinical services provided (No. 2 Accounts).
Public contributions	Donations, gifts, bequests or legacies received without any donor-specified conditions as to its use. Such contributions are restricted as a result of the requirements of the Accounts and Audit Determination for Public Health Entities in NSW.
Clinical trials	A study designed to test the safety and effectiveness of a treatment.
Research	Research to gain knowledge, understanding and insight.
Section 19(2) primary care - exemption initiative	Improving access to primary care in rural and remote areas under the Council of Australian Governments (COAG) s19(2) Exemptions Initiative.
Staff welfare	Staff benefits such as staff recognition awards, functions and staff amenity improvements.
Training and education including conferences	Professional training, education and conferences.
Other	Includes unallocated monies and outstanding settlements. Outstanding settlements refers to expenses and revenue processed in the respective restricted asset cost centres, however awaiting cash settlements to take place. Majority of it relates to private patient fund transfer from trust (No.1 Accounts) to restricted asset private practice disbursement funds (No.2 Accounts) and is awaiting physical settlement/transfer of cash between those bank accounts.

#### **Unclaimed monies**

All money and personal effects of patients which are left in the custody of the consolidated entity by any patient who is discharged or dies in hospital and which are not claimed by the person lawfully entitled thereto within a period of twelve months are recognised as the property of the respective health entity.

All such money and the proceeds of the realisation of any personal effects are lodged to the credit of the Samaritan Fund which is used specifically for the benefit of necessitous patients or necessitous outgoing patients.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 28. Payables

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				_
Accrued salaries, wages and on-costs	661,733	445,309	5,493	4,253
Salaries and wages deductions	109,373	111,648	41	3
Payroll tax and fringe benefits tax	1,853	1,802	1,327	1,251
Trade operating creditors	1,501,245	1,301,257	411,738	316,222
Other creditors				
- Capital works	192,780	217,538	-	-
- Payables to controlled health entities	-	-	130,547	363,546
- Other	6,183	7,163	-	-
	2,473,167	2,084,717	549,146	685,275
Non-current				
Other creditors				
- Capital works	72,185	106,396	_	-
	72,185	106,396	-	-

Details regarding liquidity risk, including a maturity analysis of the above payables are disclosed in Note 41.

The entire non-current payables relate to the purchase of EPIC software license for the Single Digital Patient Record program, which is payable over 5 years. Amounts payable after 12 months has been included as non-current payable.

#### **Recognition and Measurement**

Payables represent liabilities for goods and services provided to the consolidated entity and other amounts. Short-term payables with no stated interest rate are measured at the original invoice amount where the effect of discounting is immaterial.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 29. Contract liabilities

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				
Contract liabilities	39,311	36,785	33	647
	39,311	36,785	33	647
Non-current				
Contract liabilities	83	198	-	-
	83	198	-	-

## **Recognition and Measurement**

Contract liabilities are in respect of consideration received in advance from the sale of goods and services from contracts with customers and grants and other contributions.

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Revenue recognised that was included in the contract		<u> </u>		_
liability balance at the beginning of the year	27,343	56,360	131	29
Revenue recognised from performance obligations				
satisfied in previous periods	6,090	3,828	-	-
Transaction price allocated to the remaining				
performance obligations from contracts with				
customers	175,300	131,074	380	982

The transaction price allocated to the remaining performance obligations relates to the following revenue classes and is expected to be recognised as follows:

CONSOLIDATED	2026	2027	2028	≥ 2029	Total
Specific revenue class	\$000	\$000	\$000	\$000	\$000
Sales of goods and services from					
contracts with customers	55,599	1,362	573	573	58,107
Grants and other contributions	83,824	17,377	3,504	12,488	117,193
	139,423	18,739	4,077	13,061	175,300
PARENT	2026	2027	2028	≥ 2029	Total
Specific revenue class	\$000	\$000	\$000	\$000	\$000
Grants and other contributions	380	-	-	-	380
	380	-	-	-	380

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 30. Borrowings

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				_
Derivatives	471	679	-	-
Other loans and deposits	7,244	7,304	-	-
Lease liabilities (see Note 24)	152,954	148,498	70	171
Service concession financial liabilities	1,757	1,655	-	-
Public, private partnerships (PPP)				
Long Bay Forensic Hospital	4,017	3,632	-	-
Calvary Mater Newcastle Hospital	3,964	3,451	-	-
Orange Hospital & Associated Health Services	6,199	5,164	-	-
Royal North Shore Hospital Redevelopment	20,714	16,492	-	-
	197,320	186,875	70	171
Non-Current				
Derivatives	2,382	37	-	-
Other loans and deposits	16,278	23,522	-	-
Lease liabilities (see Note 24)	589,026	610,566	50	485
Coming consequent financial liabilities				
Service concession financial liabilities	24,643	26,400	-	-
Public, private partnerships (PPP)	24,643	26,400	-	-
	24,643 50,392	26,400 54,408	-	-
Public, private partnerships (PPP)			-	- - -
Public, private partnerships (PPP)  Long Bay Forensic Hospital	50,392	54,408	- - -	- - -
Public, private partnerships (PPP)  Long Bay Forensic Hospital  Calvary Mater Newcastle Hospital	50,392 51,968	54,408 55,932	- - - -	- - - -

No assets have been pledged as security / collateral for liabilities and there are no restrictions on any title to property.

Details regarding liquidity risk, including a maturity analysis of the above borrowings are disclosed in Note 41.

Borrowings represents interest bearing liabilities mainly through NSW Treasury Corporation, lease liabilities, service concessions arrangement liabilities, other interest bearing liabilities and derivatives.

The consolidated entity has entered into various public, private partnership (PPP) financing arrangements with the private sector for the provision of service-enabling infrastructure that includes private sector delivering a combination of design, construction, financing, maintenance, operations and delivery of clinical and non-clinical services. Payments are made by the consolidated entity to the private sector entities on the basis of delivery of assets, service delivery or by granting a right to the operator to generate revenue by charging customers.

Assets under the PPP arrangements that fall within the scope of AASB 1059 are classified as service concession assets (SCA). Assets under the PPP arrangements that fall outside the scope of AASB 1059 are classified as normal property, plant and equipment (PP&E). Both SCA and PP&E are disclosed in Note 23. Liabilities under these arrangements are classified as either a PPP liability or service concession financial liability (SCFL) under Note 30 or grant of right to operate liability under service concessions (GORTO) under Note 32.

#### Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 30. Borrowings (continued)

List of all such arrangements is as follows:

Name of arrangement	Type of Asset	Type of Liability
Orange Hospital & Associated Health Services PPP	PP&E (Note 23)	PPP Liability (Note 30)
Long Bay Forensic Hospital PPP	PP&E (Note 23)	PPP Liability (Note 30)
Calvary Mater Newcastle Hospital PPP	PP&E (Note 23)	PPP Liability (Note 30)
Royal North Shore Hospital Redevelopment PPP		
- Royal North Shore Hospital	PP&E (Note 23)	PPP Liability (Note 30)
- Royal North Shore Hospital Car Park No.1	SCA (Note 23)	GORTO (Note 32)
- Royal North Shore Hospital Car Park No.2	SCA (Note 23)	SCFL (Note 30)
Northern Beaches Hospital PPP		
- Northern Beaches Public Hospital	SCA (Note 23)	Nil
- Northern Beaches Hospital - Shared portion	SCA (Note 23)	GORTO (Note 32)
- Northern Beaches Hospital Car Park	SCA (Note 23)	GORTO (Note 32)

The consolidated entity has also entered into other arrangements, similar to PPP arrangements, with the private sector for the provision of public services, however the arrangement does not require the construction of assets by the private sector. The assets are provided by the consolidated entity to the private operator which are the existing assets of the consolidated entity and meets the definition of service concession assets. Details of these arrangements are as follows:

Name of arrangement	Type of Asset	Type of Liability
Mercy Care Centre Young	SCA (Note 23)	Nil

#### **Recognition and Measurement**

Financial liabilities at amortised cost

Borrowings classified as financial liabilities at amortised cost are initially measured at fair value, net of directly attributable transaction costs. These are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in the net result when the liabilities are derecognised as well as through the amortisation process.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held-for-trading such as derivative financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held-for-trading if they are incurred for the purpose of repurchasing in the near term or on initial recognition are part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking. Derivatives are economic hedges classified as at fair value through profit or loss unless they are designated as effective hedging instruments.

Derivatives are carried as financial liabilities when the fair value is negative. Gains or losses on derivative liabilities are recognised in the net result as the consolidated entity has elected not to apply hedge accounting.

The consolidated entity has not designated any financial liability as at fair value through profit or loss.

The consolidated and parent entity has not granted any financial guarantees.

## Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 30. Borrowings (continued)

Changes in liabilities arising from financing activities

## **CONSOLIDATED**

				Service	
		Other loans		concession	
	Derivatives	and deposits	Leases	arrangements	Total
	\$000	\$000	\$000	\$000	\$000
1 July 2023	624	990,169	639,926	29,612	1,660,331
Cash flows	(1,198)	(30,307)	(163,440)	(1,557)	(196,502)
New leases	-	-	166,878	-	166,878
Lease terminations	-	-	(14,104)	-	(14,104)
Lease reassessments	-	-	129,804	-	129,804
Other non-cash changes	1,290	-	-	-	1,290
30 June 2024	716	959,862	759,064	28,055	1,747,697
44.4.0004	740	050 000	750.004	00.055	4 7 47 007
1 July 2024	716	959,862	759,064	28,055	1,747,697
Cash flows	(165)	(36,042)	(160,400)	(1,655)	(198,262)
New leases	-	-	84,921	-	84,921
Lease terminations	-	-	(9,111)	-	(9,111)
Lease reassessments	-	-	67,506	-	67,506
Other non-cash changes	2,302		=	-	2,302
30 June 2025	2,853	923,820	741,980	26,400	1,695,053

Cash flows from derivatives in the above table will not reconcile to the Statement of Cash Flows as the Statement of Cash Flows presents a net cash movement of financial assets and liabilities.

#### **PARENT**

	Leases	Total
	\$000	\$000
1 July 2023	785	785
Cash flows	(170)	(170)
New leases	44	44
Lease reassessments	(3)	(3)
30 June 2024	656	656
1 July 2024	656	656
Cash flows	(41)	(41)
New leases	104	104
Lease terminations	(598)	(598)
Lease reassessments	(1)	(1)
30 June 2025	120	120

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

## 31. Provisions

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current				
Employee benefits and related on-costs				
Annual leave				
Obligations expected to be settled within 12 months	1,913,094	1,765,660	21,637	18,398
Obligations expected to be settled after 12 months	861,412	900,622	6,740	7,553
Long service leave consequential on-costs				
Obligations expected to be settled within 12 months	47,527	45,954	937	848
Obligations expected to be settled after 12 months	438,409	451,733	8,437	7,546
Allocated days off	86,524	85,769	-	-
Sick leave	120	130	-	-
Parental leave				
Obligations expected to be settled within 12 months	143,423	111,703	1,939	1,525
Provision for other employee benefits	5,006	-	-	-
	3,495,515	3,361,571	39,690	35,870
Other Provisions				
Restoration costs	16,503	13,734	-	-
Other	120,115	94,160	37,656	66,904
	136,618	107,894	37,656	66,904
Total current provisions	3,632,133	3,469,465	77,346	102,774
		_		_
Non-current				
Employee benefits and related on-costs				
Long service leave consequential on-costs	53,815	55,116	1,042	933
	53,815	55,116	1,042	933
Other Provisions				
Restoration costs	18,506	16,757	-	-
Other	6,700	5,903	6,700	5,903
	25,206	22,660	6,700	5,903
Total non-current provisions	79,021	77,776	7,742	6,836
Aggregate employee benefits and related on-costs				
Provisions - current	3,495,515	3,361,571	39,690	35,870
Provisions - non-current	53,815	55,116	1,042	933
Accrued salaries, wages and on-costs and salaries				
and wages deductions (Note 28)	771,106	556,957	5,534	4,256
	4,320,436	3,973,644	46,266	41,059

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 31. Provisions (continued)

### Movements in provisions (other than employee benefits)

Movements in each class of provision during the financial year, other than employee benefits, are set out below:

#### **Restoration costs**

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Carrying amount at beginning of year	30,491	23,969	-	
- Additional provisions recognised	7,089	8,474	-	-
- Amounts used	(1,225)	(1,722)	-	-
- Unused amounts reversed	(1,346)	(230)	-	<u>-</u>
Carrying amount at end of year	35,009	30,491	-	-

The majority of 'restoration costs' represent the expected cost to restore a leased asset at the end of the lease term. Lease end dates vary across the consolidated entity's lease portfolio and therefore the timing of the payments to restore the leased asset at the end of the term will vary. The majority of the 'restoration cost' provision is as per the lease contracts.

#### Other

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Carrying amount at beginning of year	100,063	79,954	72,807	50,600
- Additional provisions recognised	63,328	60,960	16,736	22,499
- Amounts used	(34,910)	(37,922)	(43,987)	(292)
- Unused amounts reversed	(1,666)	(2,929)	(1,200)	
Carrying amount at end of year	126,815	100,063	44,356	72,807
- Amounts used - Unused amounts reversed	(34,910) (1,666)	(37,922) (2,929)	(43,987) (1,200)	(292

The majority of the 'other' provision represent various contractual related obligations. The consolidated and parent entity has recognised the provision amount by taking into consideration all available information at the reporting date and making the best management estimation of the obligation. The timing of the payments will vary for each contractual related obligations.

# **Recognition and Measurement**

# Employee benefits and related on-costs

# Salaries and wages, annual leave, allocated days off (ADOs), parental leave, sick leave and on-costs

Salaries and wages (including non-monetary benefits) and paid sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the service are recognised and measured at the undiscounted amounts of the benefits.

Annual leave, ADOs and parental leave are not expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related service. As such, it is required to be measured at present value in accordance with AASB 119 *Employee Benefits* (although short-cut methods are permitted).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 31. Provisions (continued)

**Recognition and Measurement (continued)** 

Employee benefits and related on-costs (continued)

# Salaries and wages, annual leave, allocated days off (ADOs), parental leave, sick leave and on-costs (continued)

Actuarial advice obtained by NSW Treasury, an entity controlled by the ultimate parent, has confirmed that using the nominal annual leave balance plus the annual leave entitlements accrued while taking annual leave (calculated using 8.4% to 11.4% of nominal value of annual leave) can be used to approximate the present value of the annual leave liability. The consolidated entity has assessed the actuarial advice based on the consolidated entity's circumstances to annual leave, ADOs and parental leave and has determined that the effect of discounting is immaterial. All annual leave is classified as a current liability even where the consolidated entity does not expect to settle the liability within 12 months as the consolidated entity does not have an unconditional right to defer settlement.

Unused non-vesting sick leave does not give rise to a liability as it is not considered probable that sick leave taken in the future will be greater than the benefits accrued in the future.

# Long service leave and superannuation

The consolidated entity's liability for long service leave and defined benefit superannuation are assumed by The Crown in right of the State of New South Wales. The consolidated entity accounts for the liability as having been extinguished resulting in the amount assumed being shown as part of the non-monetary revenue item described as 'Acceptance by the Crown of employee benefits and other liabilities'.

Specific on-costs relating to long service leave assumed by The Crown in right of the State of New South Wales are borne by the consolidated entity.

Long service leave is measured at the present value of expected future payments to be made in respect of services provided up to the reporting date. Consideration is given to certain factors based on an actuarial review, including expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using the long-term Commonwealth Government bond rate at the reporting date.

The superannuation expense for the financial year is determined by using the formula specified in the NSW Treasury's, an entity controlled by the ultimate parent entity, Directions. The expense for certain superannuation schemes (i.e. Basic Benefit and Aware Super) is calculated as a percentage of the employees' salary. For other superannuation schemes (i.e. State Superannuation Scheme and State Authorities Superannuation Scheme), the expense is calculated as a multiple of the employees' superannuation contributions.

### Consequential on-costs

Consequential costs to employment are recognised as liabilities and expenses where the employee benefits to which they relate have been recognised. This includes outstanding amounts of payroll tax, workers' compensation insurance premiums and fringe benefits tax.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

### 32. Other liabilities

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Current		_		_
Unearned revenue	26,540	78,383	25,000	-
Grant of right to operate liability under service				
concessions*	9,389	9,646	-	-
Liabilities under transfer to acquire or construct non-				
financial assets to be controlled by the entity	13,871	14,726	276	187
Other	784	-	-	-
	50,584	102,755	25,276	187
Non-current				
Unearned revenue	95,056	100,372	-	-
Grant of right to operate liability under service				
concessions*	146,284	155,673	-	-
Liabilities under transfer to acquire or construct non-				
financial assets to be controlled by the entity	59,319	54,432	2,814	2,766
Other	34	35	-	-
	300,693	310,512	2,814	2,766

<sup>\*</sup> This is the unearned revenue portion of the revenue from exchange of assets and is progressively reduced over the period of the arrangement. Refer to Note 12 and Note 23 for further information on service concession arrangements.

Reconciliation of financial assets and corresponding liabilities arising from transfers to acquire or construct non-financial assets:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$'000	\$'000
Opening balance of liabilities arising from transfers to				_
acquire / construct non-financial assets to be				
controlled by the entity	69,158	89,000	2,953	3,000
Add: receipt of cash during the financial year	38,646	5,361	550	-
Less: income recognised during the financial year	(34,614)	(25,203)	(413)	(47)
Closing balance of liabilities arising from transfers to				
acquire / construct non-financial assets to be				
controlled by the entity	73,190	69,158	3,090	2,953

Refer to Note 10 for a description of the consolidated and parent entity's obligations under transfers received to acquire or construct non-financial assets to be controlled by the consolidated and parent entity.

The consolidated and parent entity expects to recognise as income any liability for unsatisfied obligations as at the end of the reporting period evenly during the next 1 to 2 financial years, as the related asset(s) are constructed. There are also some liabilities in relation to future replacement of capital assets, the timing of revenue recognition is mostly unknown at this stage.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 33. Equity

# Increase / (decrease) in net assets from equity transfers

	Consolidated 2025 \$000	Consolidated 2024 \$000	Parent 2025 \$000	Parent 2024 \$000
Transfer of property, plant and equipment (a)	(20,261)	-	4,017	-
	(20,261)	_	4,017	-
(a) Carrying amount at transfer date				
Land & buildings	(15,947)	-	4,017	-
Plant and equipment	(4,314)	<u>-</u>	-	
Fair value at transfer date	(20,261)		4,017	-

#### **CONSOLIDATED**

During the year, the consolidated entity transferred specialist equipment and building works to Viral Vector Manufacturing Facility Pty Ltd (VVMF), an entity controlled by the ultimate parent, at no consideration. VVMF is a NSW Government entity, set up to operate the viral vector manufacturing facility based at Westmead. The transfer of assets is part of the ongoing support the NSW Government has agreed to provide to VVMF. The asset transfer was treated as an equity transfer. The carrying amount of the assets prior to the transfer was \$20.26 million.

#### **PARENT**

In 2025, in accordance with the Real Property Disposal Framework, the following assets were transferred at fair value from South Western Sydney and Western NSW Local Health Districts, entities controlled by the Ministry of Health: 72 Menangle Road, Camden NSW 2570; 86 Menangle Road, Camden NSW 2570; and 84 Menangle Road, Camden NSW 2570, with a combined value of \$3.64 million, as well as 35 Woodiwiss Avenue, Cobar, valued at \$0.38 million.

#### 34. Commitments

# (a) Capital commitments

Aggregate capital expenditure for the acquisition of land and buildings, plant and equipment, infrastructure and intangible assets, contracted for at balance date and not provided for:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Within one year	2,014,425	1,761,845	11,835	-
Later than one year and not later than five years	1,428,901	1,156,330	4,824	-
Later than five years	1,181	2,272	-	-
Total (including GST)	3,444,507	2,920,447	16,659	-

### (b) Input tax receivable related to capital commitments for expenditure

The total of capital 'commitments' payable, i.e. \$3,444.51 million as at 30 June 2025, includes input tax credits of \$313.10 million that are expected to be recoverable from the Australian Taxation Office (2024: \$265.50 million).

# (c) Output tax payable related to commitments for revenue

The total of 'commitments' receivable, i.e. \$165.65 million as at 30 June 2025, includes input tax of \$15.10 million that is expected to be payable to the Australian Taxation Office (2024: \$14.90 million).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 35. Trust funds

# **CONSOLIDATED**

The consolidated entity holds money in trust in relation to patient trusts, refundable deposits, private patient trust funds and third party funds. As the consolidated entity performs only a custodial role in respect of trust monies, they are excluded from the financial statements as the consolidated entity cannot use them for the achievement of its own objectives. The following is a summary of the transactions in the trust accounts:

2025	Cash balance at	Add:	Less:	Cash balance at
	the beginning of	receipts	expenditure	the end of the
	the financial year			financial year
	\$000	\$000	\$000	\$000
Patient Trust	17,858	4,369	(3,447)	18,780
Refundable Deposits	6,827	3,205	(2,583)	7,449
Private Patient Trust Funds	143	637,035	(634,894)	2,284
Third Party Funds	62,129	159,496	(164,326)	57,299
Other	52,215	15,825	(3,173)	64,867
Total trust funds	139,172	819,930	(808,423)	150,679
2024	Cash balance at	Add:	Less:	Cash balance at
	the beginning of	receipts	expenditure	the end of the
	the financial year			financial year
	\$000	\$000	\$000	\$000
Patient Trust	15,345	6,487	(3,974)	17,858
Refundable Deposits	10,580	1,368	(5,121)	6,827
Private Patient Trust Funds	1,813	579,483	(581,153)	143
Third Party Funds	74,114	194,725	(206,710)	62,129
Other	20,987	43,348	(12,120)	52,215

# **PARENT**

2025	Cash balance at	Add:	Less:	Cash balance at
	the beginning of	receipts	expenditure	the end of the
	the financial year			financial year
	\$000	\$000	\$000	\$000
Third Party Funds	18,756	6,582	(19,459)	5,879
Total trust funds	18,756	6,582	(19,459)	5,879
2024	Cash balance at	Add:	Less:	Cash balance at
2024	Cash balance at the beginning of	Add: receipts	Less: expenditure	Cash balance at the end of the
2024				
2024	the beginning of			the end of the
2024 Third Party Funds	the beginning of the financial year	receipts	expenditure	the end of the financial year

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 35. Trust funds (continued)

The following list provides a brief description of the purpose of the trust fund categories.

Category	Purpose
Patient Trust	The safe custody of patients' valuables including monies.
Refundable Deposits	A sum of money held in trust as a security deposit.
Private Patient Trust Funds	The revenue derived from private patient and other billable services provided by Staff Specialists.
Third Party Funds	A sum of money held in trust on behalf of external parties, e.g. external foundations, volunteer groups and auxiliaries.
Other	Includes unallocated monies and outstanding settlements. Outstanding settlements refers to expenses and revenue processed in the respective trust fund cost centres, however awaiting cash settlements to take place. Majority of it relates to private practice fund transfer from trust (No.1 Accounts) to restricted funds (No.2 Accounts), awaiting physical settlement/transfer of cash between those bank accounts.

### 36. Contingent liabilities and contingent assets

# **CONSOLIDATED AND PARENT**

# a) Contingent liabilities

Several industrial relations matters, relating to employee award entitlements have been brought against the consolidated entity. The consolidated entity is defending all the claims. It is not practical to estimate the potential effect of these claims at the present time.

# b) Contingent assets

The consolidated entity is not aware of any contingent assets which would have a material effect on the disclosures in these financial statements.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 37. Interests in other entities

#### a) Interests in associates

Set out below are the associates of Hunter New England Local Health District (HNELHD) and Illawarra Shoalhaven Local Health District (ISLHD) as at 30 June 2025. The proportion of ownership interest held by the group equals the voting rights held by the group.

	Place of business and		Ownership interest			Measurement	Carrying	amount
Name of entity	country of	Class of shares	2025	2024	Reporting Period		2025	2024
	incorporation	incorporation %	%		method	\$000	\$000	
Hunter Medical Research Institute	Australia	Not applicable	25	25	31 December	Equity method	-	-
Keira Institute of Health and Medical	Australia	Not applicable	33	33	30 June	Equity method	-	-
Research Limited								

Hunter Medical Research Institute is a company limited by guarantee, whose constitution prohibits the distribution of funds to its members. Accordingly the carrying amount has been equity accounted at \$Nil value and as such no financial information has been disclosed.

Keira Institute of Health and Medical Research Limited is a company limited by guarantee, whose constitution prohibits the distribution of funds to its members. Accordingly the carrying amount has been equity accounted at \$Nil value and as such no financial information has been disclosed.

# b) Interests in joint control

Central Coast Local Health District has entered into an agreement called Affiliation Agreement for the Central Coast Research Institute (CCRI) with the University of Newcastle, to undertake research.

The agreement requires equal appointment of directors to the CCRI's Governance Board, which will be managing the relevant activities of the CCRI. Both parties have direct rights to the assets of the CCRI and are jointly and severally liable for the liabilities incurred. CCRI is therefore classified as a joint operation and Central Coast Local Health District recognises its direct right to the jointly held assets, liabilities, revenues and expenses and its share of any jointly held or incurred assets, liabilities, revenues and expenses. These have been incorporated in the financial statements under the appropriate headings.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 38. Budget Review - Consolidated

The budgeted amounts are drawn from the original budgeted financial statements presented to Parliament in respect of the reporting period. Subsequent amendments to the original budget (e.g. adjustment for transfer of functions between entities as a result of Administrative Arrangements Orders) are not reflected in the budgeted amounts. Major variances between the original budgeted amounts and the actual amounts disclosed in the financial statements are explained below.

#### **NET RESULT**

The actual net result (surplus of \$1,134 million) is lower than the budgeted net result (surplus of \$1,959 million) by \$825 million for the year ended 30 June 2025.

A reconciliation of the movements between the actual and budgeted net result is presented below:

Net result - actual	\$000 1,133,996
Employee related expenses were higher than budget due to negotiated wage policy changes on some awards, higher than expected redundancy payments, and the impact of the Workers Compensation Annual Performance Adjustment.	366,329
Operating expenses were above budget, primarily driven by higher costs associated with specialised health services, medical and surgical supplies, and visiting medical officers. These increases reflect the sustained focus on reducing elective surgery waitlists throughout the year.	252,125
Depreciation and amortisation were higher than budget due to the timing of new capital projects coming into service and the impact of the prior and current year comprehensive revaluations of land, buildings and infrastructure.	29,909
Grants and subsidies expenses were lower than expected with lower than anticipated grants provided to research organisations during the year.	(44,793)
Finance costs exceeded budget due to the exercise of extension options on certain right-of-use leases for rotor contracts and bases, leading to increased interest expenses on the related lease liabilities.	15,877
Appropriations drawdowns were lower than budget primarily driven by lower than expected spend against the capital program.	508,304
Acceptance by the Crown of employee benefits and other liabilities was lower than budget due to the lower than anticipated actuarial valuation to long service leave benefits assumed by the Crown.	2,828
Revenue from the sale of goods and services from contracts with customers surpassed the budget, driven by higher fees for medical services rendered and motor accident third party insurance.	(223,101)
Investment revenue and other income exceeded budget as a result of higher interest received on financial assets at amortised cost due to a higher restricted cash and cash equivalent balance during the year and additional insurance refunds received.	(54,928)
Grants and other contributions revenue exceeded budget expectations, largely due to higher-than- anticipated in-kind grants for vaccinations under the Commonwealth Vaccination Program, grants from the Crown to support non-frontline redundancy payments, and non-cash donations and contributions.	(146,455)
Gains / (losses) on disposal exceeded budget due to the disposal of various items of property, plant and	
equipment below the written down value and other gains / (losses) was lower than budget due to a	
reduced write-off and impairment of medical and surgical supplies.	7,687
Impairment losses on financial assets were higher than expected.	111,613
Net result - budget	1,959,391

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 38. Budget Review - Consolidated (continued)

# **ASSETS AND LIABILITIES**

Net assets - budget

The actual net assets (\$31,164 million) is lower than the budgeted net assets (\$31,390 million) by \$226 million as at 30 June 2025.

A reconciliation of the movements between significant assets and liabilities is presented below:

Net assets - actual	\$000 31,163,860
Cash and cash equivalents were higher than expected resulting from the timing of year end creditor and payroll payments and higher restricted financial asset holdings.	(724,696)
Receivables exceeded budget, mainly due to higher trade receivables from contracts with customers. This was driven by increased patient fee receivables and higher amounts owing from other jurisdictions related to interstate patient inflows.	(353,986)
Inventories were lower than budget due to slightly higher consumption rates of medical and surgical supplies and a larger write down of medical and surgical supplies than anticipated due to items expiring before they could be used.	35,329
Financial assets at fair value were less than budget primarily as a result of marginally lower returns on medium and long term TCorpIM fund investments throughout the financial year.	5,127
Property, plant and equipment was lower than expected primarily due to the timing of capital projects being delivered and lower than expected revaluation adjustments. Higher than budgeted depreciation from large revaluations in prior years also contributed to the position.	275,750
Right-of-use assets were higher than budget due to the exercise of extension options on certain right-of-use assets for rotor contracts and associated bases.	(30,863)
Other financial assets were above budget due to the timing of the recognition of new receivables on finance leases as a lessor.	(9,864)
Intangibles were lower than original budget primarily resulting from reduced capital spend.	126,635
Payables were higher than expected due to the impact of wage policy changes on accrued salaries, wages and on-costs and trade operating creditors increased due to payment terms returning to a 30 day payment term for correctly rendered invoices (excluding small businesses who are paid immediately for a correctly rendered invoice).	458,370
Contract liabilities were lower than budget due to the timing of meeting the specific performance obligations within the contracts.	(18,193)
Borrowings were higher than expected resulting from exercising some extension lease options and additional recognition of leases.	44,378
Provisions were higher than expected as a result of the impact of negotiated wage policy changes on some awards resulting in higher than anticipated annual leave provisions and parental leave balances increased as a result of the number of employees with submitted applications to take parental leave in the next 2 years.	417,606
Other liabilities were below budget, primarily due to a decrease in unearned revenue. Prior year funds related to a specific building project were utilised to fully derecognise the building, which is now recognised as a finance lease.	(50,831)

31,390,309

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 38. Budget Review - Consolidated (continued)

# **CASH FLOWS**

Operating activities net cash inflows were lower than budget by \$386.3 million attributable to receipts being lower than budget for appropriations, grants and other contributions and other receipts, but slightly offset by higher receipts from the sale of goods and services. Similar to receipts, payments were lower than budget due mainly to lower payments to suppliers for goods and services.

Investing activities net cash outflows were lower than budget by \$552.7 million attributable to decreases in purchases of property, plant and equipment and intangibles and proceeds from the sale of property, plant and equipment and intangibles and increases in other investing activities.

Financing net cash outflows were lower than expected by \$12.3 million. This was attributable primarily to lower payments of borrowings and advances but mostly offset by higher repayments of principal portion of lease liabilities than budgeted.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 39. Reconciliation of cash flows from operating activities to net result

Reconciliation of cash flows from operating activities to the net result as reported in the Statement of Comprehensive Income as follows:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Net cash used on operating activities	3,128,870	2,703,436	293,778	335,552
Depreciation and amortisation expense	(1,577,540)	(1,477,854)	(11,706)	(11,420)
Allowance for impairment	(138,788)	(176,768)	(7,712)	120
Effects of exchange rate changes	448	198	-	-
(Increase) / decrease in other liabilities	13,690	25,354	(25,137)	47
(Increase) / decrease in provisions	(163,911)	(205,231)	24,522	(27,700)
Increase / (decrease) in inventory	(6,267)	(37,726)	64,628	5,218
Increase / (decrease) in prepayments and other assets	283,918	124,714	(33,281)	107,168
Increase / (decrease) in contract assets	5,166	418	5,665	175
(Increase) / decrease in payables	(411,285)	(86,385)	136,020	(125,423)
(Increase) / decrease in contract liabilities	(2,411)	20,604	614	(102)
(Increase) / decrease in financial instruments at fair				
value	8,007	7,933	-	-
Net gain / (loss) on sale of property, plant and				
equipment	(18,769)	(12,474)	(56)	(5)
Net gain / (loss) on disposal of right-of-use assets	1,158	727	39	-
Assets donated or brought to account (Note 40)	9,877	2,314	(678)	4
Other	1,833	957	-	1
Net result	1,133,996	890,217	446,696	283,635

# 40. Non-cash financing and investing activities

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Assets donated or brought to account	9,877	2,314	(678)	4
Property, plant and equipment acquired by a lease	85,098	166,878	104	44
	94,975	169,192	(574)	48

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments

The consolidated entity's principal financial instruments are outlined below. These financial instruments arise directly from the consolidated entity's operations or are required to finance its operations. The consolidated entity does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

The consolidated entity's main risks arising from financial instruments are outlined below, together with the consolidated entity's objectives, policies and processes for measuring and managing risk. Further quantitative and qualitative disclosures are included throughout these financial statements.

The Secretary of NSW Health has overall responsibility for the establishment and oversight of risk management and reviews and agrees policies for managing each of these risks. Risk management policies are established to identify and analyse the risks faced by the consolidated and parent entities, to set risk limits and controls and to monitor risks. Compliance with policies is reviewed on a continuous basis.

# (a) Financial instrument categories CONSOLIDATED

			Carryin	g amount
			2025	2024
Class	Note	Category	\$000	\$000
Financial Assets				
Cash and cash equivalents	17	Amortised cost	3,139,759	2,781,203
Receivables <sup>1</sup>	18	Amortised cost	939,612	854,540
Contract assets <sup>2</sup>	19	Amortised cost	7,843	2,677
Financial assets at fair	21	Fair value through profit or loss - mandatory		
value		classification	80,287	74,872
Other financial assets	22	Amortised cost	97,641	90,771
Total financial assets			4,265,142	3,804,063
Financial Liabilities				
Payables <sup>3</sup>	28	Financial Liabilities (at amortised cost)	2,543,499	2,189,311
Borrowings	30	Financial Liabilities (at amortised cost)	1,692,200	1,746,981
	30	Fair value through profit or loss - mandatory		
		classification	2,853	716
Other liabilities <sup>3</sup>	32	Financial Liabilities (at amortised cost)	818	35
Total financial liabilities			4,239,370	3,937,043

# Notes

<sup>&</sup>lt;sup>1</sup> Excludes statutory receivables and prepayments (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

<sup>&</sup>lt;sup>2</sup> While contract assets are also not financial assets, they are explicitly included in the scope of AASB 7 Financial Instruments: Disclosures for the purpose of the credit risk disclosures.

<sup>&</sup>lt;sup>3</sup> Excludes statutory payables and unearned revenue (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

# (a) Financial instrument categories (continued)

# **PARENT**

			Carryin	g amount
			2025	2024
Class	Note	Category	\$000	\$000
Financial Assets				
Cash and cash equivalents	17	Amortised cost	1,070,802	683,561
Receivables <sup>1</sup>	18	Amortised cost	263,797	308,504
Contract assets <sup>2</sup>	19	Amortised cost	6,301	636
Other financial assets	22	Amortised cost	184,620	281,133
Total financial assets			1,525,520	1,273,834
Financial Liabilities				
Payables <sup>3</sup>	28	Financial Liabilities (at amortised cost)	547,819	684,024
Borrowings	30	Financial Liabilities (at amortised cost)	120	656
Total financial liabilities			547,939	684,680

#### **Notes**

The consolidated entity determines the classification of its financial assets and liabilities after initial recognition and, when allowed and appropriate, re-evaluates this at each financial year end.

#### (b) Derecognition of financial assets and financial liabilities

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised when the contractual rights to the cash flows from the financial assets expire; or if the entity transfers its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a pass through arrangement and either:

- the consolidated entity has transferred substantially all the risks and rewards of the asset; or
- the consolidated entity has neither transferred nor retained substantially all the risks and rewards for the asset, but has transferred control.

When the consolidated entity has transferred its rights to receive cash flows from an asset or has entered into a pass through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. Where the consolidated entity has neither transferred nor retained substantially all the risks and rewards or transferred control, the asset continues to be recognised to the extent of the consolidated entity continuing involvement in the asset. In that case, the consolidated entity also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the entity has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the consolidated entity could be required to repay.

<sup>&</sup>lt;sup>1</sup> Excludes statutory receivables and prepayments (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

<sup>&</sup>lt;sup>2</sup> While contract assets are also not financial assets, they are explicitly included in the scope of AASB 7 Financial Instruments: Disclosures for the purpose of the credit risk disclosures.

<sup>&</sup>lt;sup>3</sup> Excludes statutory payables and unearned revenue (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

# (b) Derecognition of financial assets and financial liabilities (continued)

A financial liability is derecognised when the obligation specified in the contract is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the net result.

#### (c) Offsetting financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the Statement of Financial Position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

#### (d) Financial risks

#### i. Credit risk

Credit risk arises when there is the possibility that the counterparty will default on their contractual obligations, resulting in a financial loss to the consolidated entity. The maximum exposure to credit risk is generally represented by the carrying amount of the financial assets (net of any allowance for credit losses or allowance for impairment).

Credit risk arises from financial assets of the consolidated entity, including cash, receivables and authority deposits. No collateral is held by the consolidated entity. The consolidated entity has not granted any financial guarantees.

Credit risk associated with the consolidated entity's financial assets, other than receivables, is managed through the selection of counterparties and establishment of minimum credit rating standards.

The consolidated entity considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the consolidated entity may also consider a financial asset to be in default when internal or external information indicates that the entity is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the consolidated entity.

# Cash and cash equivalents

Cash comprises cash on hand and bank balances within the NSW Treasury Banking System. Interest is earned on daily bank balances at the monthly average NSW Treasury Corporation (TCorp) 11am unofficial cash rate, adjusted for a management fee to NSW Treasury. The TCorp IM Funds cash facility is discussed in market risk below.

# Accounting policy for impairment of trade receivables and other financial assets

#### Receivables - trade receivables, other receivables, contract assets and lease receivables

Collectability of trade receivables, other receivables, contract assets and lease receivables is reviewed on an ongoing basis. Procedures as established in the Treasurer's Directions are followed to recover outstanding amounts, including letters of demand.

The consolidated entity applies the AASB 9 *Financial Instruments* simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables, other receivables, contract assets and lease receivables.

To measure the expected credit losses, trade receivables, other receivables, contract assets and lease receivables have been grouped based on shared credit risk characteristics and the days past due.

The expected loss rates are based on historical observed loss rates. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The consolidated entity has not identified any relevant factors, and accordingly has not adjusted the historical loss rates.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 41. Financial instruments (continued)

# (d) Financial risks (continued)

### i. Credit risk (continued)

Trade receivables, other receivables, contract assets and lease receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others a failure to make contractual payments for a period of greater than 90 days past due.

The loss allowance for trade receivables, other receivables, contract assets and lease receivables as at 30 June 2025 and 2024 was determined as follows:

Current

<30 days 30-60 days

61-90 days

>91 days

Total

#### **CONSOLIDATED**

	Current	SU days	30-00 uays	01-30 uays	-91 uays	TOTAL
30 June 2025	\$000	\$000	\$000	\$000	\$000	\$000
Expected credit loss rate	1.70%	4.61%	16.75%	25.65%	57.87%	15.16%
Estimated total gross						
carrying amount <sup>1</sup>	814,708	86,071	36,751	23,489	270,826	1,231,845
Expected credit loss	13,863	3,966	6,155	6,026	156,739	186,749
	Current	<30 days	30-60 days	61-90 days	>91 days	Total
30 June 2024	Current \$000	<30 days \$000	30-60 days \$000	61-90 days \$000	>91 days \$000	Total \$000
30 June 2024 Expected credit loss rate						
	\$000	\$000	\$000	\$000	\$000	\$000
Expected credit loss rate	\$000	\$000	\$000	\$000	\$000	\$000

#### **PARENT**

PARENI						
	Current	<30 days	30-60 days	61-90 days	>91 days	Total
30 June 2025	\$000	\$000	\$000	\$000	\$000	\$000
Expected credit loss rate	0.01%	0.00%	16.08%	0.00%	1.48%	0.77%
Estimated total gross						
carrying amount <sup>1,2</sup>	176,831	27,284	8,763	179	31,611	244,668
Expected credit loss	11	-	1,409	-	468	1,888
	Current	<30 days	30-60 days	61-90 days	>91 days	Total
30 June 2024	\$000	\$000	\$000	\$000	\$000	\$000
30 June 2024 Expected credit loss rate	<b>\$000</b> 0.00%	<b>\$000</b> 0.00%	<b>\$000</b> 0.00%	<b>\$000</b> 0.00%	<b>\$000</b> 0.85%	\$000 0.20%
	• • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	
Expected credit loss rate	• • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	
Expected credit loss rate Estimated total gross	0.00%	0.00%	0.00%	0.00%	0.85%	0.20%

# Notes

The consolidated entity is not materially exposed to concentrations of credit risk to a single trade debtor or group of debtors as at 30 June 2025 and 30 June 2024.

<sup>&</sup>lt;sup>1</sup> The analysis excludes statutory receivables and prepayments as these are not within the scope of AASB 7 Financial Instruments: Disclosures. Therefore the 'total' will not reconcile to the receivables total in Note 18 and the contract assets total in Note 19.

<sup>&</sup>lt;sup>2</sup> The estimated total gross carrying amount for the parent entity also excludes receivables from controlled health entities.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

### 41. Financial instruments (continued)

### (d) Financial risks (continued)

# ii. Liquidity risk

Liquidity risk is the risk that the consolidated entity will be unable to meet its payment obligations when they fall due. The consolidated entity continuously manages risk through monitoring future cash flows and maturities planning to ensure adequate holding of high quality liquid assets. The objective is to maintain a balance between continuity of funding and flexibility through effective management of cash, investments and liquid assets and liabilities.

The consolidated entity has negotiated no loan outside of arrangements with the Crown. During the current and prior year, there were no defaults of loans payable. No assets have been pledged as collateral.

Liquidity risk is minimised by the use of service agreements between the Secretary of NSW Health and controlled health entities. The annual service agreements, requires controlled entities to manage their financial liquidity and in particular, meet benchmarks for the payment of creditors. Where the controlled entities fail to meet service agreement performance standards, the parent as the state manager can take action in accordance with annual performance framework requirements, including providing financial support and increased management interaction.

Liabilities are recognised for amounts due to be paid in the future for goods or services received, whether or not invoiced. For all suppliers, that has a correctly rendered invoice, a matched purchase order and where goods have been received, a 30 day payment term is applied.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 41. Financial instruments (continued)

# (d) Financial risks (continued)

# ii. Liquidity risk (continued)

The following table summarises the maturity profile of the consolidated entity's financial liabilities together with the interest rate exposure.

Maturity analysis and interest rate exposure of financial liabilities:

			Interest Rate Exposure				Maturity Dates		
			Fixed	Variable	Non -				
		Nominal	Interest	Interest	Interest				
	EIR <sup>3</sup>	Amount 1	Rate	Rate	Bearing	< 1 Year	1-5 Years	> 5 Years	
	%	\$000	\$000	\$000	\$000	\$000	\$000	\$000	
CONSOLIDATED									
2025									
Payables <sup>2</sup>		2,552,452	114,199	-	2,438,253	2,476,320	76,132	-	
Borrowings:									
- Other loans and									
deposits	2.88	24,627	24,627	-	-	7,738	15,584	1,305	
- Lease liabilities	4.38	849,618	849,618	-	-	178,954	468,710	201,954	
- Service concession									
financial liabilities	2.42	30,354	30,354	-	-	2,376	10,137	17,841	
- PPP	11.15	1,636,493	1,549,929	86,564	-	134,083	568,708	933,702	
		5,093,544	2,568,727	86,564	2,438,253	2,799,471	1,139,271	1,154,802	
2024									
Payables <sup>2</sup>		2,197,114	144,462	-	2,052,652	2,082,915	114,199	-	
Borrowings:									
- Other loans and									
deposits	2.51	32,609	32,609	-	-	7,981	21,379	3,249	
- Lease liabilities	3.93	872,048	872,048	-	-	176,189	458,910	236,949	
- Service concession									
financial liabilities	2.42	32,670	32,670	-	-	2,316	9,881	20,473	
- PPP	10.85	1,770,153	1,673,793	96,360	-	131,157	556,491	1,082,505	
		4,904,594	2,755,582	96,360	2,052,652	2,400,558	1,160,860	1,343,176	

#### Notes

<sup>&</sup>lt;sup>1</sup> The amounts disclosed are the contractual undiscounted cash flows of each class of financial liabilities based on the earliest date on which the consolidated entity can be required to pay. The tables include both interest and principal cash flows and therefore will not agree to the Statement of Financial Position.

<sup>&</sup>lt;sup>2</sup> Excludes statutory payables and unearned revenue (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

<sup>&</sup>lt;sup>3</sup> Weighted Average Effective Interest Rate (EIR).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 41. Financial instruments (continued)

(d) Financial risks (continued)

ii. Liquidity risk (continued)

Maturity analysis and interest rate exposure of financial liabilities:

		Interest Rate Exposure					Maturity D	ates
			Fixed	Variable	Non -			
		Nominal	Interest	Interest	Interest			
	EIR <sup>3</sup>	Amount <sup>1</sup>	Rate	Rate	Bearing	< 1 Year	1-5 Years	> 5 Years
	%	\$000	\$000	\$000	\$000	\$000	\$000	\$000
PARENT								
2025								
Payables <sup>2</sup>		547,819	-	-	547,819	547,819	-	-
Borrowings:								
- Lease liabilities	6.19	127	127	-	-	74	53	-
		547,946	127	-	547,819	547,893	53	-
2024								
Payables <sup>2</sup>		684,024	-	-	684,024	684,024	-	-
Borrowings:								
- Lease liabilities	2.16	681	681	-	-	184	497	-
		684,705	681	-	684,024	684,208	497	-

### Notes

<sup>&</sup>lt;sup>1</sup> The amounts disclosed are the contractual undiscounted cash flows of each class of financial liabilities based on the earliest date on which the consolidated entity can be required to pay. The tables include both interest and principal cash flows and therefore will not agree to the Statement of Financial Position.

<sup>&</sup>lt;sup>2</sup> Excludes statutory payables and unearned revenue (i.e. not within scope of AASB 7 Financial Instruments: Disclosures).

<sup>&</sup>lt;sup>3</sup> Weighted Average Effective Interest Rate (EIR).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 41. Financial instruments (continued)

# (d) Financial risks (continued)

# ii. Liquidity risk (continued)

The following table summarises the maturity profile of the consolidated entity's derivative financial instruments. The maturity profile of the cash flows are matched to the anticipated settlement of the commercial contracts as forecasted by the consolidated entity.

Maturity analysis of derivative financial assets at fair value through profit and loss that are hedging foreign currency

			Maturity D	ates	
	Fair Value	< 1 Year	1-5 Years	> 5 Years	
	\$000	\$000	\$000	\$000	
CONSOLIDATED					
2025					
Financial assets:					
- Derivatives - inflows	7,273	22,065	43,996	11,533	
- Derivatives - outflows	1,213	(20,423)	(38,899)	(10,046)	
	7,273	1,642	5,097	1,487	
Financial liabilities:					
- Derivatives - inflows	(2,853)	27,612	98,564	-	
- Derivatives - outflows	(2,000)	(28,012)	(100,553)	-	
	(2,853)	(400)	(1,989)	-	
2024					
Financial assets:					
- Derivatives - inflows	8,798	58,837	39,483	20,110	
- Derivatives - outflows	8,798	(56,153)	(34,749)	(17,685)	
	8,798	2,684	4,734	2,425	
Financial liabilities:					
- Derivatives - inflows	(7.2)	26,238	31,743	-	
- Derivatives - outflows	(716)	(26,828)	(31,648)	-	
	(716)	(590)	95	-	

# Notes

Cash outflows in foreign currencies are translated at prevailing spot rates on reporting dates.

The parent entity had no derivative financial assets or liabilities for the year ended 30 June 2025 or 2024.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

### (d) Financial risks (continued)

### iii. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. The consolidated entity's exposures to market risk are primarily through interest rate risk on the consolidated entity's borrowings, foreign exchange risk and other price risks associated with the movement in the unit price of the TCorpIM funds. The consolidated entity does not enter into commodity contracts.

The effect on net result and equity due to a reasonably possible change in risk variable is outlined in the information below for interest rate risk, foreign currency risk and other price risk. A reasonably possible change in risk variable has been determined after taking into account the economic environment in which the consolidated entity operates and the time frame for the assessment (i.e. until the end of the next annual reporting period). The sensitivity analysis is based on risk exposures in existence at the Statement of Financial Position reporting date. The analysis was performed on the same basis for 2024. The analysis assumes that all other variables remain constant.

#### Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Exposure to interest rate risk arises primarily through the consolidated entity's interest bearing liabilities.

However, controlled entities are not permitted to borrow external to the Ministry of Health (energy loans which are negotiated through NSW Treasury are excepted).

Both NSW Treasury and Ministry of Health loans are set at fixed rates and therefore are generally not affected by fluctuations in market rates. The consolidated entity does not account for any fixed rate financial instruments at fair value through profit or loss or at fair value through other comprehensive income. Therefore, for these financial instruments, a change of interest rates would not affect the carrying value or interest paid / earned.

A reasonably possible change of +/-1% is used consistent with current trends in interest rates (based on official RBA interest rate volatility over the last five years). The basis will be reviewed annually and amended where there is a structural change in the level of interest rate volatility.

The following table demonstrates the sensitivity to a reasonably possible change in interest rates:

CONSOLIDATED		2025		2024
		\$000		\$000
	-1%	1%	-1%	1%
Net result	(30,854)	30,854	(27,232)	27,232
Equity	(30,854)	30,854	(27,232)	27,232
PARENT		2025		2024
		\$'000		\$'000
	-1%	1%	-1%	1%
Net result	(10,708)	10,708	(6,836)	6,836
Equity	(10,708)	10,708	(6,836)	6,836

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

### (d) Financial risks (continued)

# iii. Market risk (continued)

#### Foreign exchange risk

Exposure to foreign exchange risk arises primarily through the contractual commercial transactions denominated in a foreign currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The consolidated entity manages its foreign exchange risk by maintaining foreign currency denominated bank accounts or buying foreign currency from TCorp at the time of purchase commitment, or enters into derivative economic hedges with TCorp in accordance with the consolidated entity's risk management policies.

At year end, the consolidated entity did not hold any material foreign currency denominated monetary assets and monetary liabilities, except for cash held in a US dollar denominated bank account. All funds held at year end in foreign currency are expected to be used to settle existing purchase commitments that are denominated in US currency.

The consolidated entity has outstanding forward foreign exchange contracts entered with TCorp to hedge foreign currency risks. The forward foreign exchange contracts enable the consolidated entity to exchange fixed foreign currency for fixed AUD at specified future date, enabling cash flow certainty.

The consolidated entity is exposed to foreign exchange risks associated with commercial contracts payments denominated in foreign currency. The consolidated entity's risk management strategy is to hedge foreign currency risks by maintaining foreign currency denominated bank accounts, buying foreign currencies from TCorp at the time of purchase commitment or entering into foreign exchange derivative contracts as approved within internal policies and guidelines set out under NSW Health's Procurement Policy and broader framework under NSW Government Financial Risk Management Policy (TPP21-04). The forward foreign exchange derivative contracts are economic hedges which enables the consolidated entity to exchange a fixed amount of foreign currency for fixed AUD amount at a specified future settlement date, ensuring cash flow certainty.

A sensitivity analysis has been disclosed for the cash held in foreign currency bank account and outstanding derivative contracts at year end. A sensitivity of 10% movement in the exchange rates has been selected for use in the sensitivity analysis at the reporting date, as this is considered reasonable, based on the current Australian dollar level and the historical volatility of the Australian dollar against the US currency. Based on the value of the Australian dollar at the reporting date as compared with the currencies below, adverse or favourable movements in the foreign exchange rates would result in an increase or decrease in the Australian dollar fair value respectively.

#### **CONSOLIDATED**

2025		+10%	-10%	ó	
	Fair value	Net result	Equity	Net result	Equity
	\$000	\$000	\$000	\$000	\$000
Denominated US Dollars	860	(78)	(78)	96	96
Derivatives	4,420	(17,163)	(17,163)	20,977	20,977
2024		+10%	%	-10%	6
	Fair value	Net result	Equity	Net result	Equity

	Fair value	Net result	Equity	Net result	Equity
	\$000	\$000	\$000	\$000	\$000
Denominated US Dollars	4,662	(424)	(424)	518	518
Derivatives	8,082	(14,609)	(14,609)	17,856	17,856

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

# (d) Financial risks (continued)

### iii. Market risk (continued)

#### Other price risk - TCorpIM Funds

Exposure to 'other price risk' primarily arises through the investment in the TCorpIM Funds, which are held for strategic rather than trading purposes. The consolidated entity has no direct equity investments. The consolidated entity holds units in the following TCorpIM Funds trusts:

Facility	Investment Sectors	Investment Horizon	2025	2024
			\$000	\$000
TCorpIM Medium Term Growth Fund	Cash and fixed income, credit, equities, alternative assets and real assets	3 years to 7 years	32,143	29,729
TCorpIM Long Term Growth Fund	Cash and fixed income, credit, equities, alternative assets and real assets	7 years and over	40,871	36,345

The unit price of each facility is equal to the total fair value of net assets held by the facility divided by the total number of units on issue for that facility. Unit prices are calculated and published daily. TCorp as trustee for each of the above facilities is required to act in the best interest of the unit holders and to administer the trusts in accordance with the trust deeds. As trustee, TCorp has appointed external managers to manage the performance and risk of each facility in accordance with a mandate agreed by the parties. A significant portion of the administration of the facilities is outsourced to an external custodian.

Investment in the TCorpIM Funds facilities limits the consolidated entity's exposure to risk, as it allows diversification across a pool of funds with different investment horizons and a mix of investments.

TCorp provides sensitivity analysis information for each of the Investment facilities, which is used to demonstrate the impact on the funds' net assets as a result of a change in the unit price. This impact is based on a sensitivity rate of 10%, multiplied by the redemption value as at 30 June each year for each facility (balance from TCorpIM Funds statement). Actual movements in the price risk variables may differ to the sensitivity rate used due to a number of factors. The TCorpIM Funds are measured at fair value through profit or loss and therefore any change in unit price impacts directly on net results / equity.

	Impact on net result			
	Change in unit price		/ equity	
	2025	2024	2025	2024
	%	%	\$000	\$000
TCorpIM Medium Term Growth Fund	+/- 10%	+/- 10%	3,214	2,973
TCorpIM Long Term Growth Fund	+/- 10%	+/- 10%	4,087	3,635

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

### 41. Financial instruments (continued)

#### (e) Fair value measurement

### i. Fair value compared to carrying amount

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability.

The consolidated entity's fair value does not differ from the carrying amount.

# ii. Fair value recognised in the Statement of Financial Position

Derivative economic hedges and TCorpIM Funds Investment Facilities are measured at fair value. Management assessed that cash and short-term deposits, trade receivables, trade payables and other current liabilities approximate their fair values, largely due to the short-term maturities of these instruments.

When measuring fair value, the valuation technique used maximises the use of relevant observable inputs and minimises the use of unobservable inputs. Under AASB 13 Fair Value Measurement, the consolidated entity categorises, for disclosure purposes, the valuation techniques based on the inputs used in the valuation techniques as follows:

- Level 1 quoted (unadjusted) prices in active markets for identical assets / liabilities that the entity can access at the measurement date.
- Level 2 inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.
- Level 3 inputs that are not based on observable market data (unobservable inputs).

The consolidated entity recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

	Level 1	Level 2	Level 3	Total
2025	\$000	\$000	\$000	\$000
Financial assets at fair value				
Derivatives	-	7,273	-	7,273
TCorpIM Funds Investment Facility	-	73,014	-	73,014
Financial liabilities at fair value				
Derivatives	-	2,853	-	2,853
	Level 1	Level 2	Level 3	Total
2024	Level 1 \$000	Level 2 \$000	Level 3 \$000	Total \$000
2024 Financial assets at fair value				
Financial assets at fair value		\$000		\$000
<b>Financial assets at fair value</b> Derivatives		<b>\$000</b> 8,798	\$000	\$000 8,798

The parent entity had no financial assets or liabilities at fair value in the Statement of Financial Position for the year ended 30 June 2025 or 2024.

There were no transfers between Level 1, 2 or 3 during the year ended 30 June 2025 (2024: \$Nil).

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

#### 41. Financial instruments (continued)

### (e) Fair value measurement (continued)

# ii. Fair value recognised in the Statement of Financial Position (continued)

The value of the TCorpIM Funds Investments is based on the consolidated entity's share of the value of the underlying assets of the facility, based on the market value. All of the TCorpIM Funds Investment facilities are valued using 'redemption' pricing.

The fair values of derivative economic hedges are determined using standard valuation technique based on the applicable market observable rates including spot rate and forward points.

# 42. Related party disclosures

#### (a) Key management personnel compensation

Key management personnel compensation is as follows:

	Consolidated	Consolidated	Parent	Parent
	2025	2024	2025	2024
	\$000	\$000	\$000	\$000
Short-term employee benefits	4,198	4,306	4,198	4,306
Post-employment benefits	202	164	202	164
	4,400	4,470	4,400	4,470

Compensation for the Minister for Health is paid by the Legislature and is not reimbursed by the Ministry of Health and its controlled entities. Accordingly no such amounts are included in the key management personnel compensation disclosures above.

# (b) Transactions and outstanding balances with key management personnel of the consolidated entity and its parent during the financial year

There were no material transactions or outstanding balances with key management personnel of the consolidated entity and its parent during the financial year.

# (c) Transactions the consolidated entity had with government related entities during the financial year

During the financial year and comparative year, the consolidated entity entered into the various transactions with other entities consolidated as part of the NSW Total State Sector (the ultimate parent) within the normal course of business.

Operating expenses incurred as follows:

- Payroll and fringe benefits taxes
- Audit of the statutory financial statements
- Cost for mobile radio network services
- Utilities, including electricity, gas and water expenses
- Property occupancy and maintenance expenses
- Insurance costs
- Legal and consultancy costs
- Records storage and retrieval expenses
- Grants and subsidies to health cluster agencies
- Revenue collection services
- Project management and advisory costs for capital works projects
- Traineeship program contributions
- Various grants and other contributions.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

### 42. Related party disclosures (continued)

### (c) Transactions the consolidated entity had with government related entities during the financial year (continued)

#### Revenue earned as follows:

- Appropriations as per the Appropriations Act received from Consolidated Fund
- Motor Accident Third Party revenue is received from State Insurance Regulatory Authority and Lifetime Care and Support Authority of New South Wales
- Clinical services revenue was received from the NSW Police Force and Transport for NSW
- Various grants and other contributions
- Interest income on restricted financial assets from the Crown
- Distributions and unit price movements on TCorpIM Funds facilities
- Motor vehicle rebates
- Contract revenue for the construction works
- Insurance refunds
- Revenue from acceptance of long service leave liabilities and defined benefit superannuation.

#### Assets and Liabilities as follows:

- Receivables / payables in respect of the above noted related party revenue and expense transactions
- Some sale proceeds for non-current property, plant and equipment assets
- Right-of-use assets with Department of Customer Service
- Some funds are invested in TCorpIM Funds Investment facilities
- Forward foreign exchange derivative contracts purchased through NSW Treasury Corporation
- Energy Efficient Government Program loans are held with the Crown.

### (d) Transactions the parent entity had with government related entities during the financial year

Further to the above transactions entered into by the consolidated entity, the parent entity entered into the following transactions within the normal course of business with entities it controlled which are consolidated as part of these financial statements:

# Operating expenses incurred as follows:

- Grants and subsidies provided to health entities
- Information technology service charges.

#### Revenue earned as follows:

- Revenue from short term lease arrangements
- Recovery of outgoings from short term lease arrangements.

# Assets and Liabilities as follows:

- Intra-health receivables and payables
- Receivable for loans and advances made to health entities.

# Notes to and forming part of the Financial Statements

for the year ended 30 June 2025

# 42. Related party disclosures (continued)

# (e) Individually significant transactions with Government-related entities

Peppercorn Lease 1: Doonside Lease

NSW Land & Housing Corporation (LHC), an entity controlled by the ultimate parent, entered into a lease agreement with Western Sydney Local Health District (WSLHD) for the lease of the land at 32 Birdside Avenue, Doonside for a 99 year period commencing on 2 December 1991 and ending on 1 December 2090. WSLHD pays a lease rental of \$1 per year to the LHC.

Peppercorn Lease 2: Mt Druitt Lease

Department of Planning, Housing and Infrastructure (DPHI), an entity controlled by the ultimate parent, has entered into a lease agreement with Western Sydney Local Health District (WSLHD) for lease of the land located at Lots 29 and 30 in Rooty Hill, Cumberland County for a 77 year period commencing from 4 November 1973 to 31 December 2050. WSLHD pays a lease rental of \$1 per year to the DPHI.

# 43. Events after the reporting period

No other matters have arisen subsequent to balance date that would require these financial statements to be amended.

**END OF AUDITED FINANCIAL STATEMENTS**